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Abstract 
Huntington’s disease (HD) is a fatal, autosomal dominant neurodegenerative 
disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene. 
Expression of the mutant (m)HTT protein is the primary cause of disease 
pathology, so lowering intracellular levels of mHTT is a promising therapeutic 
strategy. The aim of this thesis was to achieve allele-selective suppression of 
mHTT using siRNA targeted to single nucleotide polymorphisms (SNPs) in 
the HTT gene. HD patients were genotyped for three SNPs before the mRNA 
and protein knockdown efficacy of a panel of siRNAs was tested in primary 
human myeloid cells. Functional validation was carried out by characterising 
the effects of selective siRNAs on the cells’ hyper-reactive cytokine profile. 
In parallel, RNA sequencing was used to carry out the first whole 
transcriptome analysis of primary human HD myeloid cells. HD myeloid cells 
are functionally abnormal, and there is mounting interest in the peripheral 
immune system as a modifier of HD progression. In contrast with previous 
studies that have required stimulation to elicit phenotypic abnormalities, this 
thesis demonstrates significant transcriptional changes in unstimulated HD 
monocytes, including increased resting expression of proinflammatory 
cytokines. Pathway analysis revealed enrichment of gene sets relating to 
innate immunity and inflammation, while upstream regulator analysis 
suggests this transcriptional dysregulation is mediated by abnormal basal 
activation of the NFĸB intracellular signalling pathway; this was later 
confirmed by western blotting. These data are consistent with a priming 
Abstract 
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effect of mHTT, whereby resting dysfunction leads to an exaggerated 
response once a stimulus is encountered. 
Finally, the contribution of adaptive immunity to HD peripheral immune 
dysfunction is yet to be satisfactorily investigated. This thesis demonstrates 
that mHTT expression does not affect the intrinsic phenotype of human HD T 
lymphocytes, suggesting that HD peripheral immune disturbance is not 
universal but is primarily the result of altered innate immunity. 
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1 Introduction 
1.1 Huntington’s disease 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative 
disorder caused by a CAG repeat expansion in exon 1 of the huntingtin 
(HTT) gene on chromosome 4 (The Huntington's Disease Collaborative 
Research Group, 1993). Patients are affected by a combination of symptoms 
ranging from movement disorders to psychiatric disturbances, with death 
occurring 15-20 years after symptom onset (Ross and Tabrizi, 2011). The 
disease affects approximately 10.6-13.7 individuals per 100,000 in Western 
populations (Bates et al., 2015); however, there is considerable variability 
between different regions and ethnic groups, (Warby et al., 2011). 
1.1.1 The genetics of HD 
While the clinical features of HD were first comprehensively described by 
George Huntington in 1872 (Huntington, 1872), the genetic cause was not 
mapped to chromosome 4 until 1983 (Gusella et al., 1983). The IT15 region 
at 4p16.3 was then found to contain an expanded CAG repeat in HD patients 
(The Huntington's Disease Collaborative Research Group, 1993); this gene 
was later renamed HTT. Further study revealed that HTT is a large gene of 
180 kb containing sixty-seven exons; these are alternatively spliced to form 
two mRNA transcripts of ten and twelve kb respectively (Ross and Tabrizi, 
2011).   Surprisingly for a neurodegenerative disease-causing gene, HTT is 
controlled by a housekeeping promoter, with relatively consistent expression 
in all cells and tissues that have been studied to date (Li et al., 1993).  
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The length of the CAG repeat is highly heterogeneous in the general 
population, with a healthy normal range of approximately ten to twenty-six. A 
repeat length of forty or more causes HD with complete penetrance, (Ross 
and Tabrizi, 2011), although shorter repeats between thirty-five and thirty-
nine also cause HD with reduced penetrance. There have even been reports 
of subtle abnormalities with repeats ranging from twenty-seven to thirty-five 
CAGs (Squitieri and Jankovic, 2012). Onset itself occurs at a mean of 45 
years of age, although this is highly variable (Bates et al., 2015). The length 
of the CAG repeat is strongly associated with age at onset (AAO), with 
longer repeats resulting in progressively earlier disease onset (Bates et al., 
2014). Repeat lengths greater than sixty result in juvenile HD, which 
produces a more aggressive phenotype with onset in young adulthood or 
even childhood (Squitieri et al., 2006). The CAG repeat is subject to meiotic 
instability, with increasing CAG repeat length between generations leading to 
earlier onset; this phenomenon is known as anticipation, and is particularly 
common on paternal inheritance (Trottier et al., 1994). The existence of a 
defined mutation allows individuals to undergo predictive genetic testing. 
Indeed, the length of the CAG repeat is the most important factor for 
determining AAO in HD. This occurs dominantly with no contribution from the 
shorter allele, regardless of its length (Lee et al., 2012). Studies on 
Venezuelan cohorts determined that genetic and environmental factors 
account for 59 % of AAO variability (Wexler et al., 2004), while a study of 
siblings found that 65-71 % of AAO variation was due to the length of the 
CAG repeat expansion (Rosenblatt et al., 2001). However, CAG repeat 
length correlates poorly with disease progression (Rosenblatt et al., 2006).  
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1.1.2 Clinical features of HD 
The main clinical features of HD are caused by central nervous system 
(CNS) degeneration, resulting in a range of symptoms including motor 
abnormalities, cognitive impairment and psychiatric disturbances (Ross and 
Tabrizi, 2011). The degree to which patients are affected by each symptom 
type is highly variable; however, most will experience each aspect to at least 
some extent. A formal clinical diagnosis of HD is made when an otherwise 
unexplained extrapyramidal movement disorder (e.g. chorea or dystonia) 
develops in an individual with a genetically diagnosed CAG repeat expansion 
(Ross et al., 2014). However, the cognitive and psychiatric aspects of HD 
may develop many years before this. 
The motor abnormalities caused by HD may be broadly divided between 
worsening involuntary movements and impairment of voluntary movements 
(Ross et al., 2014). Restlessness and loss of fine motor control occur early, 
before later progression to chorea (Wild and Tabrizi, 2007). Finally, 
advanced HD takes on a more Parkinsonian character, with increased rigidity 
and reduced chorea. The cognitive symptoms are highly variable, but include 
inhibition of executive function and impulsive behaviour (Novak and Tabrizi, 
2010). Psychiatric disturbances are one of the most common features of HD, 
with approximately 40-50 % of HD patients experiencing depression 
(Paulsen et al., 2005). Suicide attempts have been found to be four times 
more likely in HD patients (Farrer, 1986), while apathy, aggression and 
psychosis have also been reported (Novak and Tabrizi, 2010). 
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The clinical course of HD may be divided between pre-manifest and manifest 
disease, with the pre-manifest phase containing an additional prodromal 
period of subtle abnormalities (Ross et al., 2014); this may precede formal 
diagnosis by up to fifteen years (Bates et al., 2015). While the disease 
course is highly variable, death occurs at a median of eighteen years from 
motor onset. Clinical characterisation may be carried out using the Unified 
Huntington’s Disease Rating Scale (UHDRS) (Huntington Study Group, 
1996) and Total Functional Capacity (TFC) (Shoulson, 1981) scores. 
However, it is important to recognise that motor onset is not a dichotomous 
state, but occurs insidiously over long periods. Concerted efforts have been 
made to characterise HD progression (Tabrizi et al., 2013), leading to the 
development of detailed predictive models (Langbehn et al., 2010).  
1.1.3 CNS pathology in HD 
The CNS degeneration caused by HD is widespread, with a reduction in total 
post-mortem brain volume of 19 % (Halliday et al., 1998). The most 
prominently affected site is the striatum in the basal ganglia, where 95 % of 
GABAergic medium spiny neurons (MSNs) are lost (Vonsattel and DiFiglia, 
1998). This results in a total striatal volume loss of approximately 50 % 
(Vonsattel et al., 1985; Rosas et al., 2001). Striatal pathology is crucial for 
the HD phenotype, and has been shown to correlate with motor impairment 
(Guo et al., 2012). Other prominently affected sites include the cerebral 
cortex (Halliday et al., 1998) and hypothalamus (Politis et al., 2008). CNS 
atrophy occurs before symptom onset (Rosas et al., 2005; Tabrizi et al., 
2009), suggesting that some degree of neuronal compensation exists. 
However, it is important to note that while neuronal death is the hallmark of 
Chapter 1  Introduction   
33 
 
HD, dysfunction probably occurs earlier (Ross et al., 2014). CNS pathology 
in HD is not merely neuronal, as the mutant protein is also expressed in glial 
cells (Li et al., 1993). Indeed, the targeted astrocytic expression of mHTT is 
sufficient to produce a neurological phenotype in mice (Bradford et al., 2009).  
1.1.4 Peripheral pathology in HD 
While HD pathology was traditionally regarded as being confined to the CNS, 
in recent years it has emerged that HD is in fact a disease of the whole body 
(Fig. 1.1). The mHTT protein is expressed in all cells and tissues (Li et al., 
1993), resulting in a range of pathologies as diverse as the tissues affected 
(van der Burg et al., 2009). This should perhaps not be surprising, given that 
wild-type HTT has important roles in non-neuronal cells (see Section 1.2.2). 
This suggests that the peripheral pathology seen in HD is not just a response 
to CNS pathology, but is instead a relevant disease process in its own right. 
For example, prominent skeletal muscle wasting occurs in both patients and 
mouse models of HD (van der Burg et al., 2009), while cardiac muscle has 
also been shown to be atrophic in HD mice (Mihm et al., 2007). This is 
particularly relevant as heart failure is second only to pneumonia as the most 
common cause of death in HD patients (Lanska et al., 1988). Muscle wasting 
also plays a role in the profound weight loss seen in the latter stages of 
disease (Goodman et al., 2008). While such changes have a substantial 
effect on quality of life, they are also thought to affect disease progression, 
as patients with increased body weights show a slower rate of decline (van 
der Burg et al., 2009). 
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Figure 1.1.  Peripheral pathology in HD. Mutant HTT is expressed throughout the 
body, leading to a wide range of abnormalities in the peripheral tissues of HD patients. 
Reprinted from The Lancet Neurology, Vol. 8, “Beyond the brain: widespread pathology in 
Huntington’s disease”, 765-74, van der Burg et al., ©2009, with permission from Elsevier.   
One of the most important aspects of peripheral pathology relates to 
abnormal immune system function (see Section 1.7), with HD patients of all 
disease stages showing elevated levels of circulating proinflammatory 
cytokines and chemokines in their peripheral blood (Björkqvist et al., 2008; 
Wild et al., 2011). Further peripheral changes include endocrine dysfunction, 
osteoporosis and testicular atrophy (van der Burg et al., 2009). These data 
reinforce the conclusion that the ubiquitous expression of mHTT has cell-
intrinsic negative effects on tissues far beyond the CNS.  
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1.1.5 Disease modifiers 
While the length of the CAG repeat expansion is thought to be the single 
most important factor in determining AAO (Wexler et al., 2004; Rosenblatt et 
al., 2001), the other factors involved remain the subject of investigation. One 
key area has focused on the identification of disease-modifying genes other 
than mHTT; numerous candidates such as GRIK2, PPARGC1A and TP53 
have been suggested, although it has largely not been possible to replicate 
positive findings between studies (Gusella et al., 2014). However, a recent 
study identified a single nucleotide polymorphism (SNP) in the HTT promoter 
that acts as a bidirectional modifier of HD (Bečanović et al., 2015). The non-
coding variant of the SNP was found to impair NFκB binding, resulting in 
reduced HTT transcription and delayed AAO in familial HD cases when it 
was located on the disease allele. In contrast, when the non-coding variant 
was located on the wild-type allele it was associated with earlier AAO. 
Furthermore, a large scale genome-wide association study identified genetic 
loci on chromosomes 8 and 15 that may modify AAO (Genetic Modifiers of 
Huntington’s Disease (GeM-HD) Consortium, 2015). Pathway analysis 
implicated the MLH1 gene as a potential modifier of disease progression, 
suggesting that DNA repair mechanisms are involved in determining AAO. 
Indeed, DNA repair pathways are a common genetic mechanism affecting 
AAO in multiple polyglutamine (polyQ) diseases (Bettencourt et al., 2016). 
Somatic instability of the CAG repeat in post-mitotic neurons has also been 
suggested as an important modifier of AAO (Swami et al., 2009). 
Environmental and lifestyle factors are also thought to play an important role, 
as sedentary lifestyles lacking significant physical or intellectual exertion are 
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associated with earlier AAO (Trembath et al., 2010). This may be part of a 
more general phenomenon, as the risk of dementia has been found to 
decrease with increasing physical exercise (Hamer and Chida, 2009). 
Identifying robust modifiers of HD progression has proved to be even more 
difficult than for AAO. Numerous candidates have been suggested, from the 
CAG repeat to modifying genes and the peripheral immune system (see 
section 1.7.2). However, the majority of current studies have been 
inconclusive, and considerable further study is needed to provide a 
comprehensive profile of the factors involved in modifying HD progression. 
1.1.6 Biomarkers of HD 
The advent of clinical trials for HD has necessitated the search for robust 
biomarkers to monitor disease progression. A biomarker is a quantifiable 
measure by which a biological or pathological process can be identified or 
assessed for severity or response to treatment (Andre et al., 2014). The 
nature of HD as a predominantly CNS disorder presents challenges for the 
reliable monitoring of disease progression, as access to the main tissue of 
interest is largely restricted to post-mortem analyses.  
Potential HD biomarkers may be broadly divided into clinical, neuroimaging 
and biochemical measures (Andre et al., 2014). Clinical measures such as 
the UHDRS and quantitative motor tests are relatively easy to carry out, 
however they have limited sensitivity and are subject to significant inter-rater 
variability. Neuroimaging measures have the significant advantage of 
providing an accurate assessment of structural CNS changes; however, high 
quality neuroimaging assessments are both expensive and time consuming. 
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Biochemical measures would provide the ideal biomarker, as they are 
cheaper and easier than neuroimaging and more robust than clinical 
measures. The collection of blood and cerebrospinal fluid (CSF) is also 
significantly less invasive than direct sampling of the CNS. However, no 
biochemical measures have withstood longitudinal analysis as a biomarker of 
HD (Weir et al., 2011). While HD patients have been shown to have 
increased circulating levels of proinflammatory cytokines in their peripheral 
blood (Björkqvist et al., 2008), what is less clear is how these measurements 
are linked to progression. Measurement of mHTT protein levels has shown 
some promise, with a recent study demonstrating a significant increase in 
mHTT levels in patient CSF with advancing disease stage (Wild et al., 2015). 
Furthermore, mHTT levels in peripheral blood cells correlate with disease 
burden scores (Weiss et al., 2012). These measures are likely to be vital for 
clinical trials to lower cellular levels of mHTT, but further validation is needed. 
1.1.7 Cell and animal models of HD 
Numerous cell models exist to study HD in the lab, from ex vivo patient cells 
to neuronal cell lines with CAG repeat knock-ins, with a recent avenue of 
investigation focusing on the development of induced pluripotent stem cells 
(iPSCs) (Park et al., 2008). However, it is important to remember that HD 
pathogenesis is complex, and studying individual cell lines in isolation is 
therefore unlikely to provide a complete picture of the disease. 
Animal models of HD range from Drosophila to mammals such as primates, 
sheep and rats (Pouladi et al., 2013). Murine models of HD are the most 
commonly used, and come in a variety of different types. Fragment models 
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contain an N-terminal fragment of the human HTT gene, and display an 
aggressive phenotype with late stage disease occurring between 12-15 
weeks in the R6/2 mouse (Mangiarini et al., 1996). In contrast, full-length and 
knock-in models both contain an entire mutant gene; full-length models such 
as the YAC mouse express the entire human mHTT gene in addition to the 
normal mouse genes (Slow et al., 2003), whereas knock-in models such as 
the Hdh150Q/150Q have an artificial CAG repeat expansion inserted into both 
alleles of the mouse Htt gene (Lin et al., 2001). These models have a 
substantially longer disease course measured in months or even years.  
1.2 The HTT protein 
1.2.1 Wild-type HTT structure 
Wild-type HTT is a 348 kDa protein that is expressed ubiquitously in all cells 
and tissues, although the highest expression is found in the CNS and testes 
(Li et al., 1993). While the size of the protein prohibits structural analysis by 
spectroscopy, substantial information has been discovered using alternative 
techniques (Fig. 1.2). The CAG repeat found in exon 1 of the HTT gene 
encodes an N-terminal polyQ sequence with a largely helical secondary 
structure (Kim et al., 2009), although the conformation of the polyQ tract is 
influenced by the surrounding protein regions. Wild-type HTT also contains a 
number of HEAT repeats, which are sequences of approximately fifty amino 
acids in anti-parallel α-helices (Li et al., 2006); these are interspersed with 
disordered regions and are thought to mediate protein-protein interactions 
(Bates et al., 2015). Indeed, the many interaction partners described for HTT 
suggests it acts as a molecular scaffold.  
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Figure 1.2.  The HTT protein. HTT is a large, 348 kDa protein that contains a wide 
range of functional domains, in addition to sites for post-translational modification. Reprinted 
from The Lancet Neurology, Vol. 10, “Huntington’s disease: from molecular pathogenesis to 
clinical treatment”, 83-98, Ross and Tabrizi, ©2011, with permission from Elsevier.   
Huntingtin undergoes extensive post-translational modification, including 
phosphorylation, ubiquitination, SUMOylation, acetylation and palmitoylation 
(Steffan et al., 2004; Thompson et al., 2009; Cong et al., 2011; Yanai et al., 
2006). These modifications often occur in the disordered segments between 
HEAT repeats, and affect characteristics including half-life and aggregation, 
and can even modulate toxicity by increasing HTT clearance through the 
ubiquitin-proteasome system (UPS). Huntingtin also undergoes cleavage by 
numerous proteolytic enzymes (Ross and Tabrizi, 2011), although the 
physiological function of this is incompletely understood. However, an N-
terminal fragment of approximately one hundred amino acids is thought to be 
particularly important for pathogenesis (Bates et al., 2015). 
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1.2.2 Wild-type HTT function 
The exact functions of wild-type HTT remain similarly elusive, although much 
has been learned since the identification of mHTT as the disease-causing 
factor in HD. Huntingtin knockout mice are embryonic lethal prior to the 
period of nervous system development (Nasir et al., 1995; Zeitlin et al., 
1995), suggesting that the wild-type protein has key roles in embryogenesis 
beyond the CNS. Huntingtin knockout mice also exhibit increased apoptosis 
(Zeitlin et al., 1995), while Htt overexpression has a protective, anti-apoptotic 
effect on striatal neurons in HD mice (Leavitt et al., 2006). Indeed, HTT is 
involved in the maintenance of tissues beyond the CNS, as conditional Htt 
knockout in mice leads to death from acute pancreatitis (Wang et al., 2016) 
Wild-type HTT is thought to play a role in vesicular trafficking through the 
secretory and endocytic pathways (Velier et al., 1998), and has additional 
functions in cellular trafficking including brain-derived neurotrophic factor 
(BDNF) transport along microtubules (Gauthier et al., 2004). Huntingtin also 
affects gene transcription, for example by sequestering REST to indirectly 
increase the expression of BDNF (Zuccato et al., 2003). The localisation of 
HTT to the mitochondrial membrane further suggests that HTT is involved in 
the regulation of energy metabolism (Damiano et al., 2010). Intriguingly, a 
recent study suggested that wild-type HTT may have a novel role in immune 
cell function, as HTT-lowering was found to significantly reduce cytokine 
production by control cells following stimulation with lipopolysaccharide 
(LPS) and interferon-gamma (IFNγ) (Träger et al., 2014). These studies 
demonstrate that wild-type HTT is a multi-functional protein with diverse 
effects in both neuronal and non-neuronal cells.  
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1.2.3 Mutant HTT 
The presence of an expanded polyQ tract brings about a number of 
structural and conformational changes in the mHTT protein that are key for 
HD pathogenesis (Ross and Tabrizi, 2011). Although the exact toxic mHTT 
species remain elusive, N-terminal fragments containing the polyQ tract have 
been shown to be necessary for pathology (Graham et al., 2006). While wild-
type HTT is largely α-helical, toxic mHTT fragments form a compact β-sheet 
secondary structure (Ross and Tabrizi, 2011); this is able to form aggregates 
that are homologous to species seen in other protein misfolding diseases. 
The efficiency of this aggregation process is highly dependent on the length 
of the CAG repeat (Chen et al., 2001). The cellular localisation of mHTT also 
differs from that of the wild-type; whereas wild-type HTT is primarily 
cytoplasmic, mHTT forms inclusions in the nucleus (DiFiglia et al., 1997); 
these inclusions are largely formed from N-terminal fragments.  
The prevailing hypothesis is that a toxic gain of mHTT function, rather than a 
loss of wild-type HTT function, is the principle cause of HD pathogenesis. HD 
mouse models expressing two copies of the mutant allele, for example the 
Hdh150Q/150Q mouse, are viable (Lin et al., 2001); this contrasts with the 
embryonic lethality displayed by Htt knockout mice (Nasir et al., 1995). 
These studies suggest that mHTT is able to substitute for wild-type HTT 
function, an observation supported by the fact that homozygous mutant HD 
patients do not display a more severe disease phenotype than heterozygotes 
(Wexler et al., 1987). Regardless, mHTT-related pathogenesis occurs early 
in the disease course, with functional deficits being detectable in cultured 
cells from HD patients up to fifteen years before onset (Paulsen et al., 2008). 
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1.3 Pathogenic mechanisms of mHTT 
1.3.1 Cell-autonomous pathogenesis 
The formation of large intracellular aggregates containing mHTT is 
pathognomonic for HD, however there is debate concerning their contribution 
to pathogenesis (Fig. 1.3). Aggregates sequester cellular proteins including 
transcription factors, ubiquitin and molecular chaperones (Steffan et al., 
2000; Hay et al., 2004; Bennett et al., 2007), and reduced aggregation is 
associated with improved disease progression (Mielcarek et al., 2011). 
However, aggregate density does not correlate well with cell death in HD 
post-mortem brain (Vonsattel, 2008), and intranuclear inclusions of mHTT do 
not produce pathology in isolation (Gu et al., 2005; Gu et al., 2007). This 
suggests that aggregate formation is a protective response; this is supported 
by the association of intranuclear inclusion formation with neuronal survival 
(Arrasate et al., 2004). The primary toxic species in HD are therefore likely to 
be monomeric and oligomeric mHTT fragments (Miller et al., 2011). Aberrant 
splicing of HTT exon 1 mRNA has been shown to occur in a CAG-repeat 
dependent manner, resulting in the production of a HTT exon 1 protein 
(Sathasivam et al., 2013). This is likely to be highly pathogenic given the 
toxicity of similar species in fragment mouse models such as the R6/2.  
Cellular pathways responsible for protein degradation are adversely affected 
by mHTT, and disruption of the UPS and autophagy is a consistent feature of 
HD (Ortega and Lucas, 2014; Martin et al., 2015). Examination of HD post-
mortem brain tissue found evidence of residual autophagosomes containing 
mHTT (Sapp et al., 1997), suggesting there is a general inability of HD cells 
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to clear mHTT species, a phenomenon which is worsened by the inhibitory 
effects of mHTT on protein degradation pathways. Abnormal mitochondrial 
function is caused by the direct binding of mHTT to the outer mitochondrial 
membrane (Damiano et al., 2010), resulting in a lower calcium threshold to 
open the mitochondrial pores (Choo et al., 2004). Mitochondrial membrane 
potential regulates the release of apoptotic factors including cytochrome c, 
which along with apoptosis is upregulated in HD myoblast cultures. 
(Ciammola et al., 2006). The response to stressors is also diminished by 
progressive dysfunction in the vital heat shock response pathway (Labbadia 
et al., 2011), while neuronal metabolism is further impaired by the blocking of 
mitochondrial transport by mHTT aggregates (Chang et al., 2006). 
 
Figure 1.3.  Cell-autonomous pathogenesis in HD. Mutant HTT has been shown to 
cause pathology by a wide range of cell-autonomous mechanisms, including the formation of 
toxic oligomeric fragments and the impairment of cellular energy metabolism. Reprinted from 
The Lancet Neurology, Vol. 10, “Huntington’s disease: from molecular pathogenesis to 
clinical treatment”, 83-98, Ross and Tabrizi, ©2011, with permission from Elsevier.   
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1.3.2 Non-cell-autonomous pathogenesis 
While cell-autonomous pathogenesis is a central feature of HD, non-cell-
autonomous pathogenesis is becoming increasingly recognised (Fig. 1.4). 
Glial cells play a key role in this process, as directed astrocytic expression of 
mHTT produces a neurological phenotype in mice (Bradford et al., 2009). 
Furthermore, glial expression of mHTT causes the death of neurons which 
do not express mHTT in co-culture (Shin et al., 2005). Mutant HTT 
aggregates may also spread from cell to cell in a prion-like manner (Brundin 
et al., 2010), and neural transplants into HD brain have been found to suffer 
from disease-like degeneration (Cicchetti et al., 2014). However, while 
mechanistically interesting, the ubiquitous expression of mHTT likely limits 
the pathogenic relevance of this phenomenon (Li et al., 1993). 
Further possible mechanisms include impaired neuronal trafficking of BDNF 
(Gauthier et al., 2004), while reduced BDNF expression has also been found 
in HD patient brain (Zuccato et al., 2003). This may contribute to increased 
striatal vulnerability in HD, as MSNs are dependent on a cortical supply of 
BDNF (Ross and Tabrizi, 2011). Excitotoxicity is apoptosis occurring due to 
excessive activation of AMPA and NMDA glutamate receptors, high levels of 
which are expressed on MSNs (Nicholls, 2009). In vivo stimulation of striatal 
NMDA receptors gives an HD-like phenotype in rats (Beal et al., 1991), while 
levels of excitotoxic kynurenine 3-monooxygenase (KMO) metabolites are 
increased in HD brain (Guidetti et al., 2006). Potential excitotoxicity is likely 
worsened by impaired synaptic glutamate clearance (Liévens et al., 2001), 
while peripheral inhibition of the KMO pathway also has disease-modifying 
effects (see Section 1.7.2). 
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Figure 1.4.  Non-cell-autonomous pathogenesis in HD. Mutant HTT has also been 
shown to cause pathology via alterations in cell-cell interactions. Reprinted from The Lancet 
Neurology, Vol. 10, “Huntington’s disease: from molecular pathogenesis to clinical 
treatment”, 83-98, Ross and Tabrizi, ©2011, with permission from Elsevier.   
1.3.3 Transcriptional dysregulation in HD 
Transcriptional dysregulation is a central feature of HD pathogenesis (Fig. 
1.5) (Hodges et al., 2006), and has been demonstrated in a wide range of 
tissues in both HD patients and animal models (Seredenina and Luthi-Carter, 
2012). Indeed, experiments in primary striatal neurons have shown that 
transcriptional dysregulation is caused by a cell-intrinsic effect of mHTT 
expression (Runne et al., 2008). Transcription factors including CBP, SP1, 
TBP and p53 are sequestered by mHTT aggregates, causing reduced 
binding to DNA (Seredenina and Luthi-Carter, 2012; Chen-Plotkin et al., 
2006). The impaired protein degradation seen in HD is also likely to play a 
role in altering transcription factor processing by the UPS, while mHTT itself 
influences transcription by binding directly to DNA (Benn et al., 2008).  
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Figure 1.5.  Transcriptional dysregulation in HD. Mutant HTT expression affects gene 
expression via a wide range of mechanisms, including the sequestration of transcription 
factors and the direct binding of mHTT to DNA. Reprinted from Neurobiology of Disease, 
Vol. 45, “What have we learned from gene expression profiles in Huntington's disease?”, 83-
98, Seredenina and Luthi-Carter, ©2012, with permission from Elsevier. 
The activity of intracellular signalling pathways involved in regulating gene 
expression is similarly affected by mHTT. Mitogen-activated protein kinases 
(MAPKs) such as ERK show increased activity in HD (Apostol et al., 2006), 
while mHTT has a profound effect on NFκB signalling through a direct 
interaction with the IKK complex (Khoshnan et al., 2004). IKK phosphorylates 
IκB, one of the key cytoplasmic inhibitors of NFκB; this results in the 
dissociation of IκB from NFκB, which is then free to translocate to the 
nucleus and influence gene expression. Mutant HTT has been shown to 
increase IκB phosphorylation through its interaction with IKK, resulting in a 
decrease in NFκB inhibition and an upregulation in gene transcription. 
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Mutant HTT further affects gene expression through its influences on 
chromatin structure. Hyper-methylation of the H3K9 histone is associated 
with transcriptional repression, and occurs at increased rates in HD post-
mortem brain (Ryu et al., 2006). Similar effects have been demonstrated for 
hypo-acetylation of H3 and H4 in HD (Labbadia et al., 2011; Sadri-Vakili et 
al., 2007), suggesting that the chromatin structure of HD cells may have 
more a repressive effect on transcription than in healthy controls. 
It is important to note that transcriptional dysregulation may affect or be 
affected by the additional mechanisms of HD pathogenesis described above. 
For example, expression of BDNF promoters has been found to be reduced 
in a neuronal model of HD (Gambazzi et al., 2010); this is likely to worsen 
the lack of neurotrophic support seen in HD. Individual mechanisms should 
therefore be viewed within the whole spectrum of mHTT-related 
pathogenesis, instead of being considered purely in isolation. 
1.4 HD therapeutics 
1.4.1 Current therapeutics for HD 
There are currently no therapeutics available to slow HD progression, with 
management instead focussing on symptomatic relief (Novak and Tabrizi, 
2010). Tetrabenazine is the first drug specifically licensed for the treatment of 
HD-related chorea, although chorea may also be treated with neuroleptics 
such as haloperidol; these drugs are further useful for the management of 
non-motor symptoms including psychosis and irritability. Psychiatric 
manifestations are treated conventionally, for example with selective 
serotonin reuptake inhibitors for depression. Further treatment strategies 
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include the use of dietary supplements and physiotherapy for cachexia, while 
social care is often more effective than pharmacological intervention for 
improving behavioural issues (Ross et al., 2014). Recent clinical trials have 
largely yielded disappointing results (Bates et al., 2015). 
1.4.2 Experimental therapeutics for HD 
Substantial research into experimental therapeutics for HD has involved 
targeting a specific pathogenic mechanism, with the aim of ameliorating the 
relevant cellular deficit. It has been suggested that increasing the rate at 
which cells degrade proteins may aid in the clearance of mHTT (Ross and 
Tabrizi, 2011). Consistent with this hypothesis, the induction of mTOR-
dependent autophagy protected against polyQ toxicity in fly and mouse 
models of HD (Martinez-Vicente et al., 2010). Further attempts to modulate 
cellular processing of mHTT have included the overexpression of molecular 
chaperones and administration of small molecule aggregation inhibitors 
(Vacher et al., 2005; Chopra et al., 2007). While promising, the off-target 
effects of such broad manipulation of cellular function may limit clinical utility. 
Experimental therapeutics aimed at supporting or improving neuronal 
function have included overexpression of the BDNF gene in the forebrain of 
the R6/1 mouse; this improved motor performance and reduced brain weight 
loss (Gharami et al., 2008), while the pharmacological upregulation of BDNF 
using an ampakine was able to rescue synaptic plasticity and memory in an 
HD knock-in mouse model (Simmons et al., 2009). Further strategies have 
attempted to block the neuronal damage caused by excitotoxicity, however 
riluzole was not found to have a disease-modifying on HD in human clinical 
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trials (Landwehrmeyer et al., 2007). This strategy will therefore likely depend 
on the development of more robust pharmacological agents. 
One interesting therapeutic strategy involves the use of grafts to directly 
replace neurons in the adult brain. This technique showed promise in rodent 
and primate models of HD (Hurelbrink et al., 2002; Palfi et al., 1998), 
however clinical trials in patients were inconclusive at best (Benraiss and 
Goldman, 2011). In addition, the worrying possibility remains that mHTT is 
able to spread in a prion-like manner, and disease-like degeneration of 
grafted tissue has been reported in post-mortem brain (Cicchetti et al., 2014). 
Further experimental therapeutics for HD have involved the targeting of 
transcriptional dysregulation, with both the inhibition and genetic knockdown 
of histone deacetylases improving motor function in HD mice (Labbadia et 
al., 2011; Mielcarek et al., 2011). However, the pathogenesis of mHTT is 
multi-factorial, and each of the experimental therapeutics outlined above is 
limited by the fact that it only targets a single mechanism.  
1.4.3 Post-transcriptional gene silencing 
In recent years there has been substantial interest in the use of post-
transcriptional gene silencing (PTGS) to treat genetic disorders. This strategy 
works by preventing the translation of mRNA, thereby cutting off the 
pathogenic cascade at its source (Fig. 1.6). Initial clinical trials have shown 
promising results in diseases such as Duchenne's muscular dystrophy 
(Goemans et al., 2011). There are a number of ways in which PTGS may be 
achieved, the majority of which either physically block translation or harness 
cellular RNA interference (RNAi) pathways (Sah and Aronin, 2011).  
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One of the most commonly used methods of PTGS involves the 
administration of small interfering RNA (siRNA) molecules. These are 
double-stranded oligonucleotides of approximately 20-25 bp that hijack the 
endogenous miRNA system of post-transcriptional gene expression 
regulation (Sah and Aronin, 2011). Each siRNA molecule is made up of a 
guide strand and a passenger strand. Following delivery into the cytoplasm, 
the two strands separate and the guide strand joins with the multiprotein 
RNA-induced silencing complex (RISC), where it binds to complementary 
mRNA sequences to target them for degradation (Rand et al., 2005). This is 
typically carried out by the Argonaute enzyme family. In contrast, antisense 
oligonucleotides (ASOs) are single-stranded molecules of approximately 15-
25 bp that mediate PTGS by either directing target mRNA for degradation by 
the ribonuclease H (RNase H) enzyme, or physically blocking translation by 
the ribosome (Bennett and Swayze, 2010).  
Further differences between siRNAs and ASOs include their delivery 
mechanisms, as ASOs do not require a delivery vehicle and can be directly 
taken up by cells, including neurons (Kay et al., 2014). In contrast, siRNAs 
require a reliable transfection protocol to be delivered to a target cell. 
Furthermore, siRNAs are only able to target mRNA in the cytoplasm, and as 
such are limited to silencing exonic sequences, while ASOs can also enter 
the nucleus to target nuclear pre-mRNA (Sah and Aronin, 2011). However, 
siRNAs are generally thought to be more robust, and do not need to undergo 
the substantial chemical modifications often required to achieve potency with 
ASOs (Watts and Corey, 2012). They are also likely to be more stable than 
ASOs given the fact that they are double instead of single-stranded.  
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Figure 1.6.  Post-transcriptional gene silencing techniques. After entering the 
cytoplasm, siRNAs harness the endogenous miRNA system to target complementary 
nucleotide sequences to the RISC. In contrast, ASOs mediate gene silencing by directing 
their target transcript for degradation by RNase H, or by physically blocking translation. 
Reprinted from Clinical Genetics, Vol. 86, “Personalized gene silencing therapeutics for 
Huntington disease”, 29-36, Kay et al., ©2014, with permission from John Wiley and Sons. 
1.4.4 HTT-lowering in HD 
As a monogenic disorder, HD is a prime target for treatment by PTGS. An 
initial proof of concept study using doxycycline-mediated conditional 
knockout of mHTT demonstrated a reduction in brain pathology in an HD 
mouse model (Yamamoto et al., 2000), proving the hypothesis that a 
reduction in cellular mHTT levels has a beneficial effect on survival. More 
recent studies have made use of both siRNAs and ASOs with considerable 
success. Administration of anti-HTT siRNA using a lentiviral vector reduced 
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neuropathology in a mouse model of HD (Drouet et al., 2009), while the 
infusion of ASOs into the CSF of HD mice was shown to delay disease 
progression (Kordasiewicz et al., 2012). Interestingly, the improvement in 
symptoms was found to last longer than the reduction in HTT mRNA levels, 
suggesting that even occasional HTT-lowering treatment may be sufficient to 
provide an improvement in disease progression. These findings were also 
extended to HTT mRNA levels in the primate cortex.  
These studies provide great promise for HTT-lowering as a future therapeutic 
for HD, although reliable delivery presents a significant hurdle. Traditional 
peripheral administration is likely to be futile, as the drugs will not cross the 
blood-brain barrier in sufficient quantities to have an appreciable therapeutic 
effect. Methods to directly deliver into the brain, for example implantable 
infusion systems, would bypass this issue. However, they are highly invasive 
and the extent to which they would be tolerated long-term is uncertain. One 
promising approach is the direct infusion of ASOs into the CSF, and initial 
studies of this method are currently underway (Ionis Pharmaceuticals, 2015). 
1.4.5 Allele-selective HTT-lowering 
One of the most important distinctions to draw is between those therapies 
that will non-selectively lower both wild-type and mutant HTT mRNA, and 
those that will selectively lower the mutant allele while sparing the wild-type. 
The majority of studies to date have made use of siRNAs and ASOs which 
do not discriminate between alleles, and for the purposes of this thesis will 
be referred to as ‘total’ HTT-lowering. This occurs because the target 
nucleotide sequence is present on both alleles (Sah and Aronin, 2011).  
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However, wild-type HTT has a number of important cellular roles (see 
Section 1.2.2), and it is not known what degree of wild-type HTT knockdown 
will be tolerated over extended periods. Although initial studies suggested 
that Htt knockout in the adult mouse brain causes neurodegeneration 
(Dragatsis et al., 2000), it has since been shown that non-specific HTT-
lowering is tolerated for at least nine months in HD mice (Kordasiewicz et al., 
2012; Stanek et al., 2014), while a six month reduction in HTT expression 
has no adverse effects in the rhesus putamen (Grondin et al., 2012). 
Surprisingly, death from ubiquitous Htt knockout in mice is caused by acute 
pancreatitis (Wang et al., 2016), and is therefore unlikely to be due to 
neuronal Htt depletion. Despite this, there is no information available on the 
long-term consequences of wild-type HTT suppression in the human brain, 
where therapies will necessarily be administered over the course of several 
decades. The ideal therapeutic strategy would therefore selectively lower 
mHTT while preserving wild-type. The allele-selective suppression of mHTT 
relies on the existence of polymorphisms between the two alleles, with the 
two most obvious targets being the expanded CAG repeat and SNPs. SNPs 
are genomic variants that result in a single nucleotide change between 
alleles; the HTT gene contains many such variants (Pfister et al., 2009). 
A therapeutic strategy that targets the expanded CAG repeat would be 
applicable to all HD patients, and has shown some promise in in vitro testing. 
Patient-derived fibroblasts with mutant and wild-type CAG repeats of sixty-
nine and seventeen respectively were treated with an ASO targeted to the 
CAG repeat expansion, achieving > 3.7 fold selectivity of inhibition (Gagnon 
et al., 2010). This was advanced using ssRNA molecules in place of ASOs, 
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achieving allele-selectivity > 100 fold (Yu et al., 2012). However, the 
selectivity of knockdown is markedly reduced when targeting expanded CAG 
repeats in the normal human range (forty-four vs. fifteen), with approximately 
50 % off-target knockdown (Fiszer et al., 2013). Furthermore, there is the 
possibility that these therapeutics will have off-target effects on other CAG 
repeat-containing genes. These factors mean that SNP-targeted knockdown 
may provide a more promising alternative. 
The SNP-targeted strategy involves genotyping HD patients for 
heterozygosity at specific SNP sites, before linking each SNP allele to either 
wild-type or mHTT (Sah and Aronin, 2011). The relevant SNP may then be 
targeted for knockdown using either siRNA or ASOs. While this strategy may 
allow more selective knockdown of mHTT, it is only applicable to patients 
who are heterozygous for SNPs of interest (Kay et al., 2014). The prevalence 
of heterozygosity at individual SNP sites varies between different ethnic 
groups (Lombardi et al., 2009; Warby et al., 2009), however it is estimated 
that two thirds of HD patients may be treated by targeting just two SNPs, 
rising to 75 % when three SNPs are utilised (Pfister et al., 2009). 
Furthermore, the T allele of the most prevalent SNP (rs362307 in the 3’-
untranslated region (UTR)) has been shown to be linked to the mutant allele, 
raising the possibility that these 75 % of HD patients could be treated with 
five siRNAs targeting just three SNPs. Expanding SNP coverage beyond this 
point is not expected to provide much additional benefit, as approximately 25 
% of patients do not have a heterozygous SNP associated with mHTT 
(Pfister et al., 2009). However, an alternative possibility would be to use two 
allele-selective siRNAs or ASOs to target a single SNP in both homozygous 
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and heterozygous patients; this would provide allele-selective knockdown in 
approximately half of cases and non-selective knockdown in the remainder, 
while limiting the need for an exhaustive clinical trial process for multiple 
SNP-targeted therapeutics (Skotte et al., 2014). 
SNP-targeted allele-selective suppression was first achieved using human 
HD fibroblasts heterozygous for rs363125 in exon 39 of the HTT transcript 
(van Bilsen et al., 2008), with siRNA targeted to the mutant C allele 
generating approximately 80 % mRNA knockdown. Further work has been 
done by screening a large panel of ASOs targeting fifty SNPs in human HD 
fibroblasts, mouse neurons and an HD mouse model (Carroll et al., 2011). 
The best results were seen with an ASO targeted to rs7685686 in intron 42, 
with approximately five-fold selectivity being achieved. However, it is 
important to note that the fibroblasts were all either homozygous ‘on-target’ 
or homozygous ‘off-target’ for the SNPs of interest, and that for reasons of 
convenience the ASOs were not tested in heterozygous cell lines. Indeed, 
the expression of each HTT allele was not quantified separately.  
This work was recently advanced by a study incorporating positional 
chemical modifications into an ASO targeting rs7685686, resulting in > 100 
fold selectivity for a single SNP allele in human HD fibroblasts (Østergaard et 
al., 2013). This improved allele-selectivity was also found to translate to the 
brain of a humanised HD mouse model, and an additional panel of allele-
selective ASOs has since been screened in vivo (Southwell et al., 2014). 
Interestingly, the latter study found that targeting a single SNP provided 
greater silencing than combinatorial targeting of multiple SNPs, although this 
may have been due to the potency of the ASOs in question. In this case HTT 
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quantification was also carried out using relatively insensitive immunoblotting 
techniques, with no analysis of allele-specific mRNA expression by qPCR; 
the use of certain chemical modifications was also found to produce toxicity. 
Further demonstrations of allele-selective suppression have been provided 
using adenoviral and lentiviral delivery of RNAi in mouse models and human 
stem cells (Drouet et al., 2014; Stanek et al., 2014), although in both cases 
the mouse models in question only possessed one copy of the human HTT 
gene. The extent to which selectivity is achieved in the presence of both 
alleles is therefore yet to be established. Indeed, allele-selective suppression 
is yet to be demonstrated in living ex vivo primary human HD cells. 
1.5 The innate immune system 
The immune system is responsible for the body’s response to external 
pathogens and tissue injury, and is divided into two main arms. The innate 
immune system provides an immediate, generic response to a wide range of 
pathogens, the strength of which does not vary with multiple exposures 
(Owen et al., 2013). In contrast, the adaptive immune system generates a 
highly specific secondary response. While there is substantial interplay 
between the two arms of the immune system (Iwasaki and Medzhitov, 2015; 
Shanker, 2010), they are mediated by highly varied cells and mechanisms.  
1.5.1 Cells of the innate immune system 
Microglia are the primary immunocompetent cells of the CNS, and make up 
approximately 10 % of all brain cells (Ransohoff and Perry, 2009). During 
development microglia migrate into the nascent CNS from the embryonic 
yolk sac (Kierdorf et al., 2013), however in adulthood they form a self-
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renewing population. (Ajami et al., 2007). Microglia are largely anti-
inflammatory at rest, and are kept so by direct interactions with neurons (for 
example via CD200) (Hoek et al., 2000). However, in response to tissue 
injury they rapidly expand by microgliosis before directing neuroinflammation 
(Owen et al., 2013). While peripheral immune cells are able to cross the 
blood-brain barrier into the CNS in response to pathology, this does not 
happen under normal conditions (Ajami et al., 2007). 
In contrast, peripheral immune cells are replenished by haematopoietic stem 
cells located in the bone marrow (Fig. 1.7); these differentiate into common 
myeloid progenitor or common lymphoid progenitor cells (Owen et al., 2013). 
Common myeloid progenitor cells may then undergo further differentiation to 
produce a range of cell types including monocytes, dendritic cells, 
neutrophils and megakaryocytes, while common lymphoid progenitors give 
rise to cell types including T and B lymphocytes and natural killer (NK) cells. 
Monocytes are one of the most important cell types of the peripheral immune 
system, and account for approximately 10 % of circulating white blood cells 
in humans (Auffray et al., 2009). While all monocytes express the CD14 cell 
surface molecule, they may be divided into two broad populations depending 
on the degree to which they also express CD16 (Passlick et al., 1989). 
Classical monocytes (CD14++ CD16-) primarily circulate in the bloodstream 
responding to inflammatory mediators, and are thought to be largely 
phagocytic in function with limited inflammatory properties (Mukherjee et al., 
2015). In contrast, alternative monocytes (CD14+ CD16+) are thought to 
represent a more mature phenotype which localise to a specific tissue and 
carry out the process of cytokine production (Ziegler-Heitbrock, 2007).  
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On encountering a stimulus, monocytes migrate into a specific tissue or site 
of injury and differentiate into macrophages (although some may also 
differentiate into dendritic cells) (Owen et al., 2013). Macrophages are the 
primary effector cells of the peripheral innate immune system, and form 
highly diverse populations depending on their location within the body 
(Geissmann et al., 2010). While macrophages were traditionally thought to 
be either broadly proinflammatory (M1 sub-type) or anti-inflammatory (M2 
sub-type), in recent years it has been suggested that macrophage 
phenotypes form more of a flexible continuum (Martinez and Gordon, 2014).  
Additional cell types involved in innate immune function include dendritic 
cells and granulocytes. Dendritic cells form a diverse group of cells which are 
involved in mediating the interactions between the innate and adaptive 
immune systems by the process of antigen presentation to lymphocytes 
(Owen et al., 2013). The granulocyte population is made up of a range of 
different cell types including neutrophils, eosinophils and basophils; these 
have diverse functions ranging from the phagocytosis of external pathogens 
to the release of inflammatory mediators (Owen et al., 2013). 
1.5.2 Functions of the innate immune system 
The functions of the innate immune system are as diverse as the cells which 
mediate them; however, as monocytes and macrophages form the main 
immunological focus of this thesis, this section will concentrate on describing 
their primary functions at the expense of those of alternative cell types. 
These primarily consist of immune surveillance, phagocytosis and the 
generation of inflammation through the process of cytokine production. 
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Figure 1.7.  Haematopoiesis of immune cells. The cells of the immune system are 
produced by haematopoiesis, whereby stem cells located in the bone marrow go through a 
series of differentiation steps until mature cells are produced. HSC: haematopoietic stem 
cell, CMP: common myeloid progenitor, MLP: myeloid/lymphoid progenitor, MEP: 
megakaryocyte erythrocyte progenitor, GMP: granulocyte monocyte progenitor, MDP: 
macrophage dendritic cell progenitor, CDP: common dendritic cell progenitor, CLP: common 
lymphoid progenitor, ETP: early thymic precursor, B/NP: B-cell natural killer cell progenitor. 
Reprinted from Cell Research, Vol. 21, “NF-κB in immunobiology”, 223-244, Hayden and 
Ghosh, ©2011, with permission from Nature Publishing Group. 
Once they have been released from the bone marrow, monocytes circulate in 
the bloodstream until they encounter a chemotactic stimulus, the most 
common of which is MCP-1 (Deshmane et al., 2009). Monocytes then 
migrate into a tissue along the chemotactic gradient formed by the 
chemokine. At this point the monocyte differentiates into a mature 
macrophage phenotype and releases a range of cytokines to direct the 
immune response (Owen et al., 2013). The traditional view refers to either 
classical activation, involving pathogen associated molecules such as LPS, 
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or alternative activation, involving cytokines such as IL-4 and IL-10 (Owen et 
al., 2013). While the reality of this dichotomy is likely more complex, it is a 
useful paradigm for the limited discussion of macrophage function presented 
here. Classically activated macrophages largely produce proinflammatory 
cytokines such as IL-6 and TNFα, while alternatively activated macrophages 
primarily produce anti-inflammatory cytokines such IL-10 and TGF-β. 
Cytokine release itself is a diverse process, and occurs in response to 
activation of the cellular signalling pathways described in Section 1.5.3. The 
classical method of cytokine release takes place via secretory granules or 
vesicles, although some cytokines are released via alternative methods 
(Lacy and Stow, 2011). For example, TNFα is synthesised as a membrane-
bound precursor that is cleaved in response to cellular activation (Black et 
al., 1997). The specific mechanism of release for an individual cytokine may 
even vary between cell types, with IL-1β having been found to be secreted in 
numerous different ways including exocytosis and cell lysis (Eder, 2009). 
A further essential macrophage function is that of phagocytosis (although this 
is a function shared by additional innate immune cell types including dendritic 
cells and neutrophils). Once a pathogen is recognised by a phagocytic cell, it 
is engulfed by a change in morphology of the cell membrane; this forms a 
phagosome, which is then internalised and fused with a lysosome containing 
enzymes capable of degrading the pathogen (Owen et al., 2013). Additional 
innate immune cell killing is carried out by NK cells, which insert granules 
containing cytotoxic substances into the cytoplasm of a target cell.  
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Macrophages and dendritic cells of the innate immune system, in addition to 
B lymphocytes of the adaptive immune system, also carry out an essential 
role as professional antigen presenting cells. Following internalisation of a 
specific antigen, these cells process a specific epitope of the antigen before 
presenting it to T lymphocytes in combination with the major 
histocompatibility complex (MHC) class II molecule (Owen et al., 2013) This 
allows T lymphocytes to begin directing the highly specific secondary 
immune response mediated by the adaptive immune system. 
 
Figure 1.8.  TLR signalling cascades. Following activation by LPS, TLR4 activates 
numerous intracellular signalling cascades, resulting in an increase in the transcription of 
proinflammatory genes. Reprinted from Nature Reviews Immunology, Vol. 13, “The history 
of Toll-like receptors — redefining innate immunity”, 453-460, O’Neill et al., ©2013, with 
permission from with permission from Nature Publishing Group. 
Chapter 1  Introduction   
62 
 
1.5.3 Innate immune signalling pathways 
Activation of innate immune cells typically occurs in response to pathogen-
associated molecular patterns (PAMPs), for example on LPS (Owen et al., 
2013). LPS is a component of the outer membrane of Gram-negative 
bacteria that is frequently used as an artificial experimental stimulus (Okun et 
al., 2009). PAMPs are identified by pathogen recognition receptors (PRRs) 
located on the cell membrane. One of the most important classes of PRRs is 
the toll-like receptors (TLRs), which form homo or heterodimers that are 
highly specific for particular PAMPs (Kumar et al., 2009). For example, LPS 
is detected by homodimers of TLR4. The end result of TLR activation is an 
upregulation in the expression of proinflammatory genes; this reaches a peak 
after approximately 4 h, although depending on the gene peak expression 
may occur anywhere from 2-8 h (Aung et al., 2006; Yamamoto et al., 2004).  
Once TLRs have bound their ligands, intracellular signalling cascades are 
activated via the cytoplasmic adaptor protein MyD88 (although MyD88-
independent cascades are also present) (Yamamoto et al., 2003). MyD88 
interacts with numerous signalling pathways (Fig. 1.8), including NFĸB and 
the ERK and p38 MAPKs (Akira and Takeda, 2004). Briefly, NFĸB signalling 
is activated by an interaction of MyD88 with IRAK, which activates the IĸB 
kinase (IKK) complex by phosphorylation. IKK then phosphorylates IĸB, the 
main cytoplasmic inhibitor of NFĸB; this causes IĸB to dissociate from NFĸB, 
which then translocates to the nucleus (Owen et al., 2013). The NFĸB family 
is made up of five members which form homo or heterodimeric transcription 
factors; RelA (p65), RelB, NFĸB1 (p50), NFĸB2 (p52) and c-Rel. They then 
regulate the expression of over 150 target genes (Akira and Takeda, 2004) 
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Additional signalling pathways are also activated through phosphorylation 
cascades, with an interaction of MyD88 with the TRAF6 protein causing an 
upregulation in MAPK signalling (Barton and Medzhitov, 2003). This leads to 
the induction of transcription factors including AP-1 and MYC, both of which 
contribute to the proinflammatory cellular response to LPS. It is important to 
note that these signalling pathways should not be viewed in isolation, as 
there is a great deal of crosstalk whereby one is able to influence the activity 
of the others (Hoesel and Schmid, 2013). There is also considerable overlap 
in the target genes that are regulated by each signalling pathway. 
1.6 The adaptive immune system 
1.6.1 Cells of the adaptive immune system 
The primary cell types of the adaptive immune system are T and B 
lymphocytes, which make up approximately 20-40 % of circulating white 
blood cells (Owen et al., 2013). They are so named because T lymphocytes 
mature in the thymus, while B lymphocytes mature in the bone marrow. 
While morphologically similar, T and B lymphocytes may be reliably 
distinguished by specific cell surface proteins; T lymphocytes express CD3, 
while B lymphocytes express CD19. Furthermore, they are distinct in their 
expression of either the T cell receptor (TCR) or the B cell receptor (BCR). 
These are highly antigen specific, and receptors with affinity for over a billion 
antigens are present in the normal lymphocyte population (Owen et al., 
2013). However, each individual lymphocyte will only express receptors for a 
single antigen; this is passed on to the daughter cells produced by division. 
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T lymphocytes subsets may be distinguished by their expression of 
additional cell surface proteins to the pan T cell marker CD3. The two most 
common subsets are CD4+ helper T (Th) lymphocytes, and CD8+ cytotoxic T 
lymphocytes (Owen et al., 2013). The Th lymphocyte population may be 
further divided up in a number of additional subsets, including Th1, Th2 and 
Th17 lymphocytes. Regulatory T lymphocytes (Treg) form an additional CD4+ 
population, although they are distinct from helper T lymphocytes. 
1.6.2 Functions of the adaptive immune system 
In contrast to the immediate action of the innate immune system, responses 
generated by the adaptive immune system often take up to five or six days to 
reach their peak (Owen et al., 2013). T lymphocytes are only able to 
recognise antigens that have been processed and presented in combination 
with an MHC molecule. Helper T lymphocytes primarily recognise antigens 
presented in combination with MHC class II, which is expressed on the 
surface of professional antigen-presenting cells (Owen et al., 2013). Once 
naïve CD4+ T lymphocytes have been presented with an antigen, they 
differentiate into one of a number of subsets. Th1 cells are primarily involved 
in the response to intracellular pathogens, and secrete a range of cytokines 
including IFNγ and IL-2; the main target cells of Th1 lymphocytes are 
macrophages and cytotoxic T lymphocytes (Owen et al., 2013). Th2 
lymphocytes primarily direct the immune response to extracellular pathogens 
via the release of cytokines including IL-4, IL-5 and IL-10, the main targets of 
which are B lymphocytes and granulocytes. 
Chapter 1  Introduction   
65 
 
In contrast, naïve CD8+ T lymphocytes primarily recognise antigens 
presented in combination with MHC class I, which is expressed on all 
nucleated cells. Following antigen presentation, they differentiate into mature 
cytotoxic T lymphocytes. Cytotoxic T lymphocytes act by inducing cell lysis 
through the release of cytotoxins such as granzymes; the simultaneous 
release of the pore-forming protein perforin allows these cytotoxins to enter 
the cytoplasm of the target cell (Owen et al., 2013). Further mechanisms 
include direct cell-cell interactions, including binding of Fas ligand to Fas. 
Additional effector functions are carried out by Th17 lymphocytes, which are 
characterised by their secretion of the proinflammatory cytokine IL-17, and 
are thought to play a key role in the immune response at mucosal surfaces 
(Owen et al., 2013). Treg lymphocytes are characterised by expression of the 
cell surface protein CD25, in addition to the transcription factor FoxP3. They 
are primarily anti-inflammatory in function, and are involved in the inhibition 
of immune activity, in addition to the avoidance of autoimmune responses 
that have not been prevented by alternative processes.  
B lymphocytes are responsible for antibody production, and express surface 
immunoglobulin (Ig) in the form of the BCR. Once the BCR has bound an 
antigen, it is internalised and presented to T lymphocytes in combination with 
MHC class II (Owen et al., 2013). Helper T lymphocytes then provide co-
stimulation with cytokines including IL-4, in addition to cell-cell interactions 
mediated via the B lymphocyte surface protein CD40. Some antigens are 
also able to induce T cell independent activation. After activation, B 
lymphocytes proliferate and differentiate into plasma cells, which produce 
Chapter 1  Introduction   
66 
 
vast quantities of antibody; these molecules direct pathogens for degradation 
by other immune cells, in addition to neutralising pathogens by direct binding.  
Both T and B lymphocytes are responsible for immunological memory. 
Following clearance of a pathogen, a proportion of T and B lymphocytes will 
become memory cells; these retain their specificity for a particular antigen, 
and are able to rapidly proliferate in response to it being encountered a 
second time (Owen et al., 2013). This results in a greatly enhanced 
secondary immune response and more rapid clearance of the pathogen. 
1.6.3 Adaptive immune signalling pathways 
There is considerable overlap between the pathways involved in innate and 
adaptive immune signalling, with the NFκB and MAPK pathways also known 
to play an important role in T lymphocytes (Owen et al., 2013). However, the 
mechanisms by which these signalling pathways are activated, and the effect 
they have on cellular function, may vary considerably. For example, NFκB 
activation in T lymphocytes primarily takes place in response to TCR instead 
of TLR signalling (Brownlie and Zamoyska, 2013). While TLR4 is expressed 
by T lymphocytes, its function is not fully understood, and it has even been 
suggested to have a repressive effect (González-Navajas et al., 2010). 
Furthermore, while NFκB is almost exclusively proinflammatory in myeloid 
cells, it has been suggested to have anti-inflammatory effects in T 
lymphocytes, with overexpression of NFκB1 in naïve CD4+ T lymphocytes 
leading to reduced expression of IL-2 (Kang et al., 1992). Additional 
signalling molecules such as the NFAT family of transcription factors are also 
heavily involved (Macian, 2005).  
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1.7 Immune dysfunction in HD 
1.7.1 Central immune dysfunction 
Inflammatory changes in the CNS, commonly referred to as 
neuroinflammation, have recently emerged as a crucial component in the 
pathogenesis of neurodegenerative diseases including Alzheimer’s disease 
and Parkinson’s disease (Björkqvist et al., 2009). Activated microglia 
accumulate in the post-mortem brains of HD patients of all disease stages 
(Sapp et al., 2001), while functional imaging studies have shown that 
microglia are abnormally activated even in the brains of premanifest HD 
gene carriers (Tai et al., 2007; Pavese et al., 2006); this activation correlates 
with neuronal loss, striatal dysfunction and disease severity. Abnormal 
microglial activation has also been demonstrated in the brains of R6/2 mice, 
demonstrating a common feature between species (Simmons et al., 2007).  
One of the key areas of debate has centred on whether this abnormal 
microglial activation is harmful or protective. While microglia are considered 
to be largely neuroprotective, it has been suggested that an increase in their 
activation could result in healthy neurons being removed accidentally as part 
of a ‘bystander effect’ (Brown and Neher, 2010). Production of inflammatory 
complement components has been found to be upregulated in striatal HD 
microglia (Singhrao et al., 1999), with significantly increased levels of striatal 
IL6, IL8, and TNF mRNA being demonstrated in HD post-mortem brain 
tissue (Björkqvist et al., 2008). Furthermore, wild-type glia have a protective 
effect on mHTT-expressing neurons in co-culture, while mHTT-expressing 
glial cells only serve to increase neuronal vulnerability (Shin et al., 2005). 
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The expression of mHTT in glial cells also exacerbates neurological 
symptoms in HD mice (Bradford et al., 2010).  
However, it must still be determined whether neuroinflammation is primarily a 
secondary response to neuronal pathology, or if mHTT has a cell-
autonomous effect on microglial function. A recent study using a murine HD 
microglial cell line has shown that mHTT directly promotes autonomous 
microglial activation, likely via a priming effect that increases proinflammatory 
gene expression (Crotti et al., 2014). This suggests that central inflammatory 
changes are likely to occur both in response to and independently of 
neuronal death and dysfunction. It is also important to consider the possibility 
of peripheral changes contributing to central pathology, as proinflammatory 
cytokines such as IL-6 have been shown to cross the blood-brain barrier. 
Indeed, peripheral immune cells may also infiltrate the CNS, although no 
changes in the HD blood-brain barrier have been described to date. 
1.7.2 Peripheral immune dysfunction 
Immune-related pathology in HD is not merely restricted to the CNS (Fig. 
1.9), and a wide range of peripheral immune abnormalities have been 
described in both HD patients and animal models of the disease (Ellrichmann 
et al., 2013). Proteomic profiling of HD patient plasma revealed a significant 
increase in the levels of proinflammatory mediators including IL-6 and 
complement components (Dalrymple et al., 2007), while further work showed 
that HD patients of all disease stages exhibit increased plasma levels of 
proinflammatory cytokines and chemokines (Björkqvist et al., 2008; Wild et 
al., 2011). Indeed, significant increases in IL-6 levels were detected up to 
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sixteen years before the predicted onset of motor symptoms. Interestingly, 
CSF levels of IL-6 and IL-8 were found to correlate strongly with these 
peripheral changes, while microglial activation has been shown to correlate 
with increased peripheral cytokine levels (Politis et al., 2015).  
Myeloid cells from HD patients of all disease stages express mHTT, the 
levels of which correlate with disease burden scores and caudate atrophy 
(Weiss et al., 2012). Functional investigation has revealed that they are 
hyper-reactive, producing significantly increased levels of proinflammatory 
cytokines including IL-8 and TNFα following stimulation with LPS (Träger et 
al., 2014). This effect was found to be reversible following HTT-lowering, 
suggesting it is due to a direct effect of mHTT expression. This hypothesis 
was confirmed by knocking an expanded CAG repeat into a monocyte cell 
line, as the transfected cells also produced significantly increased levels of 
IL-6 and TNFα following stimulation. Myeloid cells from HD mouse models 
further show increased cytokine production (Träger et al., 2015), suggesting 
a common HD immune signature even between species. Further functional 
investigation of HD patient myeloid cells revealed functional deficits when 
migrating to chemotactic stimuli and phagocytosing fluorescent beads 
(Träger et al., 2015; Kwan et al., 2012b). However, it is important to note that 
the majority of studies to date have only demonstrated phenotypic 
abnormalities in response to stimulation, and it remains unclear if HD 
myeloid cells are also abnormal in their basal, resting state.  
Furthermore, the vast majority of work to date has focused on the cells of the 
innate immune system, with very little information available on the adaptive 
immune system. T and B lymphocytes from HD patients express mHTT, the 
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levels of which correlate with disease burden scores (Weiss et al., 2012). 
Levels of the signature Th2 cytokine IL-4 are also increased in the plasma of 
manifest HD patients (Björkqvist et al., 2008). However, the same study 
found no difference in the levels of circulating Ig between HD patients and 
controls, arguing against any substantial dysregulation of the HD adaptive 
immune response. This is supported by a study finding no enrichment of T 
lymphocytes in post-mortem HD brain tissue (Silvestroni et al., 2009). In 
either case this evidence is largely circumstantial, and further investigation is 
required to characterise HD adaptive immunity. 
 
Figure 1.9.  Central and peripheral immune dysfunction in HD. Elevated levels of 
proinflammatory cytokines are detectable in both the CNS and peripheral blood of HD 
patients of all disease stages. This is likely related to a direct mHTT effect causing abnormal 
activation of the NFκB pathway in HD immune cells. Reprinted from The Journal of 
Experimental Medicine, Vol. 205, “A novel pathogenic pathway of immune activation 
detectable before clinical onset in Huntington's disease”, 1869-1877, Bjorkqvist et al., 
©2008, with permission from The Rockefeller University Press. 
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One of the most intriguing possibilities relates to the peripheral immune 
system as a potential modifier of HD progression. The CB2 receptor acts to 
suppress immune cell cytokine production by inhibiting NFĸB signalling, and 
genetic knockout of the CB2 receptor was found to produce earlier onset 
while worsening behavioural deficits in an HD mouse model (Palazuelos et 
al., 2009). Conversely, the administration of a CB2 agonist ameliorated 
motor deficits and CNS inflammation, in addition to extending the lifespan of 
HD mice (Bouchard et al., 2012). Interestingly, this effect was found to be 
ablated by the administration of a peripherally-restricted antagonist, 
suggesting that the improvements in disease phenotype were largely due to 
peripheral anti-inflammatory effects. Consistent with this hypothesis, the 
administration of an anti-inflammatory KMO inhibitor that does not cross the 
blood-brain barrier was found to extend life span, prevent synaptic loss and 
reduce microglial activation in HD mice (Zwilling et al., 2011). A further study 
found that inhibition of soluble TNFα is therapeutic in HD mice (Hsiao et al., 
2014), while bone marrow transplantation also offers modest benefits (Kwan 
et al., 2012a). These studies demonstrate that abnormal peripheral 
inflammatory processes have a disease-modifying effect on the CNS. 
1.7.3 Mechanisms of immune dysfunction 
As the study of peripheral immunity in HD is a relatively recent development, 
the majority of studies to date have focused on characterising phenotypic 
abnormalities at the expense of obtaining mechanistic insight (Träger et al., 
2014; Kwan et al., 2012b). There has been some progress in uncovering the 
mechanisms responsible, with gene expression profiling revealing a range of 
transcriptional changes in HD blood cells (Borovecki et al., 2005; Runne et 
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al., 2007; Mastrokolias et al., 2015). However, these studies have largely 
been done on heterogeneous cell populations and have rarely been 
validated between studies.  
Mutant HTT has been shown to have a profound effect on NFκB signalling 
via a direct interaction with IKK (Khoshnan et al., 2004). HD myeloid cells 
exhibit an abnormal NFĸB signalling response to LPS, both in the magnitude 
of the initial response and in the time taken for activation to return to baseline 
(Träger et al., 2014). This effect is associated with their hyper-reactive 
cytokine phenotype (Fig. 1.10). However, it is unclear whether HD myeloid 
cells also display abnormal NFĸB signalling in their basal, resting state. 
While some changes in unstimulated NFĸB related gene expression have 
been demonstrated using polymerase chain reaction (PCR) arrays (Träger et 
al., 2014), the small number of genes studied and lack of available 
mechanistic data means it is not yet possible to draw any firm conclusions.  
Furthermore, signalling downstream of the LPS receptor TLR4 is complex, 
and includes activation of numerous signalling pathways such as those 
involving the ERK and p38 MAPKs (Akira and Takeda, 2004). The 
involvement of these alternative signalling pathways in HD myeloid cell 
dysfunction is yet to be fully explored. One signalling mechanism which 
seems unlikely to be involved in mediating HD myeloid cell dysfunction is the 
JAK/STAT pathway, as a study found that JAK/STAT signalling is not 
significantly altered in human HD monocytes (Träger et al., 2013). 
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Figure 1.10.  Mechanisms of immune dysfunction in HD. Mutant HTT has been shown 
to interact with IKK, a key regulator of the NFκB family of transcription factors. This leads to 
increased nuclear translocation of NFκB and upregulated expression of proinflammatory 
genes. Mutant HTT has also been shown to bind directly to DNA, and these mechanisms 
are associated by hyper-reactivity in HD myeloid cells. Reprinted from Brain, Vol. 137, “HTT-
lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway 
dysregulation”, 819-833, Träger et al., ©2014, with permission from Oxford University Press. 
One of the key outstanding questions surrounding HD myeloid cell 
dysfunction centres around whether these cells are only abnormal in 
response to stimulation, or if they are also abnormal in their basal, resting 
state. Experiments on an HD murine microglial cell line found evidence of 
increased proinflammatory gene expression in the absence of stimulation 
(Crotti et al., 2014). This is likely mediated by a ‘priming’ effect of mHTT, 
whereby basal dysfunction leads to an exaggerated inflammatory response 
when a stimulus is encountered. This effect was found to be mediated by a 
cell-autonomous increase in the expression of myeloid lineage-determining 
factors such as PU.1. Perhaps surprisingly, the PU.1 effect was not 
replicated in patient monocytes (Crotti et al., 2014); this was suggested to be 
due to their different developmental origins. However, NFĸB binding motifs 
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were also found to be enriched in the murine microglial cell line, suggesting 
there is at least some overlap with peripheral HD myeloid cells.  
Regardless of the mechanisms involved, it remains to be seen if mHTT has a 
similar priming effect on peripheral myeloid cells; this is likely key to 
determining whether HD myeloid cells are also abnormal in their basal, 
resting state. This has important implications for targeting the peripheral 
immune system as a therapeutic for HD, as intrinsic pathology is more likely 
to be treatable without the need to time intervention to coincide with specific 
infective or inflammatory events.  
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1.8 Thesis aims 
1. To carry out the allele-selective suppression of mHTT in primary 
human myeloid cells, using siRNA targeted to three SNPs in the HTT 
transcript. 
2. To determine the effects of selectively suppressing wild-type and 
mHTT on the hyper-reactive cytokine phenotype of HD myeloid cells.  
3. To characterise the whole transcriptome of unstimulated and 
stimulated HD monocytes, in order to determine whether HD myeloid 
cells are also abnormal in the resting state. 
4. To identify intracellular signalling pathways that may be involved in 
mediating transcriptional dysregulation in HD myeloid cells. 
5. To determine whether the frequencies of immune cell subsets are 
altered between HD and control peripheral blood. 
6. To characterise the phenotype of human HD T lymphocytes, in order 
to determine whether HD immune dysfunction is universal or restricted 
to specific cell types. 
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2 Materials and methods 
2.1 Materials   
Primary human monocytes and monocyte-derived macrophages were 
cultured in Primaria™ cell culture plates and dishes (Thermo Fisher 
Scientific), while all other immune cell types were cultured in Corning Cell 
Culture plates (Sigma-Aldrich) unless stated otherwise. All other 
consumables used for tissue culture were bought from Thermo Fisher 
Scientific, including phosphate-buffered saline (PBS), RPMI 1640 media, 
foetal bovine serum (FBS), L-glutamine and penicillin/streptomycin. All 
laboratory chemicals were bought from Sigma-Aldrich unless stated 
otherwise. Recombinant granulocyte macrophage-colony stimulating factor 
(GM-CSF) and IFNγ were bought from R&D systems, while LPS was bought 
from Sigma-Aldrich. The same batch of LPS was used for all replicates within 
experiments to eliminate batch variability. All magnetic-activated cell sorting 
(MACS) components were bought from Miltenyi Biotec. Centrifuge tubes and 
96-well plates for adenosine 5’-triphosphate (ATP) and protein assays were 
bought from Greiner Bio-One. 
2.2 Human subjects 
2.2.1 Subject recruitment and classification 
All human experiments were performed in accordance with the Declaration of 
Helsinki and approved by the University College London (UCL)/UCL 
Hospitals Joint Research Ethics Committee (REC 03/N008). All subjects 
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provided informed written consent prior to sample donation. Blood samples 
were donated by genetically-diagnosed HD patients and age-matched 
control subjects, primarily recruited from the HD clinic at the National 
Hospital for Neurology and Neurosurgery, London. Additional blood samples 
were obtained through designated research study visits that were carried out 
at the Royal London Hospital for Integrated Medicine, or at Huntington’s 
Disease Association meetings in the community. Where necessary, further 
control subjects were recruited from staff and students at the UCL Institute of 
Neurology, in accordance with the study’s ethics approval. 
The UHDRS (Huntington Study Group, 1996) was used to classify 
premanifest HD mutation carriers by the absence of diagnostic motor 
abnormalities. The UHDRS comprises motor, cognitive, behavioural and 
functional assessments, with patients being rated from 0 (normal) to 4 
(severe dysfunction) for each category. Where motor abnormalities were 
present, manifest HD patients were classified by their TFC score (Shoulson, 
1981). The TFC scale is used to assess the ability of a patient to perform 
everyday tasks, working on a reducing score ranging from 13 (normal) to 0 
(severe disability). All manifest HD subjects who donated samples for the 
experiments presented in this thesis had a TFC of 13-3, corresponding to 
early (13-7) or moderate (6-3) stage disease. Potential subjects with 
inflammatory or infective conditions were excluded for all studies, as were 
subjects on immunomodulatory medications. Current smokers were also 
excluded for the RNA sequencing (RNA-Seq) experiments contained in 
Chapter 4, due to the profound effects of smoking on the monocyte 
transcriptome (Zeller et al., 2010). 
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2.2.2 SNP genotyping of human subjects 
Genotyping of human HD subjects for the HTT SNPs rs362331 (exon 50), 
rs362273 (exon 57) and rs362307 (3’-UTR) was carried out using FlashTaq 
2X Master Mix (Empirical Bioscience). Twenty-five µl FlashTaq 2X Master 
Mix, 2 µl 10 µM primers (final concentration 400 nM; Table 2.1) and 1-5 µl 
DNA template (total DNA < 250 ng) were combined and the reaction mix was 
made up to 50 µl with H2O. The thermal cycling conditions for the PCR were 
as follows: 95 °C for 15 min, followed by thirty-five cycles of 95 °C for 30 s, 
60 °C for 30 s and 72 °C for 30 s, followed by incubation at 72 °C for 5 min 
before quickly chilling on ice. 10 µl of the PCR reaction mix was then run on 
a 1.5 % agarose, 1X Tris-acetate-EDTA (TAE) gel at 100 V for 1 h to confirm 
the presence of a single specific band. The remaining 40 µl was sent for 
sequencing by GeneWiz, Inc. (South Plainfield, NJ) to determine SNP 
genotype. Separate PCR reactions were carried out in order to genotype 
each subject for the three SNPs of interest. Subjects who were heterozygous 
for at least one SNP were recruited for the allele-selective suppression 
experiments described in Chapter 3.  
Table 2.1.  Primers used for SNP genotyping of human subjects. 
Primer Sequence 
rs362331 
Forward GGG CAT TCT GTG ACT CGG TA 
Reverse GAT AGG AAC CCA CCG TTC AT 
rs362273 
Forward AGT GAC AAA TCC CCA AGA CC 
Reverse GAG CTT TTC TCC TGG GTG TG 
rs362307 
Forward GCT CTG CTC GCT CTC CAG 
Reverse GCA GAG ACA CGC ACG TTG 
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2.3 SNP linkage by circularization 
2.3.1 Sample preparation 
Heterozygous SNPs were linked to the wild-type and mutant HTT alleles 
using the SNP linkage by circularization (SLiC) technique (Fig. 2.1) (Liu et 
al., 2008). All PCR reactions in this protocol were carried out using TaKaRa 
LA Taq DNA Polymerase with GC Buffer (Clontech). RNA was extracted 
from peripheral blood mononuclear cell (PBMC) samples (Section 2.7.2) 
before cDNA was synthesised using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche). One µg RNA was mixed with 2 µl of 10 µM Oligo(dT) 
15 Primer (Promega), before the sample volume was made up to 13 µl with 
RNase-free H2O and the sample was incubated at 65 °C for 15 min. The 
sample was then mixed with 4 µl 5X First Strand Buffer, 2 µl dNTPs (10 mM 
of each), 0.5 µl Protector RNase Inhibitor and 0.5 µl Transcriptor Reverse 
Transcriptase before incubating at 55 °C for 90 min. Synthesis of full-length 
HTT cDNA was confirmed by amplifying a section of exon 1 containing the 
expanded CAG repeat, using the primers Exon 1 Forward and Exon 1 
Reverse (Table 2.2). One µl cDNA was mixed with 25 µl GC Buffer I, 2 µl of 
each 10 µM primer solution (final concentration 400 nM), 8 µl dNTPs, 0.5 µl 
LA Taq DNA Polymerase and 11.5 µl H2O. The following thermal cycling 
conditions were used: 98 °C for 3 min followed by thirty-two cycles of 98 °C 
for 30 s, 55 °C for 30 s and 72 °C for 2 min, followed by 72 °C for 5 min.  
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Figure 2.1.  Summary of the SLiC protocol. Circularization of cDNA is used to bring 
the target SNP into close proximity with the CAG repeat in exon 1 of the HTT gene. This 
allows a relatively short section of cDNA to be sequenced to determine SNP linkage with the 
wild-type and mutant HTT alleles. Reprinted from Nature Methods, Vol. 5, “Linking SNPs to 
CAG repeat length in Huntington's disease patients”, 951-953, Liu et al., ©2008, with 
permission from Nature Publishing Group.   
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Table 2.2.  Primers used for SNP linkage by circularization. 
Primer Sequence 
Exon 1 
Forward AAG GCC TTC GAG TCC CTC AAG TC 
Reverse CGG CTG AGG CAG CAG CGG CT 
Long Forward AGC TGA TGG GCG CCT TCG AGT CCC TCA AGT C 
Inverse Reverse CGG CTG AGG CAG CAG CGG CT 
Exon 50 
Long Reverse TGC ACT GCA GGC GCC TCC AGG ATG AAG TGC ACA C 
Inverse Forward CAG ATC CCG CTG AGT CTG GAT CTC C 
 
2.3.2 Long-range PCR 
Long-range PCR was performed using the primers Exon 1 Long Forward and 
Exon 50 Long Reverse (Table 2.2); each contained a KasI restriction site. 
One µl cDNA was mixed with 25 µl GC Buffer I, 2 µl of each 10 µM primer 
solution (final concentration 400 nM), 8 µl dNTPs, 0.5 µl LA Taq DNA 
Polymerase and 11.5 µl H2O. The following thermal cycling conditions were 
used: 98 °C for 3 min followed by thirty-eight cycles of 98 °C for 25 s, 55 °C 
for 15 s and 68 °C for 15 min, followed by 68 °C for 30 min. PCR products 
were analysed using a TAE 0.9 % agarose gel containing 0.3 µg/ml ethidium 
bromide at 150 V for 2 h. Bands of the expected molecular weight were 
excised and purified using the QIAquick® Gel Extraction Kit (QIAGEN).  
To purify the RNA, the gel slice was weighed in a microcentrifuge tube 
before 300 µl Buffer QG was added for every 100 mg of gel. The sample was 
incubated at 50 °C for 10 min, vortexing every 2 min to dissolve the gel. If the 
solution was orange or violet in colour after dissolving, 10 μl of 3 M sodium 
acetate (pH 5.0) was added; this turned the mixture yellow. One gel volume 
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of 100 % isopropanol was then added before transferring the sample to a 
QIAquick® spin column and centrifuging at 17,900 ×g for 1 min to bind the 
DNA sample to the membrane. The membrane was first washed with 500 µl 
Buffer QG by centrifuging at 17,900 ×g for 1 min, before a further wash with 
750 µl Buffer PE. The QIAquick® column was placed in a fresh 2 ml 
microcentrifuge tube before centrifuging at 17,900 ×g for 2 min to remove 
any residual wash buffer. The QIAquick® column was then transferred to a 
new 1.5 ml microcentrifuge tube and DNA was eluted by adding 30-50 µl 
Buffer EB to the membrane and centrifuging at 17,900 ×g for 1 min. 
2.3.3 KasI digestion and DNA ligation 
The gel-purified PCR products were digested using 10 U KasI in NEBuffer 2 
(New England Biolabs) by incubating at 37°C for 2 h (reaction volume 40 µl). 
The enzyme was inactivated by incubating at 65 °C for 20 min, before 
NEBuffer 2 was exchanged for H2O using the QIAquick® PCR Purification 
Kit. This was done by adding five volumes of Buffer PB to the reaction; if the 
solution was orange or violet in colour, 10 μl of 3 M sodium acetate (pH 5.0) 
was added to turn the mixture yellow. The sample was then transferred to a 
QIAquick® spin column and centrifuged at 17,900 ×g for 1 min to bind the 
DNA sample to the membrane. The membrane was washed with 750 µl 
Buffer PE by centrifuging at 17,900 ×g for 1 min, before the column was 
placed in a fresh 2 ml microcentrifuge tube and centrifuged at 17,900 ×g for 
2 min to remove any residual wash buffer. The column was then transferred 
to a new 1.5 ml microcentrifuge tube before the DNA was eluted by adding 
50 µl H2O directly to the membrane and centrifuging at 17,900 ×g for 1 min.  
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The KasI-digested DNA was then circularised using E. coli DNA Ligase in 1X 
E. coli DNA Ligase Reaction Buffer (New England Biolabs) by incubating at 
16 °C for 30 min (reaction volume 20 µl). The enzyme was inactivated by 
incubating at 65 °C for 20 min, before again exchanging the buffer for H2O 
using the QIAquick® PCR Purification Kit as described above. The ligated 
product was then digested using Exonuclease V in NEBuffer 4 (New England 
Biolabs) with 50 µM ATP by incubating at 37 °C for 3 h (reaction volume 20 
µl). The enzyme was inactivated by incubating at 65 °C for 20 min, before 
the product was used directly for inverse PCR. 
2.3.4 Inverse PCR and sequencing 
Inverse PCR to bring the SNP into close proximity with the CAG repeat was 
performed using the primers Exon 1 Inverse Reverse and Exon 50 Inverse 
Forward (Table 2.2). One µl circularised cDNA was mixed with 25 µl GC 
Buffer I, 2 µl of each 10 µM primer solution (final concentration 400 nM), 8 µl 
dNTPs, 0.5 µl LA Taq DNA Polymerase and 11.5 µl H2O. The following 
thermal cycling conditions were used: 98 °C for 3 min followed by thirty-two 
cycles of 98 °C for 30 s, 55 °C for 30 s and 72 °C for 2 min, followed by 72 
°C for 5 min. PCR products were analysed by gel electrophoresis using a 
TAE 1.8 % agarose gel containing 0.3 µg/ml ethidium bromide at 150 V for 
80 min. Bands corresponding to the correct alleles were then excised using a 
scalpel and purified using the QIAquick® Gel Extraction Kit as described 
above. DNA was eluted in RNase-free water before being sent for 
sequencing by GeneWiz, Inc. (South Plainfield, NJ) to determine SNP 
heterozygosity using the relevant Inverse Forward primer. 
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2.4 Tissue culture 
Culture of primary human immune cells was carried out in a Containment 
Level 2 laboratory using strict aseptic technique. A tissue culture hood with a 
laminar flow unit was used for all procedures, including preparation of culture 
media and reconstitution of reagents. All reagents and plasticware used for 
tissue culture were bought pre-sterilised and only opened once in the tissue 
culture hood. A water bath was used to warm media to 37 °C before use, 
while an incubator set to 37 °C with 5 % CO2 was used to culture all cells. 
2.4.1  Isolation of peripheral blood mononuclear cells 
PBMCs were isolated from human peripheral blood samples by density 
centrifugation. Twenty-five ml of blood was carefully layered on top of 20 ml 
sterile 100 % Histopaque-1077 solution (Sigma-Aldrich) in a 50 ml centrifuge 
tube. Where larger blood samples were taken this process was repeated 
until the entire sample was layered on top of Histopaque-1077 in separate 
centrifuge tubes. The samples were centrifuged at 400 ×g for 30 min with no 
brake on deceleration. The middle PBMC layer was then transferred into a 
fresh 50 ml tube using a sterile Pasteur pipette (Biosigma), before washing 
with PBS by centrifuging at 400 ×g for 15 min. After washing, the cells were 
resuspended in sterile MACS buffer (PBS with 1 % bovine serum albumin 
(BSA) and 2 mM EDTA) and counted using a Neubauer counting chamber. 
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2.4.2 Magnetic-activated cell sorting 
For experiments where a specific cell type was required, magnetic cell 
sorting was used to isolate the cells from among the PBMC population. After 
counting, the cells were pelleted at 400 ×g for 15 min before the supernatant 
was removed and the cells were resuspended in 10 µl microbeads (Miltenyi 
Biotec) and 40 µl MACS buffer per 107 cells. Anti-human CD14 microbeads 
were used to isolate monocytes, while anti-human CD4 microbeads were 
used to isolate helper T lymphocytes. After incubating for 15 min at 4 °C, the 
samples were centrifuged at 400 ×g for 5 min and resuspended in 500 µl 
MACS buffer. Magnetic cell sorting was carried out by placing MACS 
columns (Miltenyi Biotec) in a magnetic field and pre-washing with 500 µl 
MACS buffer, before adding each cell suspension to an individual column. 
Once the cell suspension had passed through, the columns were washed 
twice with 2 ml MACS buffer. Magnetically labelled cells were collected by 
removing the columns from the magnetic field and plunging 2 ml MACS 
buffer through the column twice using a plunger. Isolated monocytes and 
helper T lymphocytes were then counted using a Neubauer counting 
chamber before being seeded for downstream experiments. After sorting an 
aliquot of the isolated cell suspension was taken to check the purity of the 
sorted cell population by flow cytometry. On average, the sorted cell 
populations contained 85-95 % positively labelled cells (Fig. 2.2). 
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Figure 2.2.  Analysis of MACS sorting by flow cytometry.  (A) CD14+ monocytes and 
(B) CD4+ helper T lymphocytes were isolated from peripheral blood by MACS before the 
purity of the sorted cell populations was measured by flow cytometry. On average, the 
sorted cell populations contained 85-95 % positively labelled cells. 
2.4.3 Culture of primary human immune cells  
Primary human immune cells were cultured in R10 media (RPMI 1640 
supplemented with 10 % FBS, 2 mM L-glutamine, 50 units/ml penicillin and 
50 µg/ml streptomycin). Monocyte-derived macrophages were obtained by 
adding 20 ng/ml GM-CSF to the monocyte culture media for six days to 
induce differentiation prior to experimental use. The media was changed 
after three days to provide the cells with fresh media and GM-CSF for the 
final three days of the differentiation process. Monocytes treated with GM-
CSF exhibited a macrophage phenotype after six days in culture. 
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2.4.4 Stimulation of primary human T lymphocytes 
Stimulation of primary human T lymphocytes was carried out using plate-
bound functional grade anti-human CD3 antibody (eBioscience). Five µg/ml 
antibody diluted in sterile PBS was added to each culture well the day before 
sample collection and incubated at 4 °C for 24 h. Immediately prior to 
seeding the wells were washed with PBS to remove any unbound antibody. 
Two µg/ml functional grade anti-human CD28 antibody (eBioscience) was 
also added to the culture media on seeding to provide appropriate co-
stimulation. Alternative T lymphocyte stimulation using PHA-P was carried 
out by adding PHA-P (Sigma-Aldrich) directly to the culture media for a final 
concentration of 10 µg/ml when the cells were seeded. 
2.5 HTT-lowering in primary human myeloid cells 
2.5.1 Synthesis of glucan-encapsulated siRNA particles 
β-1,3-D-glucan-encapsulated siRNA particles (GeRPs) were synthesised 
according to previously published methodology (Soto et al., 2012). 
Saccharomyces cerevisiae (100 g of SAF-Mannan; SAF Agri) was added to 
1 L of 0.5 M NaOH and incubated at 80 °C for 1 h before the mixture was 
centrifuged at 5000 ×g for 20 min to collect the insoluble material containing 
the cell walls. The incubation and centrifugation steps were then repeated 
using this insoluble pellet, before washing three times each with 1 L H2O, 
then 200 ml 100 % propan-2-ol, then 200 ml 100 % acetone. The slurry was 
dried at room temperature to produce 16.2 g of fine, off-white powder.  
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Loading of siRNA into 107 glucan particles was performed by mixing the 
appropriate siRNA (Dharmacon; Table 2.3) with 40 µl sterile saline (Sigma-
Aldrich), 30 µl HEPES buffer (0.1 M, pH 7.5 in saline; Thermo Fisher 
Scientific) and 10 µl glucan particles (109 particles/ml in saline). This mixture 
was incubated for 2 h at room temperature in the dark. After incubation, 10 µl 
Endo-Porter (EP; diluted appropriately with saline; Gene Tools) was added 
and the mixture was incubated for 15 min at room temperature to trap the 
siRNA inside the glucan particles by complex formation (Tesz et al., 2011). 
The amount of siRNA and EP used for the loading reactions was varied 
depending on the concentration required in each GeRP. After loading, the 
GeRPs were added to single use aliquots and frozen at -80 °C. The loading 
reaction was scaled up proportionately if more GeRPs were required. 
2.5.2  Transfection of primary human myeloid cell cultures 
Primary human myeloid cells were isolated from peripheral blood samples by 
density centrifugation (Section 2.4.1) and MACS (Section 2.4.2), before 
seeding in Primaria™ plates and dishes at an experiment-dependent density. 
Monocytes were rested for 16 h after isolation before transfection with GeRP 
particles, while macrophages were transfected on day 3 of the differentiation 
protocol (when fresh GM-CSF was added by media change). GeRPs 
containing the appropriate siRNA were added to the cells at a 10:1 particle to 
cell ratio, before being removed after 24 h by a complete media change. 
Analysis of huntingtin mRNA and protein levels was carried out by harvesting 
the cells 72 h after GeRP treatment, while ATP assays (Section 2.6.1) took 
place 24 h after the GeRPs were added. 
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Table 2.3.  siRNA sequences used in HTT-lowering experiments. 
siRNA Strand Sequence 
SCR 
Guide 5’-pUUUCGAAGUACUCAGCGUGAG-3’ 
Passenger 5’-CACGCUGAGUACUUCGAACUU-3’ 
Anti-total HTT 
Guide 5’-pUUCAUCAGCUUUUCCAGGGUC-3’ 
Passenger 5’-CCCUGGAAAAGCUGAUGACGG-3’ 
rs362331 anti-C 
Guide 5’-pUUACACAGUGGAUGAGGGAGC-3’ 
Passenger 5’-UCCCUCAUCCACUGUGUACAC-3’ 
rs362331 anti-U 
Guide 5’-pGUACACAGUAGAUGAGGGAGC-3’ 
Passenger 5’-UCCCUCAUCUACUGUGUAAAC-3’ 
rs362273 anti-A  
Guide 5’-pUUUGAUUUGUAGCAGCAGCUU-3’ 
Passenger 5’-GCUGCUGCUACAAAUCAACCC-3’ 
rs362273 anti-G  
Guide 5’-pUUUGCUCUGCAGCAGCAGCUU-3’ 
Passenger 5’-GCUGCUGCUGCAGAGCAACCC-3' 
rs362307 anti-U (1) 
Guide 5’-pCACACGGGCACAGACUUCCAA-3’ 
Passenger 5’-GGAAGUCUGCGCCCGUGUUCC-3’ 
rs362307 anti-U (2) 
Guide 5’-pCACAAUGGCACAGACUUCCAA-3’ 
Passenger 5’-GGAAGUCUGUGCCAUUGUUCC-3’ 
 
2.6 Analysis of immune cell function 
2.6.1 ATP assays 
Cellular ATP levels were analysed using the CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega). Prior to use the CellTiter-Glo® Buffer and 
Substrate were thawed and equilibrated to room temperature. After the Cell-
Titer-Glo® Buffer had thawed it was transferred into the Substrate bottle to 
reconstitute the lyophilised enzyme/substrate mixture; this forms the 
CellTiter-Glo® Reagent, which was mixed to obtain a homogenous solution. 
Cells populations to be analysed were cultured at 1 × 105 cells per well in 96-
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well plates; experimental cultures were changed to 100 µl fresh R10 media 
prior to analysis, while control wells containing media without cells were also 
prepared to obtain a measurement for background luminescence. After 
culture the plate and its contents were equilibrated at room temperature for 
30 min, before 100 µl CellTiter-Glo® Reagent was added to each well. The 
plate was placed on a shaker for 2 min to induce cell lysis, after which it was 
incubated at room temperature for 10 min to stabilise the luminescent signal. 
The contents of the plate were then transferred to a fresh opaque-walled 
white 96-well plate (Greiner Bio-One), before luminescence was measured 
using an Infinite® 200 PRO microplate reader (Tecan). The results were 
analysed by setting one condition as standard and converting the sample 
readings to a percentage of its ATP levels using Excel (Microsoft). 
2.6.2 Myeloid cell cytokine profiling 
Primary human monocytes were isolated from peripheral blood samples and 
seeded at 1 × 105 cells per well in 96-well plates, before being differentiated 
into macrophages (Section 2.4.3) and treated with GeRPs (Section 2.5.2). 
On day 6 of the differentiation protocol (72 hours after GeRP treatment), 
stimulation was carried out by media changing to fresh media containing 2 
µg/ml LPS and 10 ng/ml IFNγ. After 24 h the supernatants were collected 
and frozen at -80 °C, before the cells were washed once with sterile PBS and 
lysed in 60 µl radioimmunoprecipitation assay (RIPA) buffer (Section 2.11.1) 
to provide protein values for cytokine normalisation using bicinchoninic acid 
(BCA) assays (Section 2.11.2). The supernatants were then analysed using 
multiplex Meso Scale Discovery (MSD) cytokine assays (Section 2.12.2). 
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2.6.3 T lymphocyte cytokine profiling 
Primary human helper T lymphocytes were isolated from peripheral blood 
samples and seeded at 1 × 105 cells per well in 96 well plates pre-treated 
with anti-human CD3 functional grade antibody (Section 2.4.4). Unstimulated 
samples were collected by seeding T lymphocytes in wells that were not pre-
treated with antibody. After 48 h the supernatants were collected and frozen 
at -80 °C, before the cells were washed once with sterile PBS and lysed in 
60 µl RIPA buffer (Section 2.11.1) to provide protein values for cytokine 
normalisation using BCA assays (Section 2.11.2). The supernatants were 
analysed using multiplex MSD cytokine assays (Section 2.12.2). 
2.6.4 T lymphocyte proliferation assays 
T lymphocyte proliferation assays were carried out using the intracellular dye 
carboxyfluorescein succinimidyl ester (CFSE). CFSE binds covalently to 
intracellular molecules, producing a highly stable fluorescent signal that is 
split equally between the daughter cells produced when a cell divides (Quah 
et al., 2007). This allows the profiling of cell division as a sequential halving 
of fluorescence intensity on flow cytometry, up to a maximum of 
approximately seven divisions. PBMCs were isolated from peripheral blood 
samples (Section 2.4.1), before being counted using a Neubauer counting 
chamber and resuspended at 1 × 107 cells per ml of PBS with 5 % FBS to 
buffer against the toxic effects of CFSE. CFSE (eBioscience) was added to 
the cell suspension for a final concentration of 5 µM, before the sample was 
mixed vigorously and incubated for 10 min at room temperature in the dark. 
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Labelling was stopped by adding four volumes of cold RPMI media with 10 % 
FBS and incubating for 5 min on ice.  
After labelling the PBMCs were seeded at 5 × 105 cells per well in 48 well 
plates, and were either left unstimulated, stimulated with anti-human CD3 
and anti-human CD28 antibodies, or stimulated with PHA-P (Section 2.4.4). 
Unstained cells were also seeded to provide appropriate compensation 
controls for flow cytometry. Cell cultures were harvested after 72, 96 and 120 
h and transferred to 1.5 ml Eppendorf tubes. The cells were then washed 
twice with PBS by centrifuging at 400 ×g for 5 min before resuspending in 1 
ml PBS containing 1 µl Fixable Viability Dye 660 (eBioscience) to label non-
viable cells. This suspension was vortexed briefly before incubating for 30 
min at 4 °C in the dark. The cells were then washed twice with FACS buffer 
(PBS with 1 % BSA and 0.02 % sodium azide) before being fixed with 200 µl 
PBS containing 4 % paraformaldehyde (PFA) for 10 min, stained with 
antibodies to the appropriate cell surface markers (Section 2.13.1) and 
analysed by flow cytometry (Section 2.13.3). 
2.7 Quantitative polymerase chain reaction 
2.7.1 RNeasy Mini Kit RNA isolation 
RNA for all experiments except SLiC (Section 2.3) was isolated using the 
RNeasy Mini Kit (QIAGEN). Cells were lysed in Buffer RLT (350 µl for < 5 × 
106 cells, 600 µl for ≤ 1 × 107 cells) before an equal volume of 70 % ethanol 
(diluted in ddH2O) was added to precipitate the RNA. Samples were then 
added to RNeasy spin columns and centrifuged at 8,000 ×g for 15 s to bind 
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the RNA to the column membrane. The columns were washed once with 350 
µl Buffer RW1 by centrifuging at 8,000 ×g for 15 s, before RNase-free DNase 
solution (QIAGEN) was made up by adding 70 µl Buffer RDD to 10 µl DNase 
I stock solution (reconstituted in ddH2O). 80 µl of this solution was added 
directly to the column membrane and the samples were incubated for 15 min 
at room temperature to digest genomic DNA. The columns were then 
washed again with 350 µl Buffer RW1, before being washed twice with 500 
µl Buffer RPE by centrifuging at 8,000 ×g for 15 s and 2 min respectively. 
The columns were then dried by centrifuging at 8,000 ×g for 1 min, before 
the RNA was eluted by adding 15-50 µl RNase-free water directly to the 
column membrane and centrifuging at 8,000 ×g for 1 min. If higher 
concentrations of RNA were required, the RNA elution was re-added to the 
column membrane and centrifuged again. The RNA concentration in each 
sample was measured using an ND-1000 Spectrophotometer (NanoDrop). 
RNA was stored at -80 °C. 
2.7.2 TRIzol® RNA isolation 
RNA for SLiC (Section 2.3) was isolated using the TRIzol® (Thermo Fisher 
Scientific) method. PBMC pellets were isolated from peripheral blood 
samples (Section 2.4.1) and lysed in 1 ml TRIzol® Reagent by vortexing 
briefly. The sample was incubated at room temperature for 10 min before 
transferring to a microcentrifuge tube and adding 200 µl chloroform. The tube 
was then shaken vigorously by hand for 15 s before incubating at room 
temperature for 2 min and centrifuging at 12,000 ×g for 15 min at 4 °C. After 
centrifuging, the upper aqueous phase of the sample was removed by 
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angling the tube to 45 ° and pipetting the solution out. The aqueous phase 
was then added to a fresh microcentrifuge tube and mixed with 0.5 ml 100 % 
isopropanol per 1 ml TRIzol® Reagent used for cell lysis. After incubating at 
room temperature for 10 min this mixture was centrifuged at 12,000 ×g for 10 
min at 4 °C; the supernatant was then removed, leaving only the RNA pellet. 
The pellet was washed with 1 ml 75 % ethanol before vortexing briefly, 
centrifuging at 7,500 ×g for 5 min and discarding the wash. After washing, 
the microcentrifuge tube was left with the lid open for 5-10 min to allow the 
pellet to dry. The pellet was then resuspended in 20-50 µl Tris-EDTA (TE) 
Buffer by pipetting up and down and incubating in a heat block set at 55 °C 
for 10-15 min. Finally, the RNA concentration was measured using an ND-
1000 Spectrophotometer. RNA was stored at -80 °C. 
2.7.3 RNA quality control 
Confirmation of RNA integrity prior to RNA-Seq (Section 2.8) and PCR 
arrays (Section 2.9) was carried out using the 2100 Bioanalyzer system with 
the RNA 6000 Nano Kit (Agilent). This uses electrophoresis to analyse the 
integrity of the ribosomal S18 and S28 RNA molecules; samples with non-
degraded RNA will give a separate, clear band for each RNA molecule (Fig. 
2.3). This effect is quantified using the RNA Integrity Number (RIN). 
RNA analysis was carried out by adding 550 µl RNA 6000 Nano Gel Matrix 
(Agilent) to a Safe-Lock Eppendorf Tube with a Spin Filter and centrifuging at 
1,500 ×g for 10 min. After centrifuging, 1 µl of RNA Nano Dye Concentrate 
was added to 65 µl of the filtered gel. This mixture was vortexed thoroughly 
before centrifuging at 13,000 ×g for 10 min. An RNA 6000 Nano chip was 
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then placed on the chip priming station of the 2100 Bioanalyzer system and 9 
µl of the gel-dye mix was added to well G of the chip. The system was 
pressurised using a syringe, before waiting for exactly 30 s and releasing the 
pressure; 9 µl of gel-dye mix was then added to the two wells directly above 
well G. Next, 5 µl of RNA 6000 Nano Marker was added to the well labelled 
with the ladder marker, in addition to all twelve of the sample wells. As each 
well of the chip is read separately, the RNA 6000 Nano Marker allows all of 
the electrophoresis reactions to be aligned correctly. Finally, 1 µl of sample 
was added to each of the twelve sample wells, while 1 µl of Agilent RNA 
6000 Ladder was added to the well with the ladder marker. The chip was 
mixed by vortexing for 1 min before running on the Agilent 2100 Bioanalyzer 
system with 2100 Expert Software (Agilent). Each trace was inspected 
individually to confirm RNA integrity prior to use in downstream applications. 
 
Figure 2.3.  Example of RNA analysis using the Bioanalyzer system. RNA integrity 
was assessed using the 2100 Bioanalyzer system with the RNA 6000 Nano Kit. High quality 
RNA produces (A) two clear bands on the electrophoresis gel and (B) two clear peaks on 
flow cytometry for each of the ribosomal S18 and S28 RNA molecules. FU = fluorescent 
units. Nt = nucleotides. 
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2.7.4 Reverse transcription of RNA to cDNA 
SuperScript II Reverse Transcriptase (Thermo Fisher Scientific) was used to 
reverse transcribe RNA to cDNA. 100-200 ng RNA was diluted in 10 µl 
RNase-free water before 1 µl random primers (3 µg/µl) and 1 µl dNTPs (10 
mM of each) (both Thermo Fisher Scientific) were added. The mix was 
heated to 65 °C for 5 min and briefly incubated on ice before adding 4 µl 5X 
First-Strand Buffer, 2 µl 0.1 M DTT and 1 µl RNaseOUT Recombinant 
Ribonuclease Inhibitor (40 units/µl) (all Thermo Fisher Scientific). One µl 
(200 units) SuperScript II Reverse Transcriptase was then added after 
incubating at room temperature for 2 min. Reverse transcription was carried 
out by incubating the reaction mix at 25 °C for 10 min, followed by 42 °C for 
50 min. The reaction was terminated by incubating at 70 °C for 15 min, 
before cDNA was diluted to a concentration of 5 ng/µl and stored at -20 °C. 
2.7.5 SYBR® Green quantitative PCR 
SYBR® Green PCR Master Mix (Thermo Fisher Scientific) was used for 
quantitative PCR (qPCR) analysis of mRNA expression. First, 12.5 µl 
SYBR® Green PCR Master Mix, 10.75 µl H2O, 0.75 µl of 10 µM primers 
solution (final concentration 300 nM; Table 2.4) and 1 µl (5 ng) cDNA were 
mixed in MicroAmp Fast Optical 96-Well Reaction Plates (Thermo Fisher 
Scientific) to give a final reaction volume of 25 µl. The plates were covered 
with MicroAmp Optical Adhesive Film (Thermo Fisher Scientific) and 
centrifuged at 300 ×g for 10 s to collect the reaction mix at the bottom of 
each well, before being run on a 7500 Fast Real-Time PCR System (Thermo 
Fisher Scientific) using 7500 software. The following PCR cycling conditions 
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were used: 95 °C for 10 min, followed by forty cycles of 95 °C for 15 s and 60 
°C for 1 min. A melting curve of 60-95 °C was also run when new primers 
were tested to exclude the possibility of primer-dimer formation. All reactions 
were run in either duplicate or triplicate and outliers were excluded were 
appropriate. Endogenous reference genes (ACTB, B2M and GAPDH) were 
also run in order to normalise the cycle threshold (Ct) values of genes of 
interest between samples. 
Table 2.4.  Primers used for SYBR® green qPCR experiments. 
Primer Sequence 
ACTB 
Forward AAG GCC AAC CGT GAA AAG AT 
Reverse GTG GTA CGA CCA GAG GCA TAC 
B2M 
Forward GAA TTC ACC CCC ACT GAA AA 
Reverse CCT CCA TGA TGC TGC TTA CA 
CSF2 
Forward GCG TCT CCT GAA CCT GAG TA 
Reverse CCT GGA GGT CAA ACA TTT CTG A 
GAPDH 
Forward AAC AGC GAC ACC CAC TCC T 
Reverse CAT ACC AGG AAA TGA GCT TGA CAA 
HTT 
Forward AGT GAT TGT TGC TAT GGA GCG G 
Reverse GCT GCT GGT TGG ACA GAA ACT C 
IL19 
Forward TCT ACG TGG ACA GGG TGT TC 
Reverse CTG ACA TTG CCG CAG AGT TT 
IL23A 
Forward CCA AGG ACT CAG GGA CAA CA 
Reverse CCG ATC CTA GCA GCT TCT CA 
IL6 
Forward TAC CCC CAG GAG AAG ATT CC 
Reverse AGT GCC TCT TTG CTG CTT TC 
TYRO3 
Forward CCC CTT TAA CCT ACC CCT CC 
Reverse CAG GTC TCG GTG GAT GAA GT 
VEGFA 
Forward CAG ATT ATG CGG ATC AAA CCT C 
Reverse CCT TTC CCT TTC CTC GAA CTG 
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2.7.6 TaqMan® quantitative PCR 
TaqMan® Gene Expression Master Mix (Thermo Fisher Scientific) was used 
for the analysis of allele-specific HTT expression. Custom TaqMan® probes 
(Thermo Fisher Scientific) were designed for each allele of the HTT SNPs 
rs362331 (exon 50), rs362273 (exon 57) and rs362307 (3’-UTR). First, 12.5 
µl TaqMan® Gene Expression Master Mix, 0.75 µl of 5 µM probe solution for 
each SNP allele (final concentration 150 nM; Table 2.5), 1.25 µl of 10 µM 
primers solution (final concentration 500 nM; Table 2.6), 8.75 µl H20 and 1 µl 
(5 ng) cDNA were mixed in MicroAmp Fast Optical 96-Well Reaction Plates 
(Thermo Fisher Scientific) to give a final reaction volume of 25 µl. The plates 
were covered with MicroAmp Optical Adhesive Film (Thermo Fisher 
Scientific) and centrifuged at 300 ×g for 10 s to collect the reaction mix at the 
bottom of each well, before being run on a 7500 Fast Real-Time PCR 
System (Thermo Fisher Scientific) using 7500 software. The following PCR 
cycling conditions were used: 50 °C for 2 min and 95 °C for 10 min followed 
by forty cycles of 95 °C for 15 s and either 65 °C (for rs362331 and 
rs362273) or 67.5 °C (for rs362307) for 1 min. All reactions were run in either 
duplicate or triplicate and outliers were excluded where appropriate. Each 
sample was also analysed using Human ACTB (Beta Actin) Endogenous 
Control (FAM/MGB probe, non-primer limited) and Human GAPD (GAPDH) 
Endogenous Control (FAM/MGB probe, non-primer limited) mixes (Thermo 
Fisher Scientific) in order to normalise the Ct values of the SNP alleles 
between samples. 
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Table 2.5.  Probes used for TaqMan® qPCR experiments. 
Probe 5’-Dye 3’-Quencher Sequence 
rs362331 C 6-FAM MGBNFQ TCC CTC ATC CAC TGT GTG C 
rs362331 T 6-FAM MGBNFQ TCC CTC ATC TAC TGT GTG C 
rs362331 T VIC MGBNFQ TCC CTC ATC TAC TGT GTG C 
rs362273 A 6-FAM MGBNFQ GCT GCT GCT ACA GAT CAA C 
rs362273 G VIC MGBNFQ GCT GCT GCT GCA GAT CAA C 
rs362307 C 6-FAM MGBNFQ TGG AAG TCT GCG CCC TTG TG 
rs362307 T VIC MGBNFQ TGG AAG TCT GTG CCC TTG TG 
 
Table 2.6.  Primers used for TaqMan® qPCR experiments. 
Primer Sequence 
rs362331 
Forward CTG GAG CGT GGT CTC CTC CAC A 
Reverse GTG TGT TTG GAT CTA CTT CCT CC 
rs362273 
Forward CTA CTA CAG GTG CCC TCA TCA G 
Reverse GTG ACG AAG GTG CAG GGG CG TC 
rs362307 
Forward ATG GTG GGA GAG ACT GTG AGG C 
Reverse ATG GCA GAG ACA CGC ACG TTG C 
 
2.7.7 Analysis of quantitative PCR data 
Quantitative PCR data was analysed using 7500 software. The 7500 
software was used to determine the baseline and Ct values of each sample, 
before the Ct value of each gene of interest was normalised by subtracting 
the mean Ct value of the reference genes for the same sample. Relative 
gene expression was then calculated by setting one condition as standard 
and using the following formula: 
Relative gene expression = 2delta Ct (sample 1 – sample 2) 
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Delta Ct is defined as the expression of the gene of interest, normalised to 
that of the mean of the reference genes. When analysing allele-specific 
qPCR each SNP allele was analysed independently. 
2.8 RNA sequencing 
Primary human monocytes were isolated from peripheral blood and seeded 
at 5.0 × 106 cells per dish in two 60 mm Primaria™ dishes (Section 2.4). 
After resting for 16 h the cells were either left unstimulated or stimulated with 
2 µg/ml LPS and 10 ng/ml IFNγ. Stimulation was carried out for 4 h, as this 
has previously been shown to be the peak time point for TLR4-mediated 
gene activation following LPS stimulation (Aung et al., 2006; Yamamoto et 
al., 2004). The cells were then harvested before RNA was extracted (Section 
2.7.1) and its integrity was assessed by 2100 Bioanalyzer (Section 2.7.3); 
only samples with non-degraded RNA were used for sequencing. 
Sequencing of RNA samples was performed by deCODE Genetics, Iceland. 
Preparation of indexed cDNA sequencing libraries was carried out using the 
TruSeq™ poly-A mRNA method (Illumina). Briefly, poly-A mRNA transcripts 
were captured from total RNA using poly-T beads, before cDNA was 
generated using random hexamer priming. Paired-end sequencing (2 × 100 
cycles) of indexed cDNA libraries was then carried out on a HiSeq 2500 
Sequencing System (Illumina), generating at least 50 million reads (101 base 
pairs) per sample. Sequencing was performed using v4 SBS and Cluster Kits 
(Illumina). One sample failed the library generation step and was excluded 
from the study. After sequencing the indexed samples were demultiplexed 
before generation of FASTQ files for analysis. Raw data files are available 
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from the European Nucleotide Archive (http://www.ebi.ac.uk/ena) under the 
study accession number PRJEB12995.  
2.9 Human Th1 & Th2 Responses RT2 PCR Arrays 
2.9.1 Sample collection 
PCR arrays were carried out on primary human CD4+ helper T lymphocytes 
that were isolated from peripheral blood samples and seeded at 3 × 106 cells 
per well in Primaria™ 6 well plates (Section 2.4). Cells were either left 
unstimulated or stimulated with functional grade anti-human CD3 antibodies 
for 8 h (Section 2.4.4), before the cells were harvested and RNA was 
extracted (Section 2.7.1). RNA integrity was assessed using the 2100 
Bioanalyser (Section 2.7.3); only samples with non-degraded RNA were 
used for PCR arrays. 
2.9.2 Reverse transcription 
Reverse transcription for PCR arrays was carried out using the RT2 First 
Strand Kit (QIAGEN). Six hundred ng RNA was diluted in 8 µl RNase-free 
water, before 2 µl GE buffer was added and the mixture was incubated at 42 
°C for 5 min. After incubation the reaction mix was quickly chilled on ice 
before 4 µl 5X Buffer BC3, 3 µl RNase-free water, 2 µl RE3 Reverse 
Transcriptase Mix and 1 µl Control P2 were added. The mixture was then 
incubated at 42 °C for 15 min before the reaction was terminated by 
incubating at 95 °C for 5 min. Ninety-one µl RNase-free water was then 
added to the cDNA solution, which was frozen at -20 °C prior to analysis. 
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2.9.3 PCR arrays 
The PCR reaction mix was made by adding 1350 µl 2X RT2 SYBR® Green 
PCR Master Mix (QIAGEN) and 1248 µl RNase-free water to each cDNA 
sample and mixing thoroughly. The reaction mix was then transferred to a 
sterile reservoir and 25 µl was added to each well of the primer coated PCR 
array plates using a multichannel pipette. Reverse pipetting was used to 
ensure a consistent volume of reaction mix was added to each well. The 
plates were covered with MicroAmp Optical Adhesive Film (Thermo Fisher 
Scientific) before centrifuging at 300 ×g for 10 s to collect the reaction mix at 
the bottom of each well.  The plates were then run on a 7500 Fast Real-Time 
PCR System (Thermo Fisher Scientific) using 7500 software. The following 
PCR cycling conditions were used: 95 °C for 10 min followed by forty cycles 
of 95 °C for 15 s and 60 °C for 1 min. Each plate was also analysed using a 
melting curve of 60-95 °C to exclude primer-dimer formation. 
The Human Th1 & Th2 Responses RT2 Profiler PCR Array plate (QIAGEN) 
contained wells for eighty-four genes of interest and five reference genes 
(ACTB, B2M, GAPDH, HRPT1 and RPLP0), in addition to seven quality 
control (QC) wells (one for human genomic DNA contamination, three 
reverse transcription controls and three positive PCR controls). Plates were 
excluded from the final analysis if the Ct value for genomic DNA was < 35. 
2.9.4 Data analysis 
PCR array data was analysed using 7500 software. Prior to analysis a 
consistent threshold value was set for each gene to ensure consistency 
between plates, before the Ct and baseline values for each sample were 
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determined by the 7500 software. Data analysis was carried out using the 
online data analysis tool provided by the manufacturer 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). This was 
done to calculate relative gene expression by setting one condition as 
standard and using the following formula: 
Relative gene expression = 2delta Ct (sample 1 – sample 2) 
Delta Ct is defined as the expression of the gene of interest, normalised to 
that of the mean of the five reference genes. Genes with an average Ct value 
of > 35 were excluded from the final results. Fold changes were then 
calculated by dividing the mean relative gene expression of the HD samples 
by the mean relative gene expression of the control samples. 
2.10 Bioinformatic analysis 
2.10.1 RNA-Seq data processing and expression analysis 
Data QC was performed using the java program RNA-SeQC (DeLuca et al., 
2012). Metrics including mapping rate, concordance mapping rate, 
uniqueness rate and rRNA rate were determined to confirm that they were 
within acceptable parameters. Four samples failed QC and were removed 
from further analysis. After QC the remaining samples were aligned using 
TopHat2 software (Kim et al., 2013), before the read counts were 
summarised using HTSeq (keeping any read duplicates). Differential 
expression analysis was then carried out using the R package DESeq2 
(Love et al., 2014). Outlier counts were removed using a Cooks distance cut-
off of 5 in DESeq2 packages. Gender was also included as a covariate in the 
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analysis. Differential splicing analysis was carried out on the aligned datasets 
using the R package Ballgown (Frazee et al., 2015); this was done to 
analyse differential exon, intron and transcript expression. 
2.10.2 Gene Set Enrichment Analysis 
Enrichment of differential expression among functional gene sets 
corresponding to biological hypotheses (pathways) was tested using the 
Gene Set Enrichment Analysis (GSEA) method (Subramanian et al., 2005). 
Rather than defining a list of significant genes, GSEA ranks all genes 
included in a sequencing experiment in order of their differential expression 
statistic, before testing whether the genes in a particular gene set or pathway 
have a higher rank overall than would be expected by chance (i.e. whether a 
functional gene set is significantly enriched in the dataset). The analysis is 
weighted by the differential expression statistic, thus giving more weight to 
more significant genes. Significance of enrichment was obtained by 
randomly permuting gene-wide association statistics among genes; this is 
quantified by the normalised enrichment score (NES). One-sided p-values 
were calculated separately for differential upregulation and downregulation of 
expression in HD, and these were then converted into the corresponding chi-
square statistic for use in the GSEA analysis. To avoid making a priori 
assumptions, a large pathway set comprising Gene Ontology (GO) (Harris et 
al., 2004), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et 
al., 2012), Mouse Genome Informatics (MGI) (Bult et al., 2008), Reactome 
(Croft et al., 2014), PANTHER v8.1 (Mi et al., 2013), Biocarta and 
NCIpathway interaction database (Schaefer et al., 2009) pathways was 
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used. This resulted in a total of 14,243 functional gene sets, many with 
overlapping members, containing between 3 and 500 genes. To correct for 
multiple testing, the GSEA p-values were converted into q-values (Storey 
and Tibshirani, 2003), which can be interpreted as the minimum false 
discovery rate (FDR) at which that q-value would be counted as significant. 
2.10.3 Upstream regulator analysis 
Upstream regulator analysis was carried out using Ingenuity Pathway 
Analysis® (IPA®) software (QIAGEN). IPA® is used to identify potential 
upstream regulators of transcriptional change in an expression dataset; an 
upstream regulator is defined as any molecule that has a downstream effect 
on gene expression. This analysis is quantified using the p-value of overlap 
and activation z-score statistics. The p-value of overlap statistic uses Fisher’s 
exact test to determine whether there is statistically significant overlap 
between gene expression changes in a dataset and the genes that are 
affected by a specific transcriptional regulator; significance is attributed to 
regulators with a p-value of overlap of < 0.01. However, this does not take 
the direction of the expression changes into account (i.e. whether the 
relevant genes are upregulated or downregulated), so the activation z-score 
is used to predict whether potential upstream regulators are likely to be 
abnormally activated or inhibited in the dataset. An activation z-score of ≥ 2 
or ≤ -2 is generally considered to be significant. Further information on the 
activation z-score statistic is available at http://www.ingenuity.com/. A p-
value cut-off of 0.01 was used to determine which differentially expressed 
genes from the RNA-Seq dataset were included in the analysis. 
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2.11 Protein analysis 
2.11.1 Protein isolation 
RIPA buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 % NP-40, 1 % 
sodium deoxycholate, 0.1 % sodium dodecyl sulfate (SDS)) containing one 
cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail Tablet (Roche) per 
10 ml buffer was used to lyse cells for protein isolation. The culture media 
was removed and the cells were washed once with sterile PBS to remove 
exogenous protein, before adding the appropriate volume of RIPA buffer 
directly to the culture well. Lysis was then induced by shaking the cell culture 
plate for 10 min at 4 °C. Lysates were stored at -80 °C. 
2.11.2 BCA protein assay 
The Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) was used to 
quantify the amount of protein in a sample. Prior to analysis the cell lysates 
were diluted appropriately with RIPA buffer depending on total cell number, 
while BSA standards were diluted in RIPA buffer according to the 
manufacturer’s instructions. Twenty-five µl of each standard and lysate was 
added to separate wells of a clear 96-well plate (Greiner Bio-One), before 
200 µl of working solution (made up of a fifty to one ratio of BCA Reagent A 
and BCA Reagent B) was added to each well. Each sample was analysed in 
duplicate. The plate was then incubated at 37 °C for 30 min, after which a 
Tecan Sunrise Reader (Tecan) was used to measure the absorbance signal 
intensity at 562 nm using XFluor™ software (Tecan). Analysis was carried 
out by using the BSA standards to create a standard curve for comparison. 
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2.11.3 Time-resolved Förster resonance energy transfer 
assay 
Cellular levels of total and mHTT protein were analysed using a Time-
resolved Förster resonance energy transfer (TR-FRET) assay. To perform 
the assay, cells were lysed in PBS with 1 % Triton X-100 and a cOmplete™, 
Mini, EDTA-free Protease Inhibitor Cocktail Tablet; 100 µl lysis buffer was 
used per 106 cells. Next, 5 µl of lysate was added to a white 384-well 
microtiter plate (Greiner) and mixed with 1 µl detection buffer (50 mM 
NaH2PO4, 400 mM NaF, 0.1 % BSA and 0.05 % Tween with antibody). 
Soluble total HTT was detected using 1 ng 2B7-Tb and 10 ng 2166-Alexa 
Fluor® 488 antibodies, while soluble mHTT was detected using 0.25 ng 2B7-
Tb and 20 ng MW1-D2 antibodies. The microtiter plate was then centrifuged 
at 1,000 ×g for 30 s before incubating for 1 h at room temperature. The plate 
was analysed using an EnVision® Mulitilabel Plate Reader (PerkinElmer). 
The donor Tb fluorophore (CisBio) was excited at 320nm before a time delay 
of 100 ms, after which the donor Tb and acceptor Alexa Fluor® 488 (Thermo 
Fisher Scientific) or D2 (CisBio) emission signals were read at 620, 520 or 
665 nm respectively. Total and mHTT levels corresponded to the ratios of 
the 520/620 and 665/620 nm emission spectra measured by the plate 
reader. Total and mHTT protein levels are presented as a percentage of the 
signal intensity measured over the background signal generated by the lysis 
buffer; protein levels were normalised to the total protein content of the 
lysate, which was measured using a BCA assay (Section 2.11.2).  
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Figure 2.4.  Schematic representation of the TR-FRET assay. (A) Total HTT protein 
levels were measured using the 2B7-Tb and 2166-Alexa Fluor® 488 antibodies, while (B) 
mHTT protein levels were measured using the 2B7-Tb and MW1-D2 antibodies. Reprinted 
and adapted from The Journal of Clinical Investigation, Vol. 122, “Mutant huntingtin 
fragmentation in immune cells tracks Huntington's disease progression”, 3731-3736, Weiss 
et al., ©2012, with permission from The American Society for Clinical Investigation. 
2.11.4 Western blotting 
Primary human monocytes were isolated from peripheral blood samples, 
seeded at 2 × 106 cells per well in five wells of a 6 well plate and 
differentiated into macrophages (Section 2.4). On the final day of the 
differentiation protocol the macrophage cultures were stimulated with 1 µg/ml 
LPS and 10 ng/ml IFNγ for either 15, 30, 60 or 120 min, or left unstimulated. 
Following stimulation, the macrophages were lysed in RIPA buffer (Section 
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2.11.1) before mixing with 3X SDS-PAGE Loading Buffer (BioVision) and 
denaturing at 95 °C for 10 min. Protein samples were stored at -20 °C. 
Western blotting was carried out using Novex™ 12 % Tris-Glycine Mini 
Protein Gels (1.5 mm, 15-well; Thermo Fisher Scientific). An HD and a 
control sample was always run on each gel. Fifteen µl of experimental 
sample was loaded per well, while 12 µl of normaliser sample was added to 
a separate well in order to allow comparison between blots. Eight µl of 
Precision Plus Protein™ All Blue Prestained Protein Standards (Bio-Rad) 
was also run on each gel to confirm protein size. Gels were run at 70 V for 
30 min, followed by 120 V for 1.5-2.5 h using the XCell SureLock® Mini-Cell 
Electrophoresis System (Thermo Fisher Scientific) filled with 1X Tris-Glycine-
SDS PAGE Buffer (National Diagnostics). Samples were transferred onto 0.2 
µm nitrocellulose membranes at 35 V for 2 h, using the XCell II™ Blot 
Module (Thermo Fisher Scientific) filled with 1X Tris-Glycine Electroblotting 
Buffer (National Diagnostics) with 20 % methanol. Following transfer, the 
membranes were blocked with 1:1 PBS/Odyssey Blocking Buffer (LI-COR) at 
room temperature for 1 h with shaking, before incubation with primary 
antibody (Table 2.7) diluted in 1:1 PBS/Odyssey Blocking Buffer at 4 °C 
overnight with shaking. The following day the membranes were washed 
three times with PBS for 5 min, before incubating with secondary antibody 
(Table 2.8) diluted in 1:1 PBS/Odyssey Blocking Buffer for 1 h. After a further 
washing step, the signal was visualised using an Odyssey Infrared Imager 
(LI-COR) and quantified using TL100 software (TotalLab). When comparing 
between blots the signal from each sample was normalised to that of the 
normaliser sample run on the same gel prior to statistical analysis. 
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Table 2.7.  Primary antibodies used for Western blotting. 
Antibody Source Dilution Company 
Anti-human p44/42 MAPK (ERK1/2) Rabbit 1:1000 Cell Signaling Technology 
Anti-human phospho-p44/42 MAPK (ERK1/2) Rabbit 1:1000 Cell Signaling Technology 
Anti-human p38 MAPK Rabbit 1:1000 Cell Signaling Technology 
Anti-human phospho-p38 MAPK Mouse 1:1000 Cell Signaling Technology 
Anti-human β-actin Mouse 1:10000 Abcam 
 
Table 2.8.  Secondary antibodies used for Western blotting. 
Antibody Source Dilution Company 
IRDye® 680RD Anti-Mouse IgG Goat 1:5000 LI-COR 
IRDye® 800CW Goat Anti-Rabbit IgG Goat 1:5000 LI-COR 
 
2.12 Immunoassays 
2.12.1 MSD HTT assays 
While initial measurements of total and mHTT protein levels were carried out 
using TR-FRET (Section 2.11.3), later experiments were carried out using 
more sensitive MSD assays. Cell pellets were lysed in 100 µl MSD lysis 
buffer 3 (1 mM PMSF, 1 mm EDTA, 0.05 % SDS in wash buffer (0.2 % 
Tween in PBS) containing one cOmplete™, Mini, EDTA-free Protease 
Inhibitor Cocktail Tablet per 10 ml buffer) by pipetting gently, before the 
lysates were transferred to a V-bottom microtitre plate and incubated on ice 
for 15 min. During incubation, further mixing was carried out by pipetting up 
and down ten times every five minutes. The lysates were then cleared by 
centrifuging at 3220 ×g for 10 min at 4 °C, before the supernatants were 
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removed and divided into three aliquots. Two aliquots were used for MSD 
analysis of total and mHTT levels, while the third was used for BCA analysis 
of total protein levels in the cell pellet (Section 2.11.2). The aliquots were 
frozen at -80 °C until analysis. 
To run the MSD assays, the coating antibody 2B7 (CHDI; Table 2.9) was 
diluted in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) to a 
concentration of 1.5 µg/ml and added to an MA6000 96-well plate (MSD) at 
50 µl per well. The plate was centrifuged at 100 ×g for 1 min to cover the 
entire bottom surface of the well, before the plate was sealed and incubated 
overnight at 4 °C. The following day the plate was washed three times with 
100 µl wash buffer per well, with the solution being removed by inverting the 
plate. 150 µl blocking buffer (2 % Probumin® (Millipore) in wash buffer) was 
added to each well and the plate was incubated on a shaker for 1 h at room 
temperature before removing the blocking buffer. The cell lysates were then 
diluted at least five-fold in blocking buffer and 25 µl of each dilution was 
added to the appropriate wells of the MSD plate. The plate was sealed and 
incubated on a shaker for 1 h at room temperature, then washed four times 
with 100 µl wash buffer per well. After washing, the biotinylated detection 
antibodies MW1 (mHTT) and 4C9 (total HTT) (CHDI) were diluted in blocking 
buffer to final concentrations of 0.625 µg/ml and 0.5 µg/ml respectively. The 
diluted antibody was then added to the plate, which was sealed and 
incubated on a shaker for 1 h at room temperature. The antibody solution 
was removed by washing three times with 100 µl wash buffer per well.  
To read the plate, streptavidin SULFO-TAG detection antibody (MSD) was 
diluted 1:12000 in blocking buffer and added to the plate at 25 µl per well. 
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The plate was sealed and incubated on a shaker for 1 h at room 
temperature, then washed three times with 100 µl wash buffer per well. After 
removing the wash buffer, 150 µl read buffer (MSD) was added to each well 
and the plate was analysed immediately using a Meso Sector S 600 (MSD). 
Total and mHTT levels were then normalised to the total protein content of 
each sample as measured by BCA assays. 
Table 2.9.  Antibodies used for MSD HTT assays.  
Antibody Assay Purpose Description Concentration 
2B7 
Total and 
mHTT 
Coating 
Mouse monoclonal antibody 
raised against amino acids 1-17 
of human HTT 
1.5 µg/ml 
MW1 
(biotinylated) 
mHTT Detection 
Mouse monoclonal antibody 
specific to the human polyQ 
region 
0.625 µg/ml 
4C9 
(biotinylated) 
Total HTT Detection 
Mouse monoclonal antibody 
raised against amino acids 51-
71 of human HTT 
0.5 µg/ml 
 
2.12.2 MSD cytokine assays 
Cytokine profiling was carried out using V-PLEX Assay Kits from MSD. 
Myeloid cell cytokine production was analysed using the V-PLEX Human 
Proinflammatory Panel II (4-Plex) Kit (IL-1β, IL-6, IL-8, TNFα), while helper T 
lymphocyte cytokine production was analysed using the V-PLEX 
Proinflammatory Panel 1 (Human) Kit (IFNγ, IL-10, IL-12p70, IL-13, IL-1β, IL-
2, IL-4, IL-6, IL-8, TNFα) and the V-PLEX Human IL-5 Kit. Depending on the 
cell type and experimental condition, 50 µl of undiluted or 1:150, 1:500 or 
1:600 diluted cell culture supernatants were added to the MSD plate and 
incubated with vigorous shaking for 2 h at room temperature. MSD Diluent 2 
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was used to dilute samples for the two multiplex assays, while MSD Diluent 
43 was used to dilute samples for the IL-5 assay. Eight standards of known 
concentration were also added to the plates by carrying out serial fourfold 
dilutions of the Calibrator Blend included in each kit, according to the 
manufacturer’s instructions. After incubation the plate was washed three 
times with PBS containing 0.05 % Tween before the detection antibody 
solution was made up by combining 60 µl of each detection antibody and 
making the final volume up to 3000 µl with MSD Diluent 3. Twenty-five µl of 
this solution was then added to each well before incubating with vigorous 
shaking for 2 h at room temperature. The plate was washed three times in 
PBS containing 0.05 % Tween before 150 µl 2X Read Buffer T was added to 
each well. After the Read Buffer was added the plate was analysed 
immediately using a Sector Imager 6000 with Discovery Workbench 4.0 
software (MSD). Cytokine concentrations were calculated by comparing the 
samples to a standard curve made from the eight calibrators, before 
normalising to the total protein measured by BCA assays (Section 2.11.2). 
2.13 Flow cytometry 
2.13.1 Staining of cell surface markers 
Cell surface marker staining was carried out by transferring a maximum of 1 
× 106 cells into a V-bottom 96 well plate and centrifuging at 400 ×g for 5 min 
to collect the cells at the bottom of the well. The supernatant was removed 
by flicking the plate before the samples were washed once with 200 µl FACS 
buffer. The relevant panel of antibodies (Table 2.10) was then diluted in 
FACS buffer (to a final volume of 50 µl per well) and added to each well. The 
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samples were mixed by pipetting up and down before incubating for 60 min 
on a shaker at 4 °C. Samples were protected from light for the duration of the 
staining process. After incubation the samples were washed twice in 200 µl 
FACS buffer by centrifuging at 400 ×g for 5 min, before being fixed in 200 µl 
PBS containing 4 % PFA for 10 min. After fixation the samples were washed 
three times in 200 µl FACS buffer and kept at 4 °C in the dark until analysis. 
2.13.2 Staining of intracellular markers 
Staining of intracellular markers was carried out using the FOXP3 / 
Transcription Factor Staining Buffer Set (eBioscience). After cell surface 
marker staining (but before fixation), the cells were resuspended in 100 µl 
Fixation/Permeabilization Buffer (one part Fixation/Permeabilization 
Concentrate to three parts Fixation/Permeabilization Diluent) before 
incubating for 40 min on a shaker at 4 °C in the dark. The samples were then 
centrifuged at 400 ×g for 5 min before washing twice with 200 µl 1X 
Permeabilization Buffer. Staining was carried out by diluting the relevant 
panel of antibodies (Table 2.11) in 1X Permeabilization Buffer (to a final 
volume of 200 µl per well) and adding to each well. The samples were mixed 
by pipetting before incubating for 60 min on a shaker at 4 °C in the dark. 
After incubation the samples were washed twice in 200 µl FACS buffer by 
centrifuging at 400 ×g for 5 min and kept at 4 °C in the dark until analysis. 
2.13.3 Data analysis 
All flow cytometry samples were run on a MACSQuant with MACSQuantify 
software (Miltenyi Biotec). Unstained and single colour-stained controls were 
always analysed prior to the experimental samples in order to set 
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compensation values between antibodies with overlapping emission spectra. 
Data analysis was performed using FlowJo 7.2.5 (Tree Star). 
Table 2.10.  Antibodies used for staining of cell surface markers. 
Antibody Dilution Company 
Anti-human CCR2 PerCP-Cy5.5 2 µl per test BioLegend 
Anti-human CCR4/CD194 PE 5 µl per test BD Biosciences 
Anti-human CCR5 PE 2 µl per test eBioscience 
Anti-human CD3 eFluor450 2 µl per test eBioscience 
Anti-human CD4 APC-Cy7 2 µl per test BD Biosciences 
Anti-human CD8 VioGreen 4.5 µl per test Miltenyi Biotec 
Anti-human CD14 APC 2 µl per test eBioscience 
Anti-human CD16 FITC 2 µl per test eBioscience 
Anti-human CD19 APC 5 µl per test eBioscience 
Anti-human CD25 PE 10 µl per test BD Biosciences 
Anti-human CD56 FITC 2 µl per test eBioscience 
Anti-human CD62L PeCy5 5 µl per test eBioscience 
Anti-human CD138 FITC 5 µl per test eBioscience 
Anti-human CXCR3 APC 5 µl per test BioLegend 
 
Table 2.11.  Antibodies used for staining of intracellular markers. 
Antibody Dilution Company 
Anti-human Il-17 PeCy7 4.5 µl per test eBioscience 
Anti-human FOXP3 5 µl per test eBioscience 
 
2.14 Statistical analysis 
2.14.1 Chapter 3 
Statistical analysis of all experiments contained in this chapter was carried 
out using GraphPad Prism 6 (GraphPad). Optimisation of GeRP transfection 
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was analysed using two-way ANOVAs with Bonferroni post-hoc multiple 
comparison testing, as was initial testing and dose-response profiling of 
allele-selective siRNAs. Cytokine profiling following allele-selective HTT-
lowering was analysed using one-way ANOVAs with Tukey post-hoc multiple 
comparison testing. All error bars represent standard error of the mean. 
2.14.2 Chapter 4 
Statistical analysis of differential expression, splicing, GSEA and IPA® data 
was carried out using the software packages and analysis tools outlined 
above. Further statistical analysis was carried out using GraphPad Prism 6. 
IκBα western blotting experiments were analysed using unpaired two-tailed 
Student’s t-tests. MAPK western blotting experiments were analysed by two-
way ANOVAs with Bonferroni post-hoc multiple comparison testing. 
Quantitative PCR analysis of gene expression changes following HTT-
lowering was carried out using unpaired two-tailed Student’s t-tests. All error 
bars represent standard error of the mean. 
2.14.3 Chapter 5 
Statistical analysis of immune cell subset, proliferation and cytokine profiling 
data was carried out using GraphPad Prism 6, while PCR array data was 
analysed using the manufacturer’s online data analysis tool (Section 2.9.4). 
All experiments were analysed using unpaired two-tailed Student’s t-tests. 
Where appropriate, post-hoc analysis of multiple t-tests was carried out using 
a Holm-Šídák correction (alpha = 0.05) for multiple comparisons. All error 
bars represent standard error of the mean. 
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3 Allele-selective suppression of 
mHTT in HD myeloid cells 
3.1 Background 
Substantial research into HD therapeutics has focused on alleviating specific 
pathogenic mechanisms, for example via the upregulation of BDNF or the 
enhancement of autophagy (Simmons et al., 2009; Martinez-Vicente et al., 
2010). Although these approaches have yielded promising results in animal 
models, they are limited by the fact that HD pathogenesis is multi-factorial; 
while targeting a single mechanism may improve disease progression, it is 
unlikely to prevent it completely. As a monogenic disorder, HD is an ideal 
candidate for treatment by PTGS, as lowering cellular mHTT levels will stop 
the pathogenic cascade at its source. The most commonly used therapeutics 
for PTGS are siRNAs and ASOs; these are short oligonucleotide molecules 
that bind to complementary sequences on an mRNA transcript to target it for 
degradation by endogenous cellular mechanisms (Sah and Aronin, 2011). 
Numerous studies have demonstrated that lowering cellular mHTT levels is 
beneficial in animal models of HD (Drouet et al., 2009; Boudreau et al., 
2009), with the therapeutic effects persisting longer than suppression of the 
HTT transcript (Kordasiewicz et al., 2012). This suggests that even 
occasional HTT-lowering may be sufficient to alleviate HD pathology, and the 
first human studies of intrathecal ASO delivery are currently underway (Ionis 
Pharmaceuticals, 2015). However, the majority of therapeutics tested have 
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provided suppression of both wild-type and mHTT; this occurs because the 
target sequence is present on both alleles (Sah and Aronin, 2011).  
While this offers obvious therapeutic benefits, wild-type HTT has important 
roles in cellular function, and is key for neuronal development during 
embryogenesis (Godin et al., 2010; Tong et al., 2011). Furthermore, initial 
studies suggested that Htt knockout in the adult mouse brain causes 
neurodegeneration (Dragatsis et al., 2000), leading to fears about whether 
wild-type HTT suppression will be safe in patients. However, it has since 
been shown that non-specific HTT-lowering is tolerated for at least nine 
months in HD mice (Kordasiewicz et al., 2012; Stanek et al., 2014), while a 
six month reduction in HTT expression has no adverse effects in the rhesus 
putamen (Grondin et al., 2012). Indeed, a recent study found that neuronal 
Htt deletion is not deleterious in the adult mouse, with death from ubiquitous 
Htt knockout in early life instead being caused by acute pancreatitis (Wang et 
al., 2016). While this is promising, it is uncertain what percentage of wild-type 
HTT suppression would be tolerated in the adult human brain, where 
therapeutics will need to be administered over several decades. The ideal 
strategy would therefore selectively lower mHTT while sparing wild-type. 
Allele-selective suppression of mHTT relies on polymorphisms between the 
wild-type and mutant alleles which may be exploited to provide differential 
knockdown. The CAG repeat is the most obvious target; however, it has 
proved to be technically challenging to reliably discriminate between alleles 
with CAG repeats in the normal patient range (Fiszer et al., 2013). There is 
also the potential for off-target knockdown of other CAG repeat-containing 
transcripts. An alternative strategy relies on genotyping HD patients to 
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identify heterozygous SNPs in the HTT gene. Each SNP allele may then be 
linked to either wild-type or mHTT, before delivering an siRNA or ASO that is 
specific for the SNP allele located on mHTT (Sah and Aronin, 2011).  
SNP-targeted ASOs and siRNAs have been used successfully in a range of 
cell and animal models of HD, including human HD fibroblasts and mouse 
neurons (Carroll et al., 2011; Østergaard et al., 2013; Drouet et al., 2014). 
While they have been shown to be capable of providing increased allele-
selectivity compared to CAG repeat-targeted therapeutics, it is important to 
note that this approach will only be applicable to HD patients who are 
heterozygous for specific SNPs. Although the prevalence of SNP 
heterozygosities varies between ethnic groups, genotyping of large cohorts 
has suggested that 75 % of HD patients would be treatable with five siRNAs 
targeting just three SNPs (Pfister et al., 2009). This provides a promising 
alternative should total HTT-lowering prove to have deleterious effects. 
However, allele-selective suppression of mHTT is yet to be achieved in 
primary ex vivo HD patient cells. This is a key step in determining whether 
this therapeutic approach will have clinical relevance. Previous work has 
made use of GeRPs to transfect HD myeloid cells with anti-total HTT siRNA 
(Träger et al., 2014); these are yeast-derived sugar particles that are taken 
up by phagocytosis before delivering their siRNA cargo into the cytoplasm of 
the target cell (Aouadi et al., 2009). This study will use the same technology 
to deliver allele-selective siRNAs to HD patient myeloid cells, in addition to 
characterising the effect that allele-selective HTT-lowering has on the cells’ 
hyper-reactive cytokine phenotype. This will allow the relative contributions of 
wild-type and mHTT to immune cell function to be further investigated. 
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3.2 Aims 
1. To determine the optimal GeRP formulation for the transfection of 
primary human myeloid cells. 
2. To characterise the selectivity and potency of HTT mRNA knockdown 
provided by a panel of siRNAs targeted to three of the most prevalent 
SNPs in the HTT gene. 
3. To validate selective siRNAs with total and mHTT protein analysis. 
4. To characterise the effects of allele-selective HTT-lowering on the 
hyper-reactive cytokine phenotype of HD myeloid cells. 
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3.3 Methods 
HD subjects were genotyped for SNP heterozygosity (Section 2.2.2), before 
the SNP alleles were linked to either wild-type or mHTT by SLiC (Section 
2.3). PBMCs were isolated using density centrifugation (Section 2.4.1), 
before CD14+ monocytes were isolated by magnetic cell sorting (Section 
2.4.2) and differentiated into macrophages (Section 2.4.3). Macrophages 
were treated with GeRPs containing siRNA (Section 2.5.2) and harvested 72 
h after transfection. RNA was isolated using the RNeasy Mini Kit (Section 
2.7.1) and cDNA was synthesised according to Section 2.7.4. Analysis of 
HTT expression was carried out using SYBR® Green (Section 2.7.5) and 
TaqMan® qPCR (Section 2.7.6), while analysis of total and mHTT protein 
levels was carried out using TR-FRET (Section 2.11.3) and MSD HTT 
assays (Section 2.12.1). Cytokine levels were quantified using MSD cytokine 
assays (Section 2.12.2) with normalisation to total protein using BCA assays 
(Section 2.11.2). Cell viability was assessed using ATP assays (Section 
2.6.1). Statistical analysis was carried out according to Section 2.14.1. 
3.4 Contributions 
Work presented in this chapter was carried out in collaboration with 
University of Massachusetts Medical School. SNP genotyping was carried 
out by Lori Kennington, before SLiC was carried out by Dr Wanzhao Liu. 
siRNA molecules were synthesised by Dr Edith Pfister and Professor Neil 
Aronin, and loaded into GeRPs by Professor Gary Ostroff. Analysis of HTT 
protein levels was carried out by Promidis and BioFocus (assisted by CHDI). 
All remaining experiments and analyses were carried out by James Miller. 
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3.5 Results 
3.5.1 Optimisation of GeRP transfection 
Previous studies have made use of GeRP technology to transfect HD patient 
and control myeloid cells with anti-total HTT siRNA (Träger et al., 2014). This 
approach was used to demonstrate the reversibility of HD myeloid cell hyper-
reactivity to LPS following HTT-lowering. Prior to investigating the effects of 
allele-selective siRNA on HD myeloid cells, a range of GeRP formulations 
were tested in order to determine the optimal conditions for achieving 
maximal knockdown while limiting cellular toxicity. Endo-Porter (EP) is a key 
factor in the GeRP particle that acts to permeabilise the endosome following 
phagocytosis, allowing the siRNA molecules contained within the GeRP to 
be released into the cytoplasm (Summerton, 2005). However, it is possible 
that the membrane permeabilisation process has an adverse effect on 
cellular function that may be limited by using less EP. The EP concentration 
is defined as its dilution by saline during the GeRP synthesis process, with 
previous work carried out using exclusively 1.0 EP GeRPs; experiments 
carried out as part of the initial study demonstrated that these have no 
significant effect on cell death (Träger et al., 2014). However, a detailed 
assessment of their effects on the more sensitive measure of cellular viability 
is yet to be performed. 
GeRPs containing 1.0, 0.25, 0.1 and 0.05 EP were synthesised in order to 
determine whether lower EP concentrations have a beneficial effect on 
cellular viability. All GeRPs used for these experiments were synthesised as 
part of the same batch and were identical apart from the concentration of EP. 
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Monocyte-derived macrophages were isolated from peripheral blood 
samples donated by HD patient and control subjects and treated with GeRPs 
containing each concentration of EP on day three of the differentiation 
protocol; cellular viability was then assessed using ATP assays 24 h after 
transfection. Both scrambled (SCR) and anti-total HTT siRNA-containing 
GeRPs were tested in order to determine whether the siRNA used has any 
effect on cellular viability. As it has previously been shown that GeRP-
mediated HTT knockdown does not vary between HD and control myeloid 
cells (Träger et al., 2014), the samples were pooled for analysis. 
Treatment with GeRPs of all EP concentrations resulted in a decrease in 
cellular ATP levels compared to untreated control. However, GeRPs 
containing 0.25, 0.1 and 0.05 EP all provided a statistically significant rescue 
of cellular ATP levels compared to 1.0 EP GeRPs (Fig. 3.1). This 
demonstrates that using lower EP concentrations during transfection has a 
beneficial effect on cellular viability. A further significant increase in cellular 
ATP levels was seen for 0.05 EP compared to 0.25 EP GeRPs, however this 
was only the case for the anti-total HTT siRNA-containing GeRPs, with no 
difference seen for SCR. Despite this, no significant differences were seen 
between the SCR and anti-total HTT GeRPs at any of the EP concentrations 
tested, suggesting that the siRNA being delivered does not have a 
meaningful effect on cellular viability. 
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Figure 3.1.  Lower EP doses ameliorate the cellular ATP deficit associated with 
GeRP transfection. Monocyte-derived macrophages were isolated from HD and control 
peripheral blood samples and treated with GeRPs containing variable concentrations of EP. 
ATP assays were then carried out 24 h after transfection. Lower EP doses were found to 
provide significant rescue of the cellular ATP deficit caused by 1.0 EP GeRPs, with no 
difference seen between SCR and anti-total HTT siRNA-containing GeRPs at any of the EP 
doses tested. Data show mean ATP levels ± SEM (n = 7 (2 controls and 5 HD), samples 
pooled for analysis), statistical analysis carried out using two-way ANOVA with Bonferroni 
post-hoc testing. Asterisks above bars show post-test significance compared to 1.0 EP 
GeRPs containing the same siRNA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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While these data show that lowering the concentration of EP used during 
GeRP synthesis has a beneficial effect on cellular viability, it is likely that too 
much of a reduction will result in less siRNA being released into the 
cytoplasm, and therefore a reduction in the efficiency of knockdown. To 
address this, monocyte-derived macrophages were obtained from peripheral 
blood samples donated by HD patients and transfected with the GeRPs 
described above. Suppression of cellular HTT levels was then measured by 
qPCR 72 h after transfection; the anti-HTT GeRPs were each normalised to 
a SCR control of the same EP concentration to ensure consistency. As 
expected, significant knockdown of HTT mRNA was seen for all anti-HTT 
GeRP formulations compared to the equivalent SCR control (Fig. 3.2). 
However, the amount of knockdown was significantly reduced in the 0.05 EP 
GeRPs compared to the 1.0 EP GeRPs used for previous experiments. This 
confirms the hypothesis that lowering the EP concentration past a certain 
point will reduce transfection efficacy due to a decreased amount of siRNA 
entering the cytoplasm. However, no significant difference was seen in the 
knockdown provided by either the 0.25 or 0.1 EP GeRPs compared to 1.0 
EP. This demonstrates that it is possible to limit adverse effects on cellular 
viability while still maintaining adequate HTT knockdown. 
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Figure 3.2.  Characterisation of HTT mRNA suppression using lower EP GeRPs. 
Monocyte-derived macrophages were isolated from HD peripheral blood samples and 
treated with GeRPs containing variable concentrations of EP. HTT mRNA expression was 
then measured after 72 h by qPCR. Anti-HTT GeRPs of all EP concentrations suppressed 
cellular HTT levels, however the suppression provided by 0.05 EP GeRPs was significantly 
reduced compared to that provided by 1.0 EP GeRPs. Data show mean HTT levels ± SEM 
(n = 5), statistical analysis carried out using two-way ANOVA with Bonferroni post-hoc 
testing. Asterisks above bars show post-test significance compared to SCR GeRPs 
containing the same EP concentration. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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While promising, it is essential to validate such mRNA data with protein 
analysis, as the mHTT protein is the primary pathogenic species in HD. 
Further monocyte-derived macrophage cultures were obtained from 
peripheral blood samples donated by HD patients and transfected with SCR 
and anti-total HTT GeRPs containing either 0.25, 0.1 or 0.05 EP. Analysis of 
total and mHTT protein levels was then carried out 72 h after transfection 
using TR-FRET. A statistically significant reduction in both total and mHTT 
levels was seen for the anti-total HTT-treated samples compared to the 
SCR-treated samples. The overall knockdown provided was comparable to 
the approximately 50 % reduction in total HTT previously published using 1.0 
EP GeRPs (Träger et al., 2014). Post-hoc analysis revealed a significant 
reduction in mHTT for all three anti-total HTT formulations compared to the 
equivalent SCR control (Fig. 3.3), however on total HTT analysis only the 
knockdown provided by the 0.1 EP GeRPs was found to be significant (Fig. 
3.4). When combined with the ATP assay and qPCR data, this shows that 
0.1 EP GeRPs are able to alleviate the reduction in cellular ATP levels 
caused by 1.0 EP GeRPs while still retaining adequate mRNA and protein 
knockdown. 0.1 EP GeRPs will therefore be used for all experiments 
contained in the remainder of this thesis. 
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Figure 3.3.  Characterisation of mHTT protein suppression using lower EP GeRPs. 
Monocyte-derived macrophages were isolated from HD peripheral blood samples and 
treated with GeRPs containing variable concentrations of EP. Mutant HTT protein 
expression was then measured after 72 h by TR-FRET. Anti-HTT GeRPs of all EP 
concentrations suppressed cellular mHTT levels, however the suppression provided by 0.1 
EP GeRPs was more significant than that provided by 0.25 and 0.05 EP GeRPs. Data show 
mean mHTT levels ± SEM (n = 3), statistical analysis carried out using two-way ANOVA with 
Bonferroni post-hoc testing. Asterisks above bars show post-test significance compared to 
SCR GeRPs containing the same EP concentration. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 3.4.  Characterisation of total HTT protein suppression using lower EP 
GeRPs. Monocyte-derived macrophages were isolated from HD peripheral blood samples 
and treated with GeRPs containing variable concentrations of EP. Total HTT protein 
expression was then measured after 72 h by TR-FRET. Of the GeRP formulations tested, 
only the 0.1 EP GeRPs provided significant suppression of total HTT on post-hoc testing. 
Data show mean HTT levels ± SEM (n = 3), statistical analysis carried out using two-way 
ANOVA with Bonferroni post-hoc testing. Asterisks above bars show post-test significance 
compared to SCR GeRPs containing the same EP concentration. *P < 0.05, **P < 0.01. 
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3.5.2 SNP genotyping of HD patients 
Following GeRP optimisation it was necessary to genotype HD patients for 
SNP heterozygosity, in order to identify individuals who were suitable 
subjects for allele-selective silencing. Three SNPs in the HTT gene were 
selected for targeting on the basis of their high prevalence of heterozygosity 
among the HD patient population (Pfister et al., 2009); rs362331 in exon 50 
(39.4 % C/T), rs362273 in exon 57 (35.2 % A/G) and rs362307 in the 3’-UTR 
(48.6 % C/T). Allele-selective siRNAs to target these SNPs were previously 
developed by collaborators at University of Massachusetts Medical School, 
with initial testing carried out in HeLa cells (Pfister et al., 2009). 
Diagnostic DNA samples collected from HD patients from the NHNN cohort 
were genotyped for heterozygosity at each of the above SNP sites. This 
identified fifty-seven individuals who were heterozygous for rs362331, thirty-
eight who were heterozygous for rs362273 and fifty-four who were 
heterozygous for rs362307. All following experiments described in this 
chapter were carried out using peripheral blood samples collected from this 
cohort of genotyped HD patients. As initial experiments focused exclusively 
on achieving optimal allele-selectivity at each SNP site, it was not yet 
necessary to carry out SLiC for mHTT linkage (this was performed in a 
subset of patients for later protein and cytokine experiments). 
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3.5.3 Characterisation of a panel of SNP-targeted siRNAs 
Initial characterisation of allele-selective siRNA was carried out using GeRPs 
containing 36 nM siRNA, as this was the concentration of anti-total HTT 
siRNA used in previous studies of HD myeloid cells (Träger et al., 2014). 
Peripheral blood samples were collected from genotyped HD patients, before 
monocyte-derived macrophages were isolated and treated with GeRPs 
containing either SCR or allele-selective anti-HTT siRNA; an anti-total HTT 
control was also included in each experiment to allow comparison with 
previous work. Cultures were harvested after 72 h and the expression of 
each SNP allele was analysed using allele-specific qPCR. 
The first SNP investigated was rs362331 in exon 50 of the HTT transcript; 
heterozygous subjects have a C allele and a T allele. Consistent with 
previous work, treatment with anti-total HTT siRNA resulted in approximately 
75 % suppression of HTT mRNA levels (Träger et al., 2014), the degree of 
which did not differ between the C and T alleles of rs362331 (Fig. 3.5). This 
was expected as the nucleotide sequence targeted by the anti-total HTT 
siRNA is present on both HTT alleles. In contrast, treatment with siRNA 
selective for the U allele of rs362331 resulted in 74 % suppression of the on-
target U allele (equivalent to that provided by anti-total HTT siRNA), with only 
17 % suppression of the off-target C allele compared to SCR control; this off-
target knockdown was not found to be statistically significant. Perhaps 
unsurprisingly, post-hoc testing following ANOVA revealed the selectivity 
offered by the anti-U siRNA to be highly statistically significant (p < 0.001).  
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Similarly, treatment with siRNA selective for the C allele of rs362331 resulted 
in 63 % suppression of the on-target C allele, with only 30 % knockdown of 
the off-target U allele compared to SCR control. The on-target knockdown 
was again found to be statistically equivalent to that provided by anti-total 
HTT siRNA, while post-hoc testing revealed significant discrimination 
between alleles (p < 0.05). Although no statistically significant differences 
were found for off-target allele expression for either siRNA compared to SCR 
control, it is clear from the data that some off-target effects exist. However, 
these data demonstrate that such effects are minor, and that it is possible to 
achieve highly significant allele selectivity using siRNA targeted to rs362331. 
Next, the allele-selectivity of siRNAs targeting rs362273 in exon 57 of the 
HTT transcript was investigated; heterozygous subjects have an A allele and 
a G allele. As expected, treatment with anti-total HTT siRNA again resulted 
in equal SNP knockdown (Fig. 3.6). However, treatment with allele-selective 
siRNA provided greatly reduced selectivity compared to rs362331, with 77 % 
on-target and 63 % off-target suppression for the anti-A siRNA, and 78 % on-
target and 58 % off-target suppression for the anti-G siRNA. Promisingly, 
post-hoc testing demonstrated significant allelic discrimination following 
treatment with the anti-G siRNA. However, no such significant discrimination 
was seen following treatment with the anti-A siRNA. It is also important to 
note that statistical significance does not always translate to biological 
relevance; clearly, mean off-target knockdown of this degree is far too great 
for either siRNA to be considered truly selective. While the potency of the 
knockdown provided by these siRNAs is promising, their selectivity will need 
to be significantly improved for future use. 
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Figure 3.5.  Characterisation of allele-selective siRNA targeting rs362331 in exon 
50 of HTT. Monocyte-derived macrophages were isolated from SNP-genotyped HD patients 
and treated with GeRPs containing either SCR, anti-total HTT or allele-selective siRNA 
targeted to each allele of rs362331 in exon 50 of the HTT transcript. Expression of each 
SNP allele was then measured after 72 h by qPCR. Treatment with allele-selective GeRPs 
provided potent suppression of the on-target allele in each case, with no significant 
suppression of the off-target allele. The allelic discrimination provided by each allele-
selective siRNA was further found to be statistically significant. Data show mean expression 
of each SNP allele ± SEM (n = 3), statistical analysis carried out using two-way ANOVA with 
Bonferroni post-hoc testing. Asterisks above bars show post-test significance compared to 
the same allele in SCR-treated samples. Asterisks between bars denote within treatment 
allele expression differences. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Figure 3.6.  Characterisation of allele-selective siRNA targeting rs362273 in exon 
57 of HTT. Monocyte-derived macrophages were isolated from SNP-genotyped HD patients 
and treated with GeRPs containing either SCR, anti-total HTT or allele-selective siRNA 
targeted to each allele of rs362273 in exon 57 of the HTT transcript. Expression of each 
SNP allele was then measured after 72 h by qPCR. Treatment with allele-selective GeRPs 
provided potent suppression of each SNP allele, with anti-G siRNA providing significantly 
increased suppression of the G allele compared to the C allele. However, substantial off-
target suppression was observed for both of the allele-selective siRNAs. Data show mean 
expression of each SNP allele ± SEM (n = 4), statistical analysis carried out using two-way 
ANOVA with Bonferroni post-hoc testing. Asterisks above bars show post-test significance 
compared to the same allele in SCR-treated samples. Asterisks between bars denote within 
treatment allele expression differences. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Finally, allele-selective suppression targeting rs362307 in the 3’-UTR of the 
HTT transcript was investigated; heterozygous subjects have a C allele and 
a T allele. However, the T allele has previously been shown to be linked to 
mHTT, eliminating the need to target the C allele as a potential therapeutic 
for HD (Pfister et al., 2009). This SNP is also known to be the most prevalent 
among Caucasian HD patients, with approximately 48.6 % heterozygosity; 
this makes it an attractive target for potential clinical trials. Two separate anti-
U siRNAs were therefore tested for this SNP in order to maximise the 
potential for achieving selective knockdown. Again, significant non-selective 
knockdown of each allele was seen following treatment with anti-total HTT 
siRNA (Fig. 3.7). However, neither anti-U siRNA was found to provide any 
allelic discrimination, with equivalent expression of each allele being seen on 
qPCR in both cases. Furthermore, only anti-U (1) demonstrated any potency, 
achieving a 65-70 % reduction in mean HTT expression. In contrast, almost 
no change in mean HTT expression was seen following treatment with anti-U 
(2). While the lack of allelic discrimination seen with a 36 nM dose of anti-U 
(1) is disappointing, the potency of knockdown combined with the high SNP 
prevalence and observed selectivity in previous in vitro experiments 
suggests that further optimisation attempts are worthwhile. 
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Figure 3.7.  Characterisation of allele-selective siRNAs targeting rs362307 in the 
3’-UTR of HTT. Monocyte-derived macrophages were isolated from SNP-genotyped HD 
patients and treated with GeRPs containing either SCR, anti-total HTT or allele-selective 
siRNA targeted to each allele of rs362307 in the 3’-UTR of the HTT transcript. Expression of 
each SNP allele was then measured after 72 h by qPCR. Treatment with anti-U (1) provided 
potent HTT mRNA suppression, however this was not selective between alleles. Treatment 
with anti-U (2) did not provide adequate suppression of either SNP allele. Data show mean 
expression of each SNP allele ± SEM (n = 4), statistical analysis carried out using two-way 
ANOVA with Bonferroni post-hoc testing. Asterisks above bars show post-test significance 
compared to the same allele in SCR-treated samples. *P < 0.05, **P < 0.01, ***P < 0.001. 
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3.5.4 Effects of siRNA dose-ranging on allele-selectivity 
Previous studies have demonstrated that lowering the dose of the siRNAs 
used in this project is able to improve selectivity (Pfister et al., 2009). It is 
therefore possible that the lack of selectivity seen for rs362273 and rs362307 
was due to using too high a dose of siRNA. The optimal dosage was an 
unknown factor at the start of these experiments, as these siRNAs have not 
previously been tested in primary human cells and converting doses between 
different cell models is challenging. Using a lower dose may therefore reduce 
off-target effects while retaining potent suppression of the on-target allele. To 
investigate this hypothesis, GeRPs were prepared to carry out a dose-
ranging analysis of each siRNA. However, as the rs362307 anti-U (2) siRNA 
did not display potent knockdown at a dose of 36 nM, it was decided not to 
use it for further testing. Monocyte-derived macrophages were isolated from 
genotyped HD patients and transfected with GeRPs containing a range of 
concentrations of each SNP-targeted siRNA. After 72 h the expression of 
each SNP allele was measured by allele-specific qPCR, with each siRNA 
being compared to a SCR control of the same siRNA concentration. 
First, the two allele-selective siRNAs targeting rs362331 were packaged into 
GeRPs at concentrations of 36 nM, 24 nM, 12 nM and 3.6 nM, before being 
used for transfection. Consistent with the initial suppression experiments, 
reduced expression of the on-target allele was seen relative to the off-target 
allele for both siRNAs at all of the doses that were tested (Figs. 3.8 and 3.9). 
However, no significant increase in selectivity was seen with the lower siRNA 
doses, and the most selective results were again seen using the anti-U 
siRNA at a dose of 36 nM. Although this contrasts with previous in vitro 
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experiments, the highly significant selectivity seen during the initial testing of 
these siRNAs shows that they are both suitable for the allele-selective 
suppression of mHTT in HD myeloid cells at a dose of 36 nM. 
Next, the siRNAs targeting rs362273 were tested at concentrations of 36 nM, 
24 nM, 12 nM and 3.6 nM. Consistent with the initial experiments, both the 
anti-A and anti-G siRNAs achieved potent HTT knockdown at a dose of 36 
nM, although there was again considerable off-target suppression (Figs. 3.10 
and 3.11). Disappointingly, reduced doses of each siRNA resulted in an 
almost complete loss of potency, with no appreciable improvement in the 
selectivity provided between the on-target and off-target alleles. Furthermore, 
the significant discrimination seen on initial testing of the anti-G siRNA was 
not replicated during these experiments. This suggests that rs362273 is 
unlikely to serve as a reliable target for allele-selective suppression of mHTT. 
Finally, the anti-U (1) siRNA targeting rs362307 was packaged into GeRPs 
at concentrations 36 nM, 28.8 nM, 21.6 nM, 14.4 nM and 7.2 nM, before 
being used for transfection. Again, treatment with anti-U (1) resulted in a 
decrease in HTT mRNA expression; however, this was markedly reduced at 
doses of 14.4 nM and 7.2 nM (Fig. 3.12). Furthermore, none of the doses 
tested offered significant discrimination between the C and T alleles. This 
suggests that, as with rs362273, lowering the dose of siRNA packaged into 
each GeRP is not sufficient to achieve substantial allele-selectivity while 
retaining potency when targeting rs362307 with anti-U (1). Indeed, the loss of 
potency seen at the lower doses suggests that further reductions are unlikely 
to be beneficial, as even if selectivity is achieved the limited suppression of 
the on-target allele will be insufficient to have any real therapeutic benefit. 
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Figure 3.8.  Dose-ranging analysis of siRNA targeting the C allele of rs362331. 
Monocyte-derived macrophages were isolated from SNP-genotyped HD patients and treated 
with GeRPs containing varying concentrations of siRNA targeted to the C allele of rs362331 
in exon 50 of the HTT transcript. Expression of each SNP allele was measured after 72 h by 
qPCR. No significant differences were seen in the potency or selectivity of any of the siRNA 
concentrations tested. Data show mean expression of each SNP allele ± SEM (n = 5), 
statistical analysis carried out using two-way ANOVA with Bonferroni post-hoc testing. 
Asterisks between bars denote within treatment allele expression differences on post-hoc 
testing. *P < 0.05. 
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Figure 3.9.  Dose-ranging analysis of siRNA targeting the U allele of rs362331. 
Monocyte-derived macrophages were isolated from SNP-genotyped HD patients and treated 
with GeRPs containing varying concentrations of siRNA targeted to the U allele of rs362331 
in exon 50 of the HTT transcript. Expression of each SNP allele was measured after 72 h by 
qPCR. No significant differences were seen in the potency or selectivity of any of the siRNA 
concentrations tested. Data show mean expression of each SNP allele ± SEM (n = 5), 
statistical analysis carried out using two-way ANOVA with Bonferroni post-hoc testing. 
Asterisks between bars denote within treatment allele expression differences on post-hoc 
testing. *P < 0.05. 
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Figure 3.10.  Dose-ranging analysis of siRNA targeting the A allele of rs362273. 
Monocyte-derived macrophages were isolated from SNP-genotyped HD patients and treated 
with GeRPs containing varying concentrations of siRNA targeted to the A allele of rs362273 
in exon 57 of the HTT transcript. Expression of each SNP allele was then measured after 72 
h by qPCR. No significant differences were seen in the potency or selectivity of any of the 
siRNA concentrations tested. Data show mean expression of each SNP allele ± SEM (n = 
3), statistical analysis carried out using two-way ANOVA with Bonferroni post-hoc testing. 
Asterisks above bars show post-test significance compared to the same allele in the SCR-
treated samples. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 3.11.  Dose-ranging analysis of siRNA targeting the G allele of rs362273. 
Monocyte-derived macrophages were isolated from SNP-genotyped HD patients and treated 
with GeRPs containing varying concentrations of siRNA targeted to the G allele of rs362273 
in exon 57 of the HTT transcript. Expression of each SNP allele was then measured after 72 
h by qPCR. No significant differences were seen in the potency or selectivity of any of the 
siRNA concentrations tested. Data show mean expression of each SNP allele ± SEM (n = 
3), statistical analysis carried out using two-way ANOVA with Bonferroni post-hoc testing. 
Asterisks above bars show post-test significance compared to the same allele in the SCR-
treated samples. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Figure 3.12.  Dose-ranging analysis of siRNA targeting the U allele of rs362307. 
Monocyte-derived macrophages were isolated from SNP-genotyped HD patients and treated 
with GeRPs containing varying concentrations of siRNA targeted to the U allele of rs362307 
in the 3’-UTR of the HTT transcript. Expression of each SNP allele was then measured after 
72 h by qPCR. No significant differences were seen in the potency or selectivity of any of the 
siRNA concentrations tested. Data show mean expression of each SNP allele ± SEM (n = 
3), statistical analysis carried out using two-way ANOVA with Bonferroni post-hoc testing. *P 
< 0.05, **P < 0.01. 
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3.5.5 Protein validation of siRNA allele-selectivity 
This project has so far demonstrated highly selective SNP-targeted 
knockdown of HTT mRNA using siRNA targeted to both alleles of rs362331. 
However, as before it is necessary to validate mRNA readings with protein 
analysis. Previous work using anti-total HTT siRNA has demonstrated 
approximately 50 % total HTT protein knockdown 72 h after transfection, 
corresponding to a 70 % reduction in HTT mRNA (Träger et al., 2014); this 
degree of on-target mRNA knockdown was also achieved using siRNA 
targeted to rs362331. 
To address this, siRNA targeting each allele of rs362331 was packaged into 
GeRPs at a dose of 36 nM, as initial experiments showed this formulation to 
achieve the optimal combination of potency and selectivity. As the siRNAs 
targeting rs362273 and rs362307 did not achieve significant selectivity during 
initial testing by qPCR, it was decided not to advance their use to protein 
studies. Monocyte-derived macrophages were isolated from peripheral blood 
samples donated by HD subjects heterozygous for rs362331, before being 
transfected with GeRPs containing either SCR, anti-total HTT or allele-
selective siRNA. The cultures were then harvested after 72 h and the levels 
of both total and mHTT protein were measured by MSD assays. To identify 
which siRNA was targeting which HTT allele, PBMC pellets collected from 
each subject were further analysed by SLiC in order to link each SNP allele 
to either wild-type or mHTT (Liu et al., 2008). Three of the subjects used for 
protein analysis had linkage of the C allele of rs362331 to mHTT (Fig. 3.13), 
while five had linkage of the T allele to mHTT (Fig. 3.14); samples from these 
subject groups were analysed separately. 
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Consistent with previous work, treatment of C-linked subjects with anti-total 
HTT siRNA resulted in an approximately 50 % reduction in both total and 
mHTT protein levels. Furthermore, treatment with both allele-selective 
siRNAs resulted in a significant decrease in total HTT protein, the potency of 
which did not differ between the anti-U and anti-C siRNAs. This is consistent 
with the qPCR data presented earlier in this chapter. However, preferential 
suppression of mHTT protein was not seen following treatment with anti-C 
siRNA compared to anti-U siRNA.  
When analysing samples with linkage of the T allele to mHTT, significant 
knockdown of total HTT was again seen following treatment with each allele-
selective siRNA. This was equivalent to the HTT knockdown seen in the C-
linked samples, demonstrating that the effect of each siRNA on total HTT is 
independent of which SNP allele is linked to mHTT. However, significant 
knockdown of mHTT was only seen following treatment with the anti-U 
siRNA, with no significant difference in mHTT levels being seen between the 
SCR and anti-C treated samples. Furthermore, no difference in mHTT levels 
was seen between the anti-total HTT and anti-U treated samples, while 
mHTT levels were found to be significantly higher in the anti-C treated 
samples compared to the anti-total HTT treated samples. This demonstrates 
that preferential suppression of mHTT is achieved in T-linked subjects 
following treatment with anti-U compared to anti-C siRNA, and shows that 
the selective knockdown seen with mRNA also translates to protein studies. 
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Figure 3.13. Analysis of HTT protein knockdown in HD subjects with the C allele of 
rs362331 linked to mHTT. Monocyte-derived macrophages were isolated from HD patients 
heterozygous for rs362331 with linkage of the C allele to mHTT, before treating with GeRPs 
containing either SCR, anti-total HTT or allele-selective siRNA targeted to each allele of 
rs362331. Expression of (A) mutant and (B) total HTT protein was measured after 72 h using 
MSD assays, before normalisation to total protein content as measured by BCA assays. 
Data show mean protein levels ± SEM (n = 3), statistical analysis carried out using one-way 
ANOVA with Tukey post-hoc testing. Asterisks above bars show post-test significance 
compared to the SCR-treated samples. *P < 0.05, **P < 0.01. 
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Figure 3.14. Analysis of HTT protein knockdown in HD subjects with the T allele of 
rs362331 linked to mHTT. Monocyte-derived macrophages were isolated from HD patients 
heterozygous for rs362331 with linkage of the T allele to mHTT, before treating with GeRPs 
containing either SCR, anti-total HTT or allele-selective siRNA targeted to each allele of 
rs362331. Expression of (A) mutant and (B) total HTT protein was measured after 72 h using 
MSD assays, before normalisation to total protein content as measured by BCA assays. 
Data show mean protein levels ± SEM (n = 5), statistical analysis carried out using one-way 
ANOVA with Tukey post-hoc testing. Asterisks above bars show post-test significance 
compared to the SCR-treated samples. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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3.5.6 Analysis of HD myeloid cell cytokine production 
following allele-selective HTT suppression 
Previous work has shown that transfection of HD myeloid cells with anti-total 
HTT siRNA results in a significant decrease in the production of IL-6, IL-8 
and TNFα following stimulation with LPS and IFN-γ (Träger et al., 2014). To 
address whether allele-selective suppression of mutant and/or wild-type HTT 
has similar effects, monocyte-derived macrophages were isolated from HD 
subjects heterozygous for rs362331, before being transfected with GeRPs 
containing 36 nM of SCR, anti-total HTT or allele-selective siRNA. The cells 
were stimulated with LPS and IFN-γ 72 h after transfection, before the 
supernatants were harvested after a further 24 h and analysed using MSD 
assays. SNP linkage of rs362331 to mHTT was again carried out using the 
SLiC protocol; two were found to have linkage of the C allele to mHTT, while 
three had linkage of the T allele to mHTT. As no significant differences were 
seen in the mRNA knockdown provided by the anti-U and anti-C siRNAs, 
samples were grouped for analysis into anti-wild-type and anti-mutant HTT.  
Consistent with previous data, treatment with anti-total HTT siRNA produced 
a significant reduction in cytokine production for all three cytokines that were 
analysed (Fig. 3.15). Interestingly, targeting of both wild-type and mHTT with 
allele-selective siRNA also produced a significant reduction in the production 
of all three cytokines. This was the case regardless of whether wild-type or 
mHTT was targeted, and there were no significant differences in the levels of 
any of the cytokines between the allele-selective treatment groups. This 
suggests that wild-type HTT may also play a role in immune cell function, 
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and is consistent with data showing that total HTT-lowering in control cells 
significantly reduces their cytokine response to LPS (Träger et al., 2014).  
While post-hoc testing did not reveal any statistically significant differences in 
cytokine production between the samples treated with anti-total HTT and 
allele-selective siRNA, the mean levels of both IL-6 and TNFα were more 
than 50 % lower following total HTT knockdown compared to selective 
knockdown of either wild-type or mHTT. The reduction of both of these 
cytokines was also found to be more significant in the anti-total HTT samples 
compared to SCR control (p < 0.01 compared to p < 0.05). This suggests 
that the overall HTT load in a cell may be crucial to determining its cytokine 
production, as the reduced IL-6 and TNFα suppression seen in the allele-
selective siRNA-treated samples may be due to the sparing of one HTT 
allele compared to total HTT-lowering. Regardless, these data demonstrate 
that the allele-selective suppression of both wild-type and mHTT is able to 
ameliorate the hyper-reactive cytokine phenotype of HD myeloid cells. 
Figure 3.15. Analysis of HD myeloid cell cytokine production following allele-
selective HTT suppression. Monocyte-derived macrophages were isolated from SNP-
genotyped HD patients and treated with GeRPs containing either SCR, anti-total HTT or 
allele-selective siRNA targeted to each allele of rs362331. Linkage of each SNP allele to 
either wild-type or mHTT was determined using the SLiC protocol. After 72 h the 
macrophages were stimulated with LPS and IFNγ, before the culture supernatants were 
collected after a further 24 h and analysed using MSD assays. Cytokine values were 
normalised to total protein content as measured by BCA assays. Data show mean cytokine 
levels ± SEM (n = 5 for IL-6 and TNFα, n = 4 for IL-8), statistical analysis carried out using 
one-way ANOVA with Tukey post-hoc testing. Asterisks above bars show post-test 
significance compared to the SCR-treated samples. *P < 0.05, **P < 0.01, ***P < 0.001. 
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3.6 Discussion 
The monogenic nature of HD makes it an ideal target for treatment by PTGS, 
with suppression of the mHTT protein being shown to ameliorate pathology 
and improve the disease course in animal models (Drouet et al., 2009; 
Kordasiewicz et al., 2012). Indeed, clinical trials are ongoing to carry out non-
selective HTT-lowering in human HD patients using intrathecal infusion of 
ASOs, with the aim of suppressing mHTT by 50 % (Ionis Pharmaceuticals, 
2015). Work presented in this chapter demonstrates allele-selective 
suppression of mHTT in primary ex vivo patient cells, using siRNA targeted 
to rs362331 in exon 50 of the HTT transcript. siRNA targeted to the U allele 
of rs362331 was able to achieve 74 % on-target knockdown with only 17 % 
suppression of the off-target C allele, while siRNA targeted to the C allele of 
rs362331 was able to achieve 63 % on-target knockdown with only 30 % off-
target suppression of the U allele. This discrimination was found to be highly 
statistically significant at an siRNA dose of 36 nM. Crucially, the degree of 
on-target knockdown was equivalent to that provided by the previously used 
anti-total HTT siRNA, while no significant difference was seen between 
expression of the off-target allele compared to SCR control for either siRNA. 
Knockdown selectivity was also found to translate to the protein level, with 
only treatment with anti-U and not anti-C siRNA resulting in a significant 
decrease in mHTT protein when studying samples with linkage of the T allele 
of rs362331 to mHTT. As expected, the degree of total HTT suppression was 
independent of which SNP allele was linked to mHTT. This is a significant 
advance in HD therapeutics, as previous work has largely been limited to cell 
lines and animal models (Carroll et al., 2011; Drouet et al., 2014). 
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This study also demonstrates the possibility of carrying out a patient-centred 
workflow comprising SNP genotyping, SNP linkage and allele-selective 
silencing tailored specifically to an individual’s genotype in a small cohort. 
This is in contrast to previous studies that have largely made use of (often 
homozygous) pre-genotyped cell lines and animal models, and presents a 
significant advance in the potential use of personalised genomic medicine. 
These techniques will form the basis of treatment if allele-selective silencing 
is to be used in the clinic, and this study demonstrates the first instance of 
their being used in combination, instead of individually as part of a technical 
study. While this provides valuable insight into the potential applications of 
this technology, there are a number of issues that need to be addressed. 
Work presented in this chapter reinforces previous studies demonstrating 
that the potency and selectivity of mHTT suppression varies considerably 
depending on the specific SNP site being targeted (Carroll et al., 2011). 
Here, highly significant selectivity was achieved using siRNAs targeted to 
both alleles of rs362331. In contrast, considerable off-target knockdown was 
seen when targeting both alleles of rs362273, while siRNA targeting the U 
allele of rs362307 were not found to be selective at all. This variation applies 
even between SNPs that have an equivalent base mismatch, as both 
rs362331 and rs362307 are C/T in heterozygous individuals. This is likely 
due to the nucleotide sequence and tertiary structure of the transcript 
surrounding the base mismatch (Southwell et al., 2014), and demonstrates 
that the choice of SNP to target is a crucial issue to address during the 
preclinical stages of allele-selective drug design. This is particularly relevant 
given the limited number of potential sequences that may be used to target 
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each SNP, in contrast to the thousands which are available for the non-
selective lowering of both HTT alleles (Sah and Aronin, 2011). This problem 
is exacerbated when using siRNAs instead of ASOs, as over 90 % of HTT 
SNPs are intronic and therefore not targetable by siRNA (Keiser et al., 2016). 
A further issue arising from this observation is that it should not be assumed 
that the SNPs with the highest prevalence of heterozygosity will be 
targetable with allele-selective therapeutics. The rs362307 SNP in the 3’-
UTR of HTT is the most prevalent SNP in Caucasian HD patients, with a 
heterozygosity rate of approximately 48.6 % (Pfister et al., 2009). However, 
siRNAs targeted to this SNP were unable to achieve selectivity despite 
carrying out a comprehensive dose-ranging analysis. This suggests that it 
may be necessary to target less prevalent SNPs in order to improve 
selectivity. As a result, it may be that predictions about what proportion of HD 
patients may be treated are overly optimistic, if additional prevalent SNPs are 
also found to be unsuitable for therapeutic targeting.  
Furthermore, this study demonstrates that oligonucleotide therapeutics that 
have been developed in cell models must be validated in primary human 
cells to confirm their selectivity. The siRNAs targeting rs362273 and 
rs362307 were previously shown to be selective when co-transfected into 
HeLa cells with a luciferase reporter (Pfister et al., 2009), yet did not retain 
their selectivity when used to transfect HD patient myeloid cells. This may be 
because the siRNAs were only used to suppress a short construct when they 
were tested in HeLa cells, instead of the full-length HTT mRNA that is 
present in patient cells. This may be as much a reflection on the limitations of 
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the luciferase model as it is on the quality of the siRNA; regardless, the point 
remains that validation in primary cells is vital for therapeutic development. 
Indeed, it should perhaps not be surprising that some of the siRNAs tested 
were unable to achieve selectivity, as they are aiming to discriminate 
between a single base mismatch with identical nucleotide sequences on 
either side. The 3’-UTR SNP rs362307 is particularly challenging for allele-
selective silencing, as the surrounding sequence is extremely GC rich (Sah 
and Aronin, 2011), with the SNP itself comprising a pyrimidine (C/T) 
mismatch (purine (A/G) mismatches typically allow greater selectivity). 
Nucleotide sequences utilising single base mismatches have been shown to 
be inadequate when targeting this SNP (Pfister et al., 2009), which has now 
generated poor discrimination across multiple research groups and studies 
(Drouet et al., 2014). While previous studies have shown that adding an 
additional base mismatch is able to improve selectivity for the on-target allele 
(Pfister et al., 2009), the benefits of this approach are clearly limited. One 
potential solution may be chemical modification of the siRNAs in question, as 
chemical modification of ASOs has been shown to improve allele-selectivity 
(Østergaard et al., 2013). However, it should be noted that some chemical 
modifications have been found to cause toxicity. This shows that the 
discrimination achieved by targeting rs362331 should by no means be 
regarded as trivial, given the significant technical challenges involved. 
Perhaps one of the most important insights to be gained from this study 
relates to the significant practical considerations that will be associated with 
taking allele-selective silencing to clinical trials. While this study was able to 
overcome the technical hurdles involved in genotyping a large cohort of HD 
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patients and individually linking each SNP allele to either wild-type or mHTT 
in a subset of subjects, it remains to be seen whether this will be feasible in a 
clinical setting. Crucially, it is essential that the genotyping process carried 
out before dosing HD patients is 100 % specific, as incorrect genotyping will 
lead to the administration of an siRNA that selectively suppresses wild-type 
while preserving mHTT. This is a major safety concern, especially given the 
technical complexity of the SLiC protocol, which is a complicated multi-step 
procedure carried out over several days (Liu et al., 2008). Such a technique 
is unlikely to ever be available in a standard clinical laboratory, and would 
likely be confined to specialist facilities. 
Furthermore, the technical challenges associated with allele-selective 
silencing are compounded by the relatively low prevalence of heterozygous 
SNPs in the HD patient population. The rs362331 SNP that provided optimal 
selectivity in this study is only heterozygous in 39.4 % of HD subjects, with 
no linkage of either allele to mHTT (Pfister et al., 2009); this means that two 
siRNAs would be required to treat every patient heterozygous for this SNP. 
This still leaves a majority of the patient population who would be unable to 
be treated by targeting this SNP, with multiple SNPs needing to be utilised to 
treat a majority of HD patients. Current estimates suggest that 75 % of 
patients may be treatable by targeting three SNP sites (Pfister et al., 2009), 
however this does not take into account the fact that some of the most 
prevalent SNPs (e.g. rs362307) may not be amenable to allele-selective 
silencing. While the development of siRNAs to target three SNP sites may 
not appear daunting in a preclinical setting, it must be appreciated that under 
current legislation each siRNA would need to be licensed as an individual 
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drug, with no provision available for combined trials of multiple siRNAs. It is 
therefore questionable whether drug companies are likely to invest the vast 
resources required to carry out clinical trials for even a single allele-selective 
siRNA, let alone the multiple trials that would be required to cover a majority 
of HD patients. It has been suggested that using two therapeutics targeted to 
each allele of a single SNP would allow treatment of the entire patient 
population by offering selective knockdown for heterozygous patients and 
non-selective knockdown for homozygous patients (Skotte et al., 2014). 
However, this strategy would still require accurate genotyping and twice the 
resources needed to carry out clinical trials of non-selective HTT-lowering 
Although the above issues suggest that allele-selective suppression is 
unlikely to be used as a therapeutic for HD, there is considerable evidence 
that suppression of wild-type HTT in the adult brain is well tolerated. While 
conditional Htt knockout has been shown to cause neurodegeneration in 
mice (Dragatsis et al., 2000), Htt depletion at later time points was 
associated with reduced neuronal pathology. This suggests that, while HTT 
is essential for neuronal development during embryogenesis (Godin et al., 
2010; Tong et al., 2011), its role in later life is less vital. This hypothesis was 
recently advanced by a study of inducible Htt knockout mice showing that, 
while ubiquitous Htt knockout was associated with 95 % death after two 
months of life, knockout after four months and eight months was associated 
with 70 % and 95 % survival respectively (Wang et al., 2016). Selective 
knockout of neuronal Htt was then found to have no effect on survival after 4 
months of life, while no deficits were found when studying either motor 
performance or brain volume following knockout at these later time points. 
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Crucially, death at two months was found to be due to acute pancreatitis 
caused by degeneration of pancreatic acinar cells, demonstrating that Htt 
knockout in mice causes age-related death that is not due to its depletion in 
neurons. This suggests that concerns over wild-type HTT suppression may 
be exaggerated when limited to the adult CNS. 
This conclusion is supported by data showing that wild-type suppression is 
well tolerated in both mice and non-human primates. Three studies of non-
selective RNAi injection in the mouse striatum did not find any adverse 
effects up to either four or five months after treatment (McBride et al., 2008; 
Boudreau et al., 2009; Stanek et al., 2014). Indeed, a further study 
demonstrated that transient Htt-lowering does not cause any damage up to 9 
months after treatment, while a sustained 75 % Htt reduction in the normal 
adult mouse brain does not affect motor performance up to at least four 
months (Kordasiewicz et al., 2012). This work was expanded to include non-
human primates, where infusion of ASOs into the CNS of rhesus monkeys 
was tolerated for up to eight weeks after the termination of a twenty-one day 
treatment period. Furthermore, a 45 % reduction of HTT expression in the 
rhesus putamen does not induce motor deficits or neuronal degeneration up 
to six weeks after the injection of RNAi (McBride et al., 2011); this was later 
extended to show that partial RNAi-mediated HTT-lowering is well tolerated 
in the rhesus striatum for at least six months (Grondin et al., 2012). 
Indeed, excluding drug-related toxicity there is currently no evidence that 
siRNA or ASO-medated HTT-lowering is detrimental in any animal model 
that has been studied to date. This may be due to the fact that siRNAs and 
ASOs only produce partial HTT-lowering of approximately 50 %, allowing the 
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remaining wild-type protein to maintain normal cellular function; it may also 
be due to the age-related development of compensatory mechanisms (Wang 
et al., 2016). Although it is not possible to accurately scale up animal studies 
into humans, this work provides support for the use of non-selective HTT-
lowering in HD. While the results of the first-into-man HTT-lowering trials will 
still be needed to draw firm conclusions on what degree of wild-type HTT 
suppression is tolerated in the human CNS, it may well be that the success 
of total HTT-lowering eliminates the need for allele-selective silencing. 
However, the difficulties associated with using allele-selective silencing in a 
clinical setting should not be allowed to obscure the very real benefits it 
offers as a research tool. The majority of previous work has used conditional 
HTT knockout or total-HTT-lowering to examine the effects of suppressing 
mHTT on cellular function (see Section 1.2.2). While undoubtedly useful, 
these studies have been unable to definitively distinguish between the roles 
of wild-type and mHTT, as both are affected by these techniques. An 
example of this can be seen in the fact that control myeloid cells also exhibit 
reduced cytokine responses to LPS following HTT-lowering (Träger et al., 
2014), and it is therefore uncertain to what degree the reduction in cytokine 
production by HD myeloid cells is due to either wild-type or mHTT-lowering. 
Allele-selective silencing may now be used to dissect the specific functions of 
wild-type and mHTT in a wide range of cell types, providing access to a level 
of functional insight that was not previously available. The advent of iPSC 
technology further raises the possibility of creating isogenic cell lines that are 
heterozygous for specific SNPs (Park et al., 2008), thereby forgoing the 
genotyping process required when investigating primary human cells.  
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Work presented in this chapter takes some of the first steps towards the 
specific investigation of wild-type and mHTT function, using allele-selective 
suppression to investigate the cytokine response of HD myeloid cells to LPS. 
If HTT’s effects on cytokine production were limited exclusively to the mutant 
form of the protein, it would be expected that selective mHTT-lowering would 
produce a significantly greater reduction in cytokine levels compared to 
selective lowering of the wild-type. However, no significance differences 
were seen in the levels of any of the three cytokines tested between samples 
treated with either anti-mutant or anti-wild-type siRNA. This suggests that 
wild-type HTT may have an as yet undefined role in normal immune cell 
function, and is consistent with previous work showing that cytokine 
production by control myeloid cells in response to LPS is also reduced 
following total HTT-lowering (Träger et al., 2014).  
Further insight may be provided by comparing the effects of total to allele-
selective HTT-lowering. Although none of the differences reached statistical 
significance, the mean IL-6 and TNFα levels measured following total HTT-
lowering were less than 50 % of those measured following selective lowering 
of either the mutant or wild-type allele. This suggests that total cellular HTT 
load may be the key factor influencing cytokine production, as the sparing of 
one allele by the allele-selective siRNAs will result in less overall knockdown 
than that achieved by anti-total HTT siRNA. However, considerable further 
work will be required to confirm or reject this hypothesis, the full extent of 
which is beyond the scope of this thesis. Regardless, these data provide 
strong evidence that wild-type HTT has a novel immune cell function. 
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3.7 Summary 
Work presented in this chapter demonstrates for the first time the allele-
selective suppression of mHTT in primary human ex vivo patient cells. 
Following optimisation of the GeRP transfection protocol, a large cohort of 
HD patients was genotyped to identify individuals who were heterozygous for 
three SNPs in the HTT gene. A panel of siRNAs targeting each SNP was 
then screened using monocyte-derived macrophages isolated from 
genotyped HD patients. While the siRNAs targeting rs362273 in exon 57 and 
rs362307 in the 3’-UTR were not found to offer adequate selectivity of mRNA 
knockdown, siRNAs targeting rs362331 in exon 50 produced highly 
significant selectivity between alleles, with on-target suppression equivalent 
to that seen using anti-total HTT siRNA. Unfortunately, the selectivity offered 
by each of these siRNAs was not found to be improved by lowering the 
concentration packaged into each GeRP. The mRNA suppression provided 
by the anti-rs362331 siRNAs was further validated by analysis of HTT protein 
expression, with only treatment with anti-U and not anti-C siRNA found to 
provide significant knockdown of mHTT in patients with linkage of the T allele 
of rs362331 to mHTT. Finally, the effect of allele-selective HTT-lowering on 
the hyper-reactive cytokine phenotype of HD myeloid cells was investigated, 
with selective suppression of both wild-type and mHTT found to produce a 
significant reduction in IL-6, IL-8 and TNFα levels. Surprisingly, cytokine 
production following selective mHTT suppression was not found to differ from 
that following selective wild-type suppression, suggesting that wild-type HTT 
may have a novel role in immune cell function.  
Chapter 4 Whole transcriptome analysis of HD myeloid cells 
161 
 
4 Whole transcriptome analysis of 
HD myeloid cells 
4.1 Background 
Myeloid cells are perhaps the most well characterised of any peripheral 
immune cell subset in HD, with previous ex vivo studies demonstrating that 
human HD myeloid cells exhibit hyper-reactive cytokine responses to LPS 
(Träger et al., 2014), in addition to deficits when migrating to chemotactic 
stimuli and phagocytosing fluorescent beads (Kwan et al., 2012b; Träger et 
al., 2015). These changes are mirrored in both knock-in cell lines and mouse 
models of HD, suggesting that they are the result of a cell-intrinsic effect of 
mHTT expression. This is further supported by the fact that the hyper-
reactive phenotype of HD myeloid cells is reversible following HTT-lowering 
with anti-total HTT siRNA (Träger et al., 2014).  
However, studies to date have almost exclusively focused on the phenotypic 
abnormalities that occur in response to stimulation, and very little information 
is available on whether these cells are also abnormal in their basal, 
unstimulated state. Indeed, there is currently no evidence that HD myeloid 
cells have increased resting expression of the proinflammatory cytokines that 
are upregulated in response to LPS (Träger et al., 2014). This raises 
uncertainty about whether mHTT only affects HD myeloid cells following 
stimulation, or if there is an underlying mechanism producing resting 
dysfunction that is responsible for the changes seen once the cells are 
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activated. Work on a murine HD microglial line revealed a cell-autonomous 
priming effect of mHTT, leading to an increase in resting proinflammatory 
gene expression (Crotti et al., 2014); this was linked to increased levels of 
the transcription factor PU.1. This raises the possibility that the hyper-
reactive LPS response of HD myeloid cells is due to the baseline effects of 
mHTT expression, although this hypothesis is yet to be investigated. The 
potential existence of resting dysfunction in HD myeloid cells has important 
implications for targeting peripheral immunity as a novel HD therapeutic, as 
intrinsic pathology is more likely to be treatable over long periods without the 
need to time interventions to coincide with specific inflammatory events. 
Furthermore, while the phenotypic effects of mHTT are relatively well 
characterised, considerably less is known about its effect on the myeloid cell 
transcriptome. Transcriptional dysregulation is a key feature of HD 
pathogenesis (Hodges et al., 2006), and occurs via a number of mechanisms 
including the sequestration of transcription factors, direct binding of mHTT 
fragments to DNA, and changes in the activity of intracellular signalling 
pathways responsible for regulating gene expression (Seredenina and Luthi-
Carter, 2012). Mutant HTT has been shown to activate the NFκB pathway by 
directly interacting with the IKK complex (Khoshnan et al., 2004); this is 
associated with hyper-reactivity in HD myeloid cells, which exhibit an 
exaggerated NFκB response to LPS, both in the magnitude of the initial 
response and in the time taken to return to baseline (Träger et al., 2014). 
However, there is currently no evidence that HD myeloid cells also display 
increased NFκB activity in the resting state. Furthermore, the complexity of 
intracellular signalling downstream of TLR4 necessitates the investigation of 
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additional pathways to build up a complete profile of the likely mechanisms 
underlying HD myeloid cell dysfunction (Akira and Takeda, 2004). 
Numerous transcriptional changes have been demonstrated in previous 
studies of HD peripheral blood cells (Borovecki et al., 2005; Runne et al., 
2007; Mastrokolias et al., 2015); however, these were largely carried out on 
heterogeneous cell populations and have rarely been validated between 
studies. Therefore, the study of individual cell populations using modern 
sequencing technology is required to characterise the specific transcriptional 
changes associated with mHTT expression, in addition to determining 
whether HD immune dysfunction also exists in the absence of stimulation. 
4.2 Aims 
1. To carry out whole transcriptome analysis of unstimulated and 
stimulated primary human HD and control monocytes using RNA-Seq. 
2. To identify functional gene sets that are enriched in unstimulated and 
stimulated HD monocytes compared to control using GSEA. 
3. To identify upstream regulators that may be responsible for mediating 
the transcriptional changes seen in HD monocytes using IPA®. 
4. To functionally investigate potential changes in the activation states of 
specific intracellular signalling pathways in HD myeloid cells. 
5. To characterise the effects of HTT-lowering on the transcriptome of 
HD myeloid cells. 
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4.3 Methods 
PBMCs were isolated using density centrifugation (Section 2.4.1), before 
CD14+ monocytes were isolated by magnetic cell sorting (Section 2.4.2). 
Monocyte stimulation was carried out using 2 µg/ml LPS and 10 ng/ml IFNγ 
for 4 h, before RNA was extracted using the RNeasy Mini Kit (Section 2.7.1) 
and its integrity was confirmed using a 2100 Bioanalyzer (Section 2.7.3). 
RNA samples were analysed by RNA-Seq (Section 2.8), before the raw data 
files were used for differential expression, splicing, GSEA and IPA® analyses 
(Section 2.10). Analysis of NFκB, ERK and p38 MAPK signalling activity was 
carried out by Western blotting (Section 2.11.4). Potential reversal of gene 
expression changes following HTT-lowering was investigated using SYBR 
Green qPCR (Section 2.7.5) following transfection with SCR and anti-total 
HTT siRNA-containing GeRPs (Section 2.5.2). Statistical analysis was 
carried out according to Section 2.14.2. 
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4.4 Contributions 
Work presented in this chapter was carried out in collaboration with UCL 
Genetics Institute and Cardiff University School of Medicine. Sample 
collection, myeloid cell culture and RNA isolation were carried out by James 
Miller, before the samples were shipped to deCODE Genetics, Iceland for 
analysis by RNA-Seq. Differential expression, splicing and IPA® analyses 
were then carried out by Dr Kitty Lo, while GSEA was carried out by 
Professor Peter Holmans. The processed data was then returned to James 
Miller for biological analysis. Western blotting experiments were carried out 
by James Miller with assistance from Dr Lucy Carty, while qPCR 
experiments were carried out by James Miller. Cytoscape figures were 
generated in collaboration with Dr Timothy Stone. Findings presented in this 
chapter were published in Human Molecular Genetics (full manuscript 
included in the Appendices of this thesis): 
Miller, J.R., Lo, K.K., Andre, R., Hensman Moss, D.J., Träger, U., Stone, 
T.C., Jones, L., Holmans, P., Plagnol, V., Tabrizi, S.J. 2016. RNA-Seq of 
Huntington’s disease patient myeloid cells reveals innate transcriptional 
dysregulation associated with proinflammatory pathway activation. Hum Mol 
Genet [online]. Available from: doi: 10.1093/hmg/ddw142. 
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4.5 Results 
4.5.1 Sample collection and data processing 
The lack of existing knowledge regarding transcriptional alterations in HD 
monocytes necessitates a broad approach to gene expression profiling in 
these cells. To address this, CD14+ monocytes were isolated from peripheral 
blood samples donated by thirty manifest HD patients and thirty-three 
controls. All of the HD patients had early or moderate stage disease to 
control for the potential effects of disease stage on gene expression 
(Seredenina and Luthi-Carter, 2012), while all subjects were non-smokers in 
order to eliminate the myriad effects of smoking on the monocyte 
transcriptome (Zeller et al., 2010). Following isolation, monocytes were 
cultured with and without stimulation with LPS and IFNγ for 4 h, as this has 
previously been shown to be the peak time point for gene expression 
changes downstream of the LPS receptor TLR4 (Aung et al., 2006; 
Yamamoto et al., 2004). RNA-Seq of these samples was then carried out to 
provide a quantitative analysis of the entire HD monocyte transcriptome.  
Following sequencing and alignment, data QC was carried out using the 
RNA-SeQC package; this confirmed that metrics including rRNA rate and 
exonic rate were within acceptable parameters (Table 4.1). Finally, LPS 
stimulation was tested by pooling the HD and control monocytes and 
performing differential expression analysis between the unstimulated and 
stimulated datasets; 12,599 genes were differentially expressed (FDR < 
0.05; data not shown), confirming that successful stimulation took place. 
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Table 4.1.  Summary of RNA-Seq QC statistics. RNA-Seq data files were pooled and 
analysed using the RNA-SeQC package to determine data quality was within acceptable 
parameters. One sample did not meet the QC threshold and was removed from further 
analysis; this sample is not included in this summary. 
QC Statistic Mean ± SD 
End 1 mapping rate 1.013 ± 0.009 
End 2 mapping rate 0.987 ± 0.009 
Estimated library size 1.03E+08 ± 2.85E+07 
Exonic rate 0.876 ± 0.024 
Genes detected 1.79E+04 ± 7.62E+02 
Intergenic rate 0.026 ± 0.005 
Intragenic rate 0.974 ± 0.005 
Intronic rate 0.098 ± 0.020 
Mapped 1.02E+08 ± 2.11E+07 
Mean fragment length 183.427 ± 51.374 
rRNA rate 0.010 ± 0.006 
Transcripts detected 9.97E+04 ± 3.04E+03 
Unique rate of mapped 0.757 ± 0.051 
 
4.5.2 HD monocytes exhibit resting proinflammatory 
transcriptional changes 
Following data processing and QC, separate differential expression analyses 
were carried out on the unstimulated and stimulated datasets, in order to 
identify transcripts that were significantly altered between HD and control 
monocytes. Analysis of the unstimulated dataset revealed differential 
expression of 130 genes (FDR < 0.05) in resting HD monocytes compared to 
control (Table 4.2; complete list in Appendices); 101 of these genes were 
found to be significantly upregulated, while 29 were found to be significantly 
downregulated. Although the differentially expressed genes were associated 
with a wide range of effector functions, proinflammatory cytokines and 
chemokines were among the most prominent.  
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Table 4.2.  The top twenty gene expression changes in resting HD monocytes 
(ranked by FDR). 
Gene 
name 
Ensembl ID 
RPKM 
(control) 
RPKM 
(HD) 
Log2 fold 
change 
p-value FDR Protein function 
FAM124A ENSG00000150510 0.242 0.812 2.684 4.61E-08 6.05E-04 
Functionally 
uncharacterised 
IL19 ENSG00000142224 0.586 1.473 2.358 1.15E-07 7.57E-04 Proinflammatory cytokine 
IL23A ENSG00000110944 1.914 3.597 1.576 7.84E-07 2.55E-03 Proinflammatory cytokine 
FAM213B ENSG00000157870 7.837 5.201 -0.604 8.99E-07 2.55E-03 Prostaglandin metabolism 
TGFA ENSG00000163235 0.665 1.392 1.550 9.69E-07 2.55E-03 Growth factor 
FZD7 ENSG00000155760 0.397 0.246 -0.721 1.39E-06 3.04E-03 Wnt protein receptor 
C6orf223 ENSG00000181577 0.063 0.297 2.127 1.92E-06 3.60E-03 
Functionally 
uncharacterised 
PROCR ENSG00000101000 3.695 10.872 1.552 3.61E-06 5.69E-03 
Receptor for activated 
protein C 
NT5E ENSG00000135318 0.210 0.725 2.082 4.24E-06 5.69E-03 
Extracellular nucleotide 
hydrolysis 
SMO ENSG00000128602 0.259 0.124 -1.161 4.33E-06 5.69E-03 
G protein-coupled 
receptor 
CISH ENSG00000114737 2.723 5.161 1.439 5.90E-06 7.04E-03 
Negative regulation of 
JAK/STAT signalling 
C6orf165 ENSG00000213204 0.038 0.086 1.205 6.57E-06 7.20E-03 
Functionally 
uncharacterised 
CCL19 ENSG00000172724 0.518 1.767 1.763 8.79E-06 8.89E-03 
Chemoattraction of T and 
B lymphocytes 
PTGS2 ENSG00000073756 2.319 18.604 1.813 9.52E-06 8.93E-03 
Prostaglandin synthesis 
enzyme 
HPSE ENSG00000173083 11.322 24.941 1.142 1.10E-05 9.68E-03 
Extracellular matrix 
remodelling 
VEGFA ENSG00000112715 5.475 14.251 0.898 1.35E-05 1.11E-02 
Angiogenesis and 
endothelial cell growth 
ANXA11 ENSG00000122359 136.875 105.621 -0.374 1.72E-05 1.33E-02 
Phospholipid-binding 
protein 
CDK2 ENSG00000123374 5.534 7.186 0.390 1.88E-05 1.39E-02 Cell cycle regulation 
R3HCC1 ENSG00000104679 15.225 11.394 -0.421 2.18E-05 1.45E-02 Nucleic acid binding 
PGAP3 ENSG00000161395 2.943 2.310 -0.364 2.28E-05 1.45E-02 
GPI-specific 
phospholipase 
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Resting HD monocytes were found to express significantly increased levels 
of IL6, IL12B, IL19, IL23A, CCL8, CCL19, CCL20, CXCL6 and CSF2 gene 
transcripts (Table 4.3); this is the first time that increased resting expression 
of proinflammatory cytokines has been demonstrated in HD myeloid cells at 
either the mRNA or protein level. Each of these genes had a log2 fold 
change of > 1, corresponding to a > 2-fold increase in mRNA expression.  
Analysis of the stimulated dataset revealed a stark contrast in terms of 
differential expression, as only three genes were found to be significantly 
altered (FDR < 0.05; Table 4.4). Each of these genes (DNAJB13, STAC and 
RASEF) were also differentially expressed in the unstimulated dataset (these 
genes are displayed as red dots in Fig. 4.1). Comparison of the log2 fold 
changes for the differentially expressed genes revealed a general trend 
whereby the relative expression differences between HD and control were 
reduced in the stimulated compared to the unstimulated dataset; this was the 
case for 116 of the 130 genes (Fig. 4.1). This concentration of transcriptional 
change in resting HD monocytes is a marked departure from previous 
functional studies, where stimuli have been required to elicit abnormalities. 
Table 4.3.  Differentially expressed cytokines and chemokines in resting HD 
monocytes (ranked by FDR).  
Gene 
name 
Ensembl ID 
RPKM 
(control) 
RPKM 
(HD) 
Log2 fold 
change 
p-value FDR 
IL19 ENSG00000142224 0.586 1.473 2.358 1.15E-07 7.57E-04 
IL23A ENSG00000110944 1.914 3.597 1.576 7.84E-07 2.55E-03 
CCL19 ENSG00000172724 0.518 1.767 1.763 8.79E-06 8.89E-03 
CSF2 ENSG00000164400 0.680 1.369 2.888 3.00E-05 1.55E-02 
IL12B ENSG00000113302 1.772 6.429 2.531 5.69E-05 2.27E-02 
IL6 ENSG00000136244 12.656 97.048 2.678 8.73E-05 2.69E-02 
CCL8 ENSG00000108700 41.093 103.771 2.142 1.74E-04 3.54E-02 
CCL20 ENSG00000115009 9.411 46.334 2.219 2.42E-04 4.08E-02 
CXCL6 ENSG00000124875 12.417 43.757 1.805 4.23E-04 4.96E-02 
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Table 4.4.  The top twenty gene expression changes in stimulated HD monocytes 
(ranked by FDR).  
Gene 
name 
Ensembl ID 
RPKM 
(control) 
RPKM 
(HD) 
Log2 fold 
change 
p-value FDR Protein function 
DNAJB13 ENSG00000187726 0.058 0.135 1.251 2.38E-06 2.68E-02 
Heat shock protein family 
member 
STAC ENSG00000144681 0.101 0.203 1.831 5.30E-06 2.68E-02 
Neuron-specific signal 
transduction 
RASEF ENSG00000165105 0.014 0.131 3.297 6.57E-06 2.68E-02 
Regulation of membrane 
traffic 
OTOF ENSG00000115155 0.102 0.409 1.917 2.23E-05 6.09E-02 Calcium ion sensor 
SPARC ENSG00000113140 2.965 1.074 -1.518 2.49E-05 6.09E-02 Regulation of cell growth 
SP3 ENSG00000172845 11.178 14.023 0.336 4.69E-05 7.43E-02 Transcription factor 
RPS6KA2 ENSG00000071242 0.687 0.402 -0.757 5.33E-05 7.43E-02 
Serine/threonine protein 
kinase 
STEAP1 ENSG00000164647 0.369 0.585 2.051 5.84E-05 7.43E-02 Metalloreductase enzyme 
CD300E ENSG00000186407 12.516 37.032 1.427 6.06E-05 7.43E-02 Myeloid cell surface protein 
C5 ENSG00000106804 0.289 0.442 0.594 6.07E-05 7.43E-02 
Complement system 
component 
NEK11 ENSG00000114670 0.374 0.524 0.490 6.93E-05 7.72E-02 Protein kinase 
RAB3D ENSG00000105514 0.152 0.332 1.072 8.13E-05 8.05E-02 Protein transport 
PLEKHN1 ENSG00000187583 1.743 2.573 0.567 8.54E-05 8.05E-02 
Functionally 
uncharacterised 
ATXN7L3 ENSG00000087152 23.446 27.121 0.213 1.01E-04 8.34E-02 
Component of the histone 
acetylation complex SAGA 
FAM214B ENSG00000005238 12.457 16.003 0.367 1.08E-04 8.34E-02 
Functionally 
uncharacterised 
PTCRA ENSG00000171611 0.240 0.120 -0.998 1.21E-04 8.34E-02 
Pre-T-cell receptor complex 
component 
CTSK ENSG00000143387 7.331 3.847 -0.964 1.28E-04 8.34E-02 
Lysosomal cysteine 
proteinase 
TFAP2E ENSG00000116819 0.143 0.204 0.555 1.35E-04 8.34E-02 
Sequence-specific DNA-
binding protein 
KLHL6 ENSG00000172578 4.684 3.193 -0.548 1.37E-04 8.34E-02 
B lymphocyte antigen 
receptor signaling 
CPED1 ENSG00000106034 0.393 0.235 -0.719 1.38E-04 8.34E-02 
Functionally 
uncharacterised 
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Figure 4.1.  Comparison of log2 fold changes in unstimulated and stimulated HD 
and control monocytes. The log2 fold changes for the 130 differentially expressed genes 
(FDR < 0.05) were compared between the unstimulated and stimulated datasets. The 
magnitude of the relative expression difference (whether positive or negative) was greater in 
the unstimulated samples for 116 of the genes, suggesting that transcriptional differences 
between HD and control become less pronounced in response to stimulation. Genes that 
were only differentially expressed in the unstimulated samples are shown in blue, while the 
three genes that were differentially expressed in both datasets are shown in red. HTT is 
shown in green, while the NFκB transcription family member RELA (p65) is shown in purple 
(however neither of these genes were differentially expressed). The line x = y is also shown. 
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4.5.3 HD monocytes do not show changes in alternative 
splicing 
While the above data demonstrate that HD monocytes experience 
transcriptional changes at the whole mRNA level, it is also important to 
consider the potential impact of variations in alternative splicing on HD 
myeloid cell function. Alternative splicing has been shown to be an important 
pathogenic mechanism in tissues from a range of neurodegenerative 
diseases, including HD brain (Fernández-Nogales et al., 2014). The RNA-
Seq expression datasets were therefore subjected to analyses of differential 
exon, intron and transcript expression using the R package Ballgown. 
However, no significant differences were detected in either the unstimulated 
or stimulated datasets for any of these analyses (FDR < 0.05; Tables 4.5-
4.10). This suggests that, in contrast to other previously studied tissues, 
changes in alternative splicing are not a significant factor in mediating HD 
innate immune dysfunction. 
Table 4.5.  The top ten exon splicing changes in unstimulated HD monocytes 
(ranked by FDR). 
Gene ID Feature Transcript ID p-value FDR 
WDR20 Exon 11926 202144 1.11E-05 5.53E-01 
LOC100288332 Exon 13825 21865 1.39E-05 5.53E-01 
LAMB3 Exon 3539 130 1.68E-05 5.53E-01 
CCDC88C Exon 11631 200554 1.81E-05 5.53E-01 
CILP Exon 12758 209927 2.38E-05 5.53E-01 
LGR5 Exon 9329 179768 2.45E-05 5.53E-01 
LGR5 Exon 9329 179767 2.84E-05 5.53E-01 
ZFC3H1 Exon 9330 179770 3.27E-05 5.53E-01 
LGR5 Exon 9329 179769 3.45E-05 5.53E-01 
LGR5 Exon 9329 179764 4.37E-05 5.53E-01 
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Table 4.6.  The top ten exon splicing changes in stimulated HD monocytes 
(ranked by FDR). 
Gene ID Feature Transcript ID p-value FDR 
RHOT1 Exon 15773 27628 6.89E-06 9.99E-01 
ST3GAL4 Exon 7978 16708 9.80E-06 9.99E-01 
LGR5 Exon 9329 179769 2.13E-05 9.99E-01 
LILRB3 Exon 20082 62341 3.09E-05 9.99E-01 
LGR5 Exon 9329 179761 4.15E-05 9.99E-01 
LGR5 Exon 9329 179763 4.19E-05 9.99E-01 
ZFC3H1 Exon 9330 179774 4.45E-05 9.99E-01 
ZFC3H1 Exon 9330 179770 4.80E-05 9.99E-01 
LILRA6 Exon 20083 62351 5.17E-05 9.99E-01 
TRIM21 Exon 5913 150624 5.96E-05 9.99E-01 
Table 4.7.  The top ten intron splicing changes in unstimulated HD monocytes 
(ranked by FDR). 
Gene ID Feature Transcript ID p-value FDR 
PIKFYVE Intron 22445 84654 3.12E-06 3.77E-01 
PRMT1 Intron 19727 62638 4.28E-06 3.77E-01 
PEX5 Intron 8269 162867 1.41E-05 6.37E-01 
CLEC18B Intron 14702 25072 1.92E-05 6.37E-01 
PEX5 Intron 8269 162869 2.27E-05 6.37E-01 
ECM1 Intron 2270 117696 2.51E-05 6.37E-01 
FAM96A Intron 12730 19828 2.53E-05 6.37E-01 
PEX5 Intron 8269 162866 3.99E-05 6.96E-01 
PEX5 Intron 8268 162864 4.43E-05 6.96E-01 
PEX5 Intron 8269 162871 5.46E-05 6.96E-01 
Table 4.8.  The top ten intron splicing changes in stimulated HD monocytes 
(ranked by FDR). 
Gene ID Feature Transcript ID p-value FDR 
MEFV Intron 13651 204928 6.18E-06 9.93E-01 
PEX5 Intron 8269 162869 2.30E-05 9.93E-01 
ADAMTS14 Intron 4795 136356 5.57E-05 9.93E-01 
KIAA1245 Intron 2187 11729 6.53E-05 9.93E-01 
PEX5 Intron 8269 162866 9.07E-05 9.93E-01 
PEX5 Intron 8269 162867 9.09E-05 9.93E-01 
METTL1 Intron 9212 170447 9.46E-05 9.93E-01 
ZNF90 Intron 18758 56593 9.58E-05 9.93E-01 
DACH1 Intron 10490 18124 9.70E-05 9.93E-01 
PEX5 Intron 8268 162865 9.89E-05 0.99347 
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Table 4.9.  The top ten transcript splicing changes in unstimulated HD monocytes 
(ranked by FDR). 
Gene ID Feature ID p-value FDR 
LOC100505813 Transcript 30495 7.44E-06 1.11E-01 
FZD7 Transcript 22359 1.48E-05 1.11E-01 
PGAP3 Transcript 15961 1.67E-05 1.11E-01 
C1orf93 Transcript 135 1.84E-05 1.11E-01 
SPARC Transcript 30494 2.09E-05 1.11E-01 
C1orf93 Transcript 138 3.04E-05 1.35E-01 
OSGEPL1 Transcript 22222 3.57E-05 1.36E-01 
CDK2 Transcript 9078 4.88E-05 1.62E-01 
R3HCC1 Transcript 35202 6.16E-05 1.82E-01 
BCAP31 Transcript 39617 9.03E-05 2.40E-01 
Table 4.10.  The top ten transcript splicing changes in stimulated HD monocytes 
(ranked by FDR). 
Gene ID Feature ID p-value FDR 
OGG1 Transcript 25522 9.35E-05 8.54E-01 
JAG1 Transcript 23106 2.33E-04 8.54E-01 
C5orf32 Transcript 30185 2.59E-04 8.54E-01 
LRCH1 Transcript 10366 3.02E-04 8.54E-01 
P2RY6 Transcript 7304 3.51E-04 8.54E-01 
SPARC Transcript 30494 3.65E-04 8.54E-01 
RAPGEF1 Transcript 37646 3.91E-04 8.54E-01 
UBTD2 Transcript 30651 3.98E-04 8.54E-01 
WDR73 Transcript 13166 4.53E-04 8.54E-01 
RPAP3 Transcript 8708 5.35E-04 8.54E-01 
Figure 4.2.  Functional gene sets associated with innate immunity and 
inflammation are enriched in resting HD monocytes. GSEA was used to identify 
biologically relevant gene sets that are enriched in resting HD monocytes compared to 
control. A network diagram of significant biological themes among the upregulated genes is 
shown, indicating number of genes (node size), statistical significance (darkest shading = 
lowest p-value) and gene content similarity via the Jaccard coefficient (edge thickness). 
Nodes with similar gene content cluster more closely due to an edge-weighted layout 
(modified for readability). An FDR cut-off of < 0.05 was used to determine gene set inclusion 
in the diagram, before the Jaccard coefficient was used to filter out gene sets with similar 
gene content. The diagram was rendered in Cytoscape 3.3.0.  
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4.5.4 Proinflammatory functional gene sets are enriched in 
resting HD monocytes 
While the study of specific transcripts in isolation is a useful tool for 
investigating monocyte function, it is important to recognise that such a 
paradigm is open to potential bias, as the investigator will naturally focus on 
the expression of genes that they personally find the most interesting. 
Furthermore, it is questionable to what extent broader functional conclusions 
can be drawn from changes in a relatively small number of arbitrarily 
significant genes. To address this, a comprehensive GSEA was carried out 
to assign wider biological relevance to the observed expression changes. 
GSEA allows for the unbiased identification of gene sets showing evidence 
of combined differential expression, without relying on the genes being 
individually significant after correction for multiple testing; this enables 
relevant biological trends to be uncovered.  
Multiple sources were used to compile a list of over 14,000 functional gene 
sets (Section 2.10.2); each of these was then tested for enrichment, whereby 
the upregulated and downregulated genes were analysed separately. 
Analysis of the unstimulated dataset revealed a total of eighty-five 
significantly enriched gene sets (FDR < 0.05) within the upregulated genes in 
HD monocytes (Table 4.11; complete list in Appendices). Functional gene 
sets relating to innate immunity, inflammation and cytokine production were 
among the most prominently featured (Fig. 4.2); this confirms that the 
proinflammatory changes seen at the individual transcript level are also 
present across the broader HD monocyte transcriptome. Additional functional 
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gene sets including those relating to the NFκB and JAK/STAT intracellular 
signalling cascades were also found to be significantly enriched. In contrast, 
only six gene sets relating to vacuole, lysosome and catabolic function were 
found to be significantly enriched (FDR < 0.05) amongst the downregulated 
genes in unstimulated HD monocytes (Table 4.12). 
4.5.5 Analysis of functional gene set enrichment in 
stimulated HD monocytes 
GSEA of the stimulated dataset did not reveal any significant enrichment 
(FDR < 0.05) of functional gene sets among the upregulated genes in HD 
monocytes (Table 4.13); this is consistent with the above loss of significance 
for individual transcripts. However, analysis of the downregulated genes 
revealed eighty-three gene sets that were significantly enriched (FDR < 0.05) 
in stimulated HD monocytes compared to control (Table 4.14; complete list in 
Appendices). Gene sets relating to translation, protein localisation, 
cholesterol homeostasis and cellular components including the membrane, 
mitochondria and lysosome were among the most affected (Fig. 4.3). 
Figure 4.3.  Analysis of functional gene set enrichment in stimulated HD 
monocytes. GSEA was used to identify biologically relevant gene sets that are enriched in 
stimulated HD monocytes compared to control. A network diagram of significant biological 
themes among the downregulated genes is shown, indicating number of genes (node size), 
statistical significance (darkest shading = lowest p-value) and gene content similarity via the 
Jaccard coefficient (edge thickness). Nodes with similar gene content cluster more closely 
due to an edge-weighted layout (modified for readability). An FDR cut-off of < 0.05 was used 
to determine gene set inclusion in the diagram, before the Jaccard coefficient was used to 
filter out gene sets with similar gene content. The diagram was rendered in Cytoscape 3.3.0. 
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Table 4.11.  The top twenty enriched gene sets among the upregulated genes in 
resting HD monocytes (ranked by FDR). 
Pathway Description 
Number 
of genes 
NES p-value FDR 
GO: 31347 Regulation of defence response 270 5.631 8.96E-09 1.28E-04 
MGI: 2419 Abnormal innate immunity 3 5.378 3.77E-08 2.68E-04 
MGI: 8835 
Abnormal intercellular signalling peptide or 
protein level 
4 5.077 1.92E-07 6.46E-04 
GO: 6954 Inflammatory response 387 5.036 2.38E-07 6.46E-04 
GO: 31349 Positive regulation of defence response 352 5.016 2.64E-07 6.46E-04 
MGI: 8713 Abnormal cytokine level 4 5.010 2.72E-07 6.46E-04 
MGI: 3009 Abnormal cytokine secretion 6 4.923 4.26E-07 8.67E-04 
GO: 9615 Response to virus 200 4.760 9.68E-07 1.63E-03 
GO: 43900 Regulation of multi-organism process 119 4.727 1.14E-06 1.63E-03 
GO: 45088 Regulation of innate immune response 160 4.710 1.24E-06 1.63E-03 
MGI: 8469 Abnormal protein level 7 4.677 1.46E-06 1.63E-03 
KEGG: 5323 Rheumatoid arthritis 4 4.649 1.67E-06 1.63E-03 
GO: 1817 Regulation of cytokine production 151 4.647 1.68E-06 1.63E-03 
GO: 5125 Cytokine activity 366 4.643 1.72E-06 1.63E-03 
MGI: 2451 Abnormal macrophage physiology 5 4.630 1.83E-06 1.63E-03 
KEGG: 4060 Cytokine-cytokine receptor interaction 4 4.624 1.88E-06 1.63E-03 
GO: 2252 Immune effector process 92 4.617 1.95E-06 1.63E-03 
GO: 9617 Response to bacterium 369 4.590 2.22E-06 1.73E-03 
MGI: 1793 Altered susceptibility to infection 4 4.582 2.30E-06 1.73E-03 
MGI: 8568 Abnormal interleukin secretion 66 4.509 3.26E-06 2.32E-03 
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Table 4.12.  The top twenty enriched gene sets among the downregulated genes in 
resting HD monocytes (ranked by FDR). 
Pathway Description 
Number 
of genes 
NES p-value FDR 
GO: 5773 Vacuole 310 5.678 6.81E-09 9.71E-05 
GO: 44437 Vacuolar part 346 5.317 5.27E-08 2.84E-04 
GO: 5764 Lysosome 305 5.241 7.99E-08 2.84E-04 
GO: 323 Lytic vacuole 387 5.241 7.99E-08 2.84E-04 
GO: 44282 Small molecule catabolic process 373 4.381 5.91E-06 1.40E-02 
GO: 44712 Single-organism catabolic process 126 4.381 5.91E-06 1.40E-02 
GO: 5759 Mitochondrial matrix 313 3.923 4.37E-05 8.90E-02 
MGI: 745 Tremors 5 3.722 9.88E-05 1.57E-01 
GO: 19371 Cyclooxygenase pathway 170 3.704 1.06E-04 1.57E-01 
MGI: 1541 Abnormal osteoclast physiology 3 3.670 1.21E-04 1.57E-01 
GO: 5774 Vacuolar membrane 313 3.661 1.26E-04 1.57E-01 
GO: 5775 Vacuolar lumen 186 3.647 1.33E-04 1.57E-01 
KEGG: 4142 Lysosome 5 3.609 1.54E-04 1.68E-01 
REACTOME: 778 NOD1/2 signalling pathway 13 3.512 2.22E-04 2.24E-01 
GO: 43202 Lysosomal lumen 67 3.484 2.47E-04 2.24E-01 
GO: 19318 Hexose metabolic process 197 3.446 2.84E-04 2.24E-01 
GO: 16054 Organic acid catabolic process 118 3.422 3.11E-04 2.24E-01 
GO: 46395 Carboxylic acid catabolic process 64 3.422 3.11E-04 2.24E-01 
GO: 5996 Monosaccharide metabolic process 137 3.419 3.14E-04 2.24E-01 
MGI: 3106 Abnormal fear-related response 11 3.419 3.14E-04 2.24E-01 
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Table 4.13.  The top twenty enriched gene sets among the upregulated genes in 
stimulated HD monocytes (ranked by FDR). 
Pathway Description 
Number 
of genes 
NES p-value FDR 
GO: 5813 Centrosome 16 4.003 3.13E-05 3.55E-01 
GO: 5929 Cilium 393 3.766 8.29E-05 3.55E-01 
MGI: 10210 Abnormal circulating cytokine level 63 3.712 1.03E-04 3.55E-01 
GO: 7264 
Small GTPase mediated signal 
transduction 
86 3.664 1.24E-04 3.55E-01 
MGI: 2463 Abnormal neutrophil physiology 53 3.663 1.25E-04 3.55E-01 
MGI: 8713 Abnormal cytokine level 4 3.347 4.08E-04 7.68E-01 
MGI: 8835 
Abnormal intercellular signalling 
peptide or protein level 
4 3.285 5.10E-04 7.68E-01 
GO: 60271 Cilium morphogenesis 44 3.267 5.43E-04 7.68E-01 
GO: 6954 Inflammatory response 387 3.256 5.65E-04 7.68E-01 
GO: 50900 Leukocyte migration 70 3.247 5.83E-04 7.68E-01 
REACTOME: 1133 Signalling by Rho GTPases 48 3.174 7.52E-04 7.68E-01 
REACTOME: 1031 Rho GTPase cycle 19 3.174 7.52E-04 7.68E-01 
MGI: 3037 Increased myocardial infarction size 3 3.167 7.70E-04 7.68E-01 
MGI: 8588 Abnormal circulating interleukin level 5 3.119 9.07E-04 7.68E-01 
MGI: 8789 
Abnormal olfactory epithelium 
morphology 
86 3.110 9.35E-04 7.68E-01 
GO: 187 Activation of MAPK activity 17 3.099 9.71E-04 7.68E-01 
KEGG: 4062 Chemokine signalling pathway 141 3.080 1.04E-03 7.68E-01 
GO: 31514 Motile cilium 178 3.072 1.06E-03 7.68E-01 
NCI:  76 
Syndecan-1-mediated signalling 
events 
10 3.057 1.12E-03 7.68E-01 
MGI: 2462 Abnormal granulocyte physiology 6 3.055 1.13E-03 7.68E-01 
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Table 4.14.  The top twenty enriched gene sets among the downregulated genes in 
stimulated HD monocytes (ranked by FDR). 
Pathway Description 
Number 
of genes 
NES p-value FDR 
GO: 72594 
Establishment of protein localization to 
organelle 
124 5.819 2.96E-09 1.88E-05 
GO: 6412 Translation 197 5.803 3.26E-09 1.88E-05 
GO: 6605 Protein targeting 15 5.443 2.62E-08 1.01E-04 
REACTOME: 1287 Translation 8 5.222 8.85E-08 2.55E-04 
GO: 22411 Cellular component disassembly 35 5.120 1.53E-07 3.04E-04 
GO: 33365 Protein localization to organelle 321 5.113 1.59E-07 3.04E-04 
GO: 6612 Protein targeting to membrane 11 5.044 2.28E-07 3.75E-04 
GO: 5773 Vacuole 310 4.947 3.77E-07 5.43E-04 
GO: 70972 
Protein localization to endoplasmic 
reticulum 
9 4.876 5.41E-07 6.93E-04 
MGI: 3947 Abnormal cholesterol level 57 4.799 7.97E-07 9.19E-04 
GO: 6413 Translational initiation 71 4.693 1.35E-06 1.37E-03 
GO: 72599 
Establishment of protein localization to 
endoplasmic reticulum 
15 4.677 1.46E-06 1.37E-03 
GO: 45047 
Protein targeting to endoplasmic 
reticulum 
10 4.665 1.54E-06 1.37E-03 
REACTOME: 1165 
SRP-dependent co-translational 
protein targeting to membrane 
175 4.646 1.69E-06 1.39E-03 
GO: 6613 
Co-translational protein targeting to 
membrane 
4 4.623 1.89E-06 1.45E-03 
MGI: 5278 Abnormal cholesterol homeostasis 4 4.604 2.07E-06 1.49E-03 
GO: 6614 
SRP-dependent co-translational 
protein targeting to membrane 
3 4.562 2.53E-06 1.65E-03 
GO: 44391 Ribosomal subunit 15 4.547 2.72E-06 1.65E-03 
GO: 32984 Macromolecular complex disassembly 15 4.547 2.72E-06 1.65E-03 
GO: 44445 Cytosolic part 62 4.522 3.06E-06 1.76E-03 
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4.5.6 Specific intracellular signalling pathways are predicted 
to mediate transcriptional changes in HD monocytes 
Although patterns of gene expression change provide valuable insight into 
the functional state of HD monocytes, they do not on their own give any 
clues as to the cellular mechanisms responsible for mediating this 
transcriptional dysregulation. Next, upstream regulator analysis was carried 
out on the unstimulated samples using IPA® software. IPA® compares 
patterns of gene expression in an experimental dataset with lists of genes 
that are known to be regulated by specific upstream signalling molecules, in 
order to infer whether a particular regulatory molecule is likely to be 
abnormally activated or inhibited. One important caveat with IPA® is that 
there is a great deal of redundancy in the analysis, due to the considerable 
overlap in gene sets influenced by specific upstream regulators. This will 
result in multiple points along an intracellular signalling pathway being 
suggested as an upstream regulator, even if only one is driving 
transcriptional change; this means that functional validation of IPA® data is 
essential to counter this redundancy.  
Predicted changes in upstream regulatory molecules are quantified by the 
activation z-score statistic. This increases or decreases depending on the 
inferred activation/inhibition state of a particular upstream regulator, with 
significance in IPA® typically being attributed to regulators that have an 
overlap p-value of < 0.01 and an activation z-score of ≥ 2 or ≤ -2. Analysis of 
the unstimulated dataset revealed 155 upstream regulators that fulfilled 
these criteria (Table 4.15; complete list in Appendices); 125 of these were 
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predicted to be abnormally activated, while thirty were predicted to be 
abnormally inhibited. Due to the aforementioned redundancy associated with 
IPA® it is highly unlikely that this many factors are actually affected by mHTT 
expression, so focus was narrowed to the subset of upstream regulators with 
the highest activation z-scores, and therefore the strongest evidence for their 
mediating transcriptional dysregulation in resting HD monocytes. 
Crucially, a large number of molecules associated with intracellular signalling 
pathways downstream of TLR4 were represented in this group (Fig. 4.4). 
Both RELA and the NFκB complex were featured in the top ten most 
significant results ranked by activation z-score; this suggests that the NFκB 
dysfunction previously described in stimulated HD myeloid cells (Träger et 
al., 2014) may also exist basally. Other notable potential regulators included 
NFκB1, the ERK and p38 MAPKs and the transcription factor STAT3. These 
data suggest that the transcriptional changes observed in HD monocytes are 
related to the abnormal activation of specific upstream signalling molecules 
that are responsible for driving gene expression in the resting state. 
Figure 4.4.  Specific intracellular signalling pathways are predicted to be 
abnormally activated in resting HD monocytes. IPA® software was used to identify 
numerous signalling pathway components downstream of the TLR4 receptor that are 
predicted to be abnormally activated in resting HD monocytes compared to control. 
Upstream regulators with significantly inferred activation are shown in orange (darker colour 
= higher activation z-score). The activation z-score for each pathway component is also 
shown (≥ 2 is considered to be significant).  
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Table 4.15.  Pathway analysis of upstream transcriptional regulators in resting HD 
monocytes. IPA® was used to identify transcriptional regulators with significant target gene 
overlap with changes in the resting HD monocyte transcriptome. A p-value cut-off of < 0.01 
was used to determine which genes were included in the analysis. The upstream regulators 
were ranked by activation z-score and the fifteen most significant were included in the table. 
Upstream 
regulator 
Activation  
z-score 
p-value of 
overlap 
Function 
TNF 5.764 2.18E-13 Proinflammatory cytokine 
IL1B 5.754 8.08E-14 Proinflammatory cytokine 
MyD88 4.761 2.92E-12 Cytoplasmic adaptor protein for the TLR family 
IFNγ 4.635 3.09E-07 
Cytokine involved in mediating the innate immune 
response 
IL1A 4.536 1.69E-11 Proinflammatory cytokine 
TLR3 4.323 1.99E-09 
Cell surface receptor involved in the activation of 
the innate immune response 
RELA 4.122 5.86E-08 
Transcription factor; one of five NFκB family 
members 
NFκB (complex) 4.077 2.63E-08 
A family of five transcription factors that mediate 
the inflammatory response 
TLR9 3.773 4.33E-07 
Cell surface receptor involved in the activation of 
the innate immune response 
TLR2 3.770 3.94E-09 
Cell surface receptor involved in the activation of 
the innate immune response 
STAT3 3.701 2.34E-07 Transcription factor 
IL6 3.654 7.39E-06 Proinflammatory cytokine 
TICAM1/TRIF 3.651 2.59E-08 
TLR cytoplasmic adaptor protein; mediates an 
alternative pathway to MyD88 
ERK1/2 3.636 5.33E-06 Protein kinase intracellular signalling molecules 
TLR4 3.610 7.68E-12 
Cell surface receptor involved in the activation of 
the innate immune response 
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4.5.7 NFĸB but not ERK or p38 MAPK signalling is 
abnormally increased in resting HD myeloid cells 
While IPA® is an excellent starting point for identifying the molecular 
mechanisms responsible for mediating gene expression changes in HD 
monocytes, its limitations as a purely bioinformatics tool necessitate 
functional validation of predicted upstream regulators before any firm 
conclusions can be drawn. Previous work has demonstrated that the NFκB 
pathway is dysregulated in stimulated HD myeloid cells, with increased initial 
activation and a prolonged time to return to baseline (Träger et al., 2014). 
However, there is currently no evidence that this dysfunction also exists 
when HD myeloid cells are in their basal, resting state. Investigation of NFκB 
pathway activation in unstimulated HD myeloid cells was next performed to 
validate the upstream regulator analysis carried out with IPA®. 
Monocytes were isolated from peripheral blood samples donated by manifest 
HD and control subjects and differentiated into macrophages in culture. 
Western blotting was then carried out to quantify the expression of IκBα, a 
cytoplasmic inhibitor of the NFκB family of transcription factors. A decrease 
in IκBα expression is used to demonstrate an increase in NFκB activity, as 
reduced inhibition will lead to increased translocation of NFκB to the nucleus. 
Consistent with the upstream regulator analysis, resting HD myeloid cells 
had significantly reduced IκBα protein levels compared to their healthy 
counterparts (Fig 4.5). This demonstrates that the NFκB dysregulation 
previously described in stimulated HD myeloid cells also exists basally. 
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Figure 4.5.  NFκB but not ERK or p38 MAPK signalling is abnormally activated in 
resting HD myeloid cells. Monocyte-derived macrophages were obtained from HD and 
control peripheral blood samples and pulsed with LPS and IFNγ for 15, 30, 60 and 120 min, 
or left unstimulated. Western blotting was then carried out on the unstimulated samples to 
quantify basal levels of IκBα, while additional Western blotting was carried out on all 
samples to quantify the levels of total and active, phosphorylated ERK and p38 MAPK. (A) 
Resting HD myeloid cells express significantly reduced IκBα protein compared with control 
(control n = 7, HD n = 9). However, no significant differences were seen in (B) the ratio of 
phosphorylated to total enzyme, or (C) the ratio of total enzyme to β-actin for ERK or p38 at 
any of the time points that were studied (n = 10). IκBα blots were analysed using unpaired 
two-tailed Student’s t-tests. MAPK blots were analysed by two-way ANOVAs with Bonferroni 
post-hoc multiple comparison testing. Error bars represent ± SEM. *p < 0.05 
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However, signalling downstream of TLR4 is extremely complex, and the 
contribution of alternative pathways to HD myeloid cell dysfunction is yet to 
be fully characterised. Next, the ERK and p38 MAPKs were investigated to 
determine if they are also abnormally activated in HD myeloid cells; these 
signalling molecules were selected as they both play a major role in immune 
cell signalling (Akira and Takeda, 2004), and were identified by IPA® as 
potential regulators of the gene expression changes seen in resting HD 
monocytes. Both ERK and p38 are activated by phosphorylation; this allows 
their activation states to be determined by quantifying the ratio of 
phosphorylated to total protein. Monocytes were again isolated from manifest 
HD and control peripheral blood samples, before being differentiated into 
macrophages in culture. Cells from each subject were stimulated with LPS 
and IFNγ for 15, 30, 60 and 120 min, or left unstimulated, in order to build up 
a broad profile of the signalling response. However, no significant differences 
were seen in the activation of ERK or p38 between HD and control, either 
basally or at any of the time points following LPS stimulation (Fig. 4.5). 
Furthermore, there was no significant difference in the expression of total 
ERK or p38 when normalised to the reference protein β-actin. This suggests 
that, in contrast to NFκB, the ERK and p38 MAPK signalling pathways are 
not abnormally activated in HD myeloid cells; these signalling pathways are 
therefore unlikely to mediate the transcriptional changes seen in the 
unstimulated dataset.  
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4.5.8 The effects of HTT-lowering on gene expression in HD 
monocytes 
Next, it was investigated whether short term HTT-lowering has a significant 
effect on the transcriptional changes seen between HD and control 
monocytes. Monocytes were isolated from peripheral blood samples donated 
by six manifest HD patients, and treated with GeRPs containing either SCR 
or anti-total HTT siRNA. The cells were cultured for 72 h before either being 
left unstimulated or stimulated with LPS and IFNγ for 4 h in an identical 
manner to the main RNA-Seq dataset; this gave a total of four treatment 
groups.  RNA was then harvested and the samples were analysed by RNA-
Seq. Differential expression analysis using a likelihood ratios test was carried 
out to determine whether the expression changes seen in HD monocytes are 
reversed by treatment with anti-total HTT siRNA.  
Perhaps surprisingly, none of the expression changes from the unstimulated 
dataset were found to be significantly reversed following HTT-lowering. While 
seventy-one genes were found to be significantly altered (FDR < 0.05) 
between SCR and anti-total HTT siRNA-treated monocytes (Table 4.16; 
complete list in Appendices), none of these genes showed any evidence of 
differential expression in the original RNA-Seq dataset. This suggests that a 
short-term reduction in HTT expression may not be sufficient to substantially 
reverse the transcriptional changes seen in HD monocytes. 
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Table 4.16.  The top twenty gene changes in HD monocytes following HTT-lowering 
(ranked by FDR). 
Gene 
name 
Ensembl ID 
RPKM 
(SCR) 
RPKM 
(α-HTT) 
Log2 fold 
change 
p value FDR Protein function 
COX5A ENSG00000178741 120.152 41.172 -1.562 4.76E-137 3.98E-133 
Mitochondrial 
electron transport 
ECI2 ENSG00000198721 6.403 3.912 -0.737 6.82E-39 2.85E-35 
Mitochondrial fatty 
acid metabolism 
HTT ENSG00000197386 10.218 4.230 -1.280 1.00E-27 2.79E-24 
Diverse functions; 
mutations cause HD 
SRPR ENSG00000182934 62.426 43.624 -0.488 1.05E-20 2.19E-17 
ER signal 
recognition 
PPARA ENSG00000186951 2.051 1.514 -0.471 1.16E-17 1.93E-14 
Nuclear receptor 
transcription factor 
VAMP3 ENSG00000049245 52.249 37.049 -0.483 3.43E-17 4.78E-14 Vesicular transport 
SPG20 ENSG00000133104 26.372 17.912 -0.512 2.22E-13 2.57E-10 
Endosomal 
trafficking 
ACP5 ENSG00000102575 563.842 319.723 -1.050 2.46E-13 2.57E-10 
Acid phosphatase 
enzyme 
CAPZA1 ENSG00000116489 107.840 84.262 -0.319 6.40E-13 5.94E-10 
Regulates growth of 
actin filaments 
NDUFA8 ENSG00000119421 22.077 17.141 -0.385 2.92E-12 2.44E-09 
Mitochondrial NADH 
dehydrogenase  
C8orf33 ENSG00000182307 6.731 4.975 -0.445 3.81E-11 2.80E-08 
Functionally 
uncharacterised 
ARHGEF7 ENSG00000102606 6.301 5.296 -0.233 4.02E-11 2.80E-08 
Guanine nucleotide 
exchange factor 
HDGF ENSG00000143321 47.811 35.132 -0.459 1.03E-10 6.64E-08 
Mitogenic growth 
factor 
BAG5 ENSG00000166170 4.191 3.719 -0.185 1.37E-10 8.19E-08 
Anti-apoptotic 
protein  
TOMM70A ENSG00000154174 14.166 12.552 -0.152 2.22E-10 1.24E-07 
Mitochondrial import 
receptor 
CSE1L ENSG00000124207 18.510 16.133 -0.215 1.86E-09 9.69E-07 
Nuclear export 
receptor for importin 
CNOT11 ENSG00000158435 14.431 11.196 -0.355 2.56E-09 1.26E-06 
mRNA deadenylase 
component 
ACTG1 ENSG00000184009 705.135 1031.133 0.582 2.92E-09 1.35E-06 
G-actin (globular 
monomeric form) 
UBE2D4 ENSG00000078967 3.913 3.028 -0.399 1.25E-08 5.49E-06 
Ubiquitin-
conjugating enzyme 
HIF1AN ENSG00000166135 8.113 6.787 -0.241 1.99E-08 8.32E-06 Oxygen sensor 
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However, it is possible that the lack of any significant reversal is due to the 
low n number used for the HTT-lowering RNA-Seq experiments, in addition 
to the rigorous multiple testing corrections inherent in the analysis of such a 
large dataset. In order to confirm this result, monocytes were isolated from 
peripheral blood samples donated by manifest HD patients and controls, 
before being treated with GeRPs containing either SCR or anti-total HTT 
siRNA.  After 72 h, the monocytes were harvested unstimulated and RNA 
was used for qPCR analysis of gene expression. Six differentially expressed 
genes from the original unstimulated monocyte dataset were selected for 
investigation based on their biological relevance and the magnitude of their 
relative expression changes. While a significant 20 % reduction in CSF2 
expression was observed in the anti-total HTT treated samples, none of the 
other transcripts were found to be significantly altered in response to HTT-
lowering (Fig. 4.6). This is consistent with the RNA-Seq data described 
above, and suggests that a more sustained reduction in cellular HTT levels 
may be required in order to reverse the transcriptional dysregulation 
associated with mHTT expression in resting HD monocytes.  
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Figure 4.6.  Analysis of gene expression changes following HTT-lowering in HD 
monocytes. Monocytes were isolated from manifest HD patients and transfected with 
GeRPs containing either SCR or anti-total HTT siRNA. RNA was harvested after 72 h and 
used for gene expression analysis by qPCR. Consistent with the RNA-Seq data, with the 
exception of CSF2 no reversal of HD-related gene expression changes was seen in the 
samples treated with anti-total HTT siRNA. Data shown as relative expression ± SEM (n = 
9), statistical analysis carried out using two-tailed paired Student’s t-tests. *P < 0.05. 
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4.6 Discussion 
Previous studies of HD myeloid cells have primarily focused on 
characterising their responses to stimulation, for example using LPS (Träger 
et al., 2014). While this has generated a wealth of functional data, notably 
their hyper-reactive cytokine phenotype, relatively little is known about 
whether HD myeloid cells are also abnormal in their basal, resting state. 
Work presented in this chapter makes use of modern RNA-Seq technology 
to show that HD monocytes have a significantly altered resting 
transcriptome. This suggests that mHTT has a state-independent effect on 
HD myeloid cells, likely occurring via a mechanism that is not limited to 
alterations in intracellular signalling pathways following stimulation. This 
should perhaps not be surprising, as mHTT has been shown to have state-
independent effects on gene expression in a wide range of tissues from HD 
patients and animal models, including brain, skeletal muscle and whole blood 
(Seredenina and Luthi-Carter, 2012).  
Crucially, analysis of the HD monocyte transcriptome found that 
proinflammatory cytokines and chemokines are upregulated even in the 
absence of stimulation, for the first time showing increased resting cytokine 
expression at either the mRNA or protein level. Profiling of HD patient 
plasma has demonstrated elevated peripheral levels of proinflammatory 
cytokines and chemokines (Björkqvist et al., 2008; Wild et al., 2011), with 
increased IL-6 being detectable up to 16 years before predicted disease 
onset. While myeloid cells have long been regarded as the likely primary 
source, this study provides the first direct evidence that their cytokine 
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expression is increased without artificial experimental stimuli, with IL6 being 
among the gene transcripts most affected. The existence of broad 
proinflammatory changes in the resting HD monocyte transcriptome was 
confirmed by GSEA, which identified significant enrichment of numerous 
functional gene sets relating to innate immunity, inflammation and cytokine 
production. This was vital for assigning wider biological relevance to the 
RNA-Seq expression changes, in addition to avoiding the potential 
investigator bias that could result from examining specific genes in isolation. 
Examination of directionality revealed that the majority of significant 
expression changes involved upregulation; this is consistent with a previous 
RNA-Seq study carried out on post-mortem HD brain (Labadorf et al., 2015). 
Experiments on human monocyte models have shown that mHTT expression 
has cell-autonomous effects on immune cell function (Träger et al., 2014), 
and that the phenotypic changes observed in these cells are not simply a 
secondary response to CNS pathology. Furthermore, mHTT has been 
suggested to have a proinflammatory priming effect on a murine HD 
microglial cell line, with an increase in the resting expression of 
proinflammatory molecules leading to an exaggerated response once a 
stimulus is encountered (Crotti et al., 2014). This was found to occur as the 
result of an enrichment of proinflammatory transcription factors including the 
myeloid lineage-determining factor PU.1. Data presented in this thesis 
strongly suggests that mHTT has an equivalent priming effect on primary 
human myeloid cells; this is likely to contribute to the hyper-reactive cytokine 
response to LPS stimulation.  
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Furthermore, the discovery of resting proinflammatory changes in HD 
monocytes is likely to have significant relevance for the pathobiology of the 
disease in human patients. Although elevated cytokine levels have been 
demonstrated in HD plasma (Björkqvist et al., 2008), there is currently no 
evidence that HD patients have an increased incidence of infectious or 
inflammatory events compared to control subjects. Indeed, the disease-
modifying benefits of modulating the peripheral immune system in animal 
models of HD are not dependent on the amelioration of artificial inflammatory 
stimuli (Bouchard et al., 2012; Hsiao et al., 2014; Zwilling et al., 2011). These 
observations suggest that the in vivo proinflammatory changes seen in HD 
are not dependent on, or primarily caused by, episodic excessive cytokine 
release from cells undergoing repeated stimulation. Instead, they may be 
reconciled by a chronic increase in the basal release of proinflammatory 
mediators from circulating myeloid cells. Further mechanistic rationale for 
this hypothesis is provided by the fact that several of the upregulated 
cytokines in HD peripheral blood are pre-synthesised in the resting state. 
TNFα is synthesised as a membrane-bound precursor that is cleaved in 
response to stimulation (Black et al., 1997), while IL-8 undergoes vesicular 
storage prior to release (Lacy and Stow, 2011). Myeloid cell priming by 
mHTT could therefore result in increased cytokine storage in advance of 
stimulation, or indeed increased basal release in the absence of stimulation. 
The elevated cytokine levels seen in HD patient plasma perhaps suggest 
that the latter effect is more likely. 
While time and cost restrictions meant that it was only possible to include 
manifest HD patients as part of this study, it is likely that the mHTT-priming 
Chapter 4 Whole transcriptome analysis of HD myeloid cells 
197 
 
phenomenon also exists in pre-manifest subjects. Previous studies have 
shown that immune alterations are detectable many years before the onset 
of motor symptoms (Björkqvist et al., 2008); this includes the release of 
proinflammatory mediators such as IL-6. The transcriptional changes seen in 
HD monocytes therefore seem unlikely to only appear once a patient has 
progressed to manifest disease. Crucially, the short lifespan of peripheral 
blood cells precludes the possibility of a chronic effect built up over many 
years, as may be the case for long-lived cells such as neurons. This 
hypothesis is supported by the presence of cell-autonomous dysfunction in 
HD myeloid cells (Träger et al., 2014), as peripheral immune changes have 
been shown to occur independently of neurodegeneration; they are therefore 
unlikely to be closely linked to the symptoms associated with advancing 
disease in the CNS. The potential disease-modifying role of the peripheral 
immune system raises the intriguing possibility that HD myeloid cells may 
even be involved in the modification of disease onset, however this will 
remain conjecture until further studies are carried out. 
Perhaps the most surprising feature of this study was the lack of significant 
alterations in the transcriptome of stimulated HD monocytes. While the 
directions of effect between HD and control were largely consistent, 
comparison of the log2 fold changes for the 130 differentially expressed 
genes revealed that the relative size of the majority of the fold changes was 
reduced under stimulated conditions to the point that the expression 
differences were no longer significant. This may be due to the extremely 
strong activating response produced by LPS, leading to a plateau in 
transcriptional activity as the cell reaches the limits of its mRNA synthesis 
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capacity. This is likely to result in the masking of biological differences, as 
the proinflammatory transcriptional profile of resting HD monocytes is ablated 
by the stronger inflammatory stimulus provided by LPS. In view of the lack of 
differential expression in stimulated HD monocytes, the basal priming effects 
of mHTT only seem more likely to mediate the hyper-reactive LPS response.  
Interestingly, GSEA revealed significant enrichment of a number of gene sets 
among the downregulated genes in stimulated HD monocytes. Alterations in 
functional gene sets relating to protein localisation and targeting is consistent 
with established defects in the HD cytoskeleton (Gunawardena et al., 2003), 
while further enrichment was observed in gene sets relating to organelles 
known to be affected by mHTT expression, including mitochondria and the 
lysosome (Damiano et al., 2010; Turner et al., 2009; Martin et al., 2015). 
However, while these results show that mHTT has adverse effects on the 
transcriptome of stimulated HD monocytes, the small number of differentially 
expressed genes suggests that these enrichments may not have the same 
biological significance as those seen basally. 
Although the expression changes alone provide strong evidence that mHTT 
expression has a priming effect on the transcriptome of resting HD 
monocytes, further investigation of intracellular signalling pathways is 
required to identify the underlying mechanism. Studies in cell lines have 
revealed an interaction of mHTT with IKK, one of the key components of the 
NFκB pathway (Khoshnan et al., 2004); this results in increased 
phosphorylation of the NFκB inhibitor IκB, leading to an increase in the 
expression of proinflammatory genes as more NFκB molecules are free to 
translocate to the nucleus. This mechanism has been linked to hyper-
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reactivity in HD myeloid cells (Träger et al., 2014), however it was not 
previously known if it also has an effect in the resting state. Following IPA® 
identification of RELA, NFκB1 and the NFκB complex as potential regulators 
of transcriptional dysregulation, functional validation by Western blotting 
revealed a significant reduction in the expression of IκBα in unstimulated HD 
myeloid cells; this provides strong evidence that NFκB signalling is also 
affected basally. These data provide a mechanistic explanation for the 
priming hypothesis, as this abnormal resting activation of NFκB signalling is 
likely to play a key role in mediating the proinflammatory transcriptional 
changes seen in HD monocytes. 
This result, coupled with the redundancy inherent in IPA®, means it is highly 
likely that the activation of a number of other upstream regulators will have 
been inferred due to their target gene overlap with NFκB, and not because 
they are also affected by the expression of mHTT. This can be seen in the 
fact that thirteen of the fifteen upstream regulators with the most significant 
activation z-scores are known to be involved in NFκB signalling (whether as 
an activating cytokine, cell surface receptor or downstream transcription 
factor). The enrichment of a functional gene set relating to the NFκB 
signalling cascade on GSEA analysis further supports this conclusion. Other 
notable hits included the ERK and p38 MAPKs, in addition to the 
transcription factor STAT3. However, JAK/STAT signalling has previously 
been shown to be unaffected in HD myeloid cells (Träger et al., 2013); 
STAT3’s considerable target gene overlap with NFκB is therefore likely to be 
responsible for its inferred activation on IPA® (Hoesel and Schmid, 2013). 
The ERK and p38 MAPKs are vital components of the intracellular signalling 
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cascade downstream of TLR4 (Akira and Takeda, 2004). However, 
investigation of their activation states using Western blotting revealed no 
changes between HD and control myeloid cells, either basally or at any point 
during the experimental time course. While additional pathogenic interactions 
of mHTT with the transcriptional machinery cannot be ruled out, taken 
together these data further suggest that the observed transcriptional changes 
are likely to be due in large part to resting dysfunction in the NFκB pathway. 
However, it should be noted that not all mHTT-related transcriptional 
changes are pathological, as some may be compensatory or even irrelevant 
(Seredenina and Luthi-Carter, 2012). Transcriptional dysregulation in HD is 
the result of a wide range of mechanisms, including but not limited to the 
sequestration of transcription factors in aggregates and the direct binding of 
mHTT fragments to DNA (Seredenina and Luthi-Carter, 2012). It should 
therefore not be expected that alterations in intracellular signalling pathways 
will account for all of the expression changes seen in HD monocytes, as a 
number will presumably be due to the alternative effects of mHTT on the 
cellular transcriptome. Despite this, upstream regulator analysis has been 
shown to be a useful tool for investigating HD immune cell function, 
particularly when combined with subsequent functional experiments. 
Furthermore, the data presented in this chapter suggest that the pre-eminent 
pathogenic mechanisms of mHTT are likely to vary depending on the cell 
type in question. Experiments on a murine HD microglial cell line found that 
increased expression of the PU.1 transcription factor mediates resting 
proinflammatory transcriptional activation in this model (Crotti et al., 2014). 
However, neither that study nor the current study found any increase in PU.1 
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expression in HD patient monocytes. IPA® of the unstimulated dataset also 
did not infer any significant activation of PU.1 in resting HD monocytes. 
Regardless, this study demonstrates that mHTT has a similar priming effect 
on the transcriptome of HD monocytes to that described in the murine 
microglial line. The authors of the microglial study suggested that the 
prominent role for PU.1 is due to the separate developmental origins of 
microglia (Crotti et al., 2014). However, it is also likely that the relative 
importance of particular intracellular signalling pathways in specific cell types 
helps determine their varying contributions to HD pathogenesis. The fact that 
NFκB binding motifs were also found to be enriched in the microglial line 
shows that the mechanisms by which mHTT interacts with each signalling 
pathway are unlikely to be drastically altered between cell types (Crotti et al., 
2014). However, as the PU.1 and NFκB pathways are vital for microglial and 
monocyte/macrophage function respectively, it is not surprising that their 
dysregulation by mHTT will cause them to have a central role in mediating 
phenotypic dysfunction in these cell types. Conversely, equivalent 
dysfunction is unlikely to be displayed by cells where these pathways play 
less important roles. This can be seen in the results described in Chapter 5. 
Surprisingly, both RNA-Seq and qPCR analysis failed to reveal any 
substantial reversal of the expression changes described in unstimulated 
monocytes following treatment with anti-total HTT siRNA. It is possible that 
this is due to the cellular kinetics of mHTT, whereby the pathogenic species 
responsible for transcriptional dysregulation persist longer than the 72 h time 
point used for these experiments. It may also be that the transcriptional 
changes associated with mHTT expression take time to normalise following a 
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reduction in mHTT protein. While it is encouraging that qPCR revealed a 
significant reduction in CSF2 expression following anti-total HTT siRNA 
treatment, a longer time course is required to determine if more sustained 
HTT-lowering results in a similar reversal of additional expression changes. 
However, this is problematic when studying monocytes, as they are short-
lived cells that are ill-suited to lengthy experimental workflows. 
Finally, this study demonstrates that the in-depth characterisation of HD-
associated transcriptional changes requires the study of specific cell 
populations from large patient cohorts with modern sequencing techniques. 
Previous analyses of HD peripheral immune cells have largely been unable 
to replicate differentially expressed genes between studies (Borovecki et al., 
2005; Runne et al., 2007; Mastrokolias et al., 2015); this is likely due to the 
use of heterogeneous cell populations, in addition to the limitations 
associated with less advanced analytical techniques. Dramatically improved 
transcriptomic coverage compared to traditional microarrays has been 
provided by high-throughput sequencing (Wang et al., 2009), while the study 
of a specific cell subset allows the noise associated with studying multiple 
cell populations with varying transcriptional profiles to be eliminated. While 
the recruitment of such large patient cohorts raises substantial practical 
considerations, the fact that genomic studies in mice have been found to 
poorly mimic human inflammatory conditions only underlines the importance 
of thoroughly investigating primary human tissues (Seok et al., 2013). There 
is also no guarantee that observations made in one cell type will apply to 
another, as it has not been possible to establish a consistent transcriptional 
signature between different HD tissues (Seredenina and Luthi-Carter, 2012). 
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4.7 Summary 
This study used RNA-Seq to carry out whole transcriptome analysis of HD 
and control monocytes in both the unstimulated and stimulated states. The 
work presented in this chapter provides the first evidence that HD myeloid 
cells are basally abnormal, with increased expression of proinflammatory 
cytokine mRNA even in the absence of stimulation. A comprehensive GSEA 
further revealed significant enrichment of functional gene sets relating to 
innate immunity, inflammation and cytokine production. In contrast, the 
transcriptome of stimulated HD monocytes was comparatively unaffected. 
These data suggest that mHTT has a cell-autonomous priming effect on 
resting HD monocytes, leading to an exaggerated proinflammatory response 
to stimulation. IPA® combined with Western blotting was then used to 
demonstrate that the NFκB dysregulation previously described in stimulated 
HD myeloid cells also extends to the resting state; abnormal activation of this 
pathway is likely to be a key mechanism in mediating the observed 
transcriptional changes. However, no differences were seen in ERK and p38 
MAPK signalling between either unstimulated or stimulated HD and control 
myeloid cells. Surprisingly, HTT-lowering did not produce a substantial 
reversal of gene expression changes; this was likely due to the persistence 
of pathogenic mHTT species beyond the time point used for the experiment. 
The existence of basal dysfunction is encouraging for the potential use of 
immunomodulatory drugs to modify HD progression, as the beneficial effects 
are likely to extend beyond ameliorating the consequences of time-limited 
infectious or inflammatory events. This only serves to reinforce the 
importance of systemic immunity in the wider study of neurodegeneration. 
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5 Adaptive immune biology in HD 
5.1  Background 
While changes in the immune system are now an established feature of HD 
pathogenesis (Ellrichmann et al., 2013), it remains unclear if HD immune 
dysfunction is universal, or is instead restricted to specific cell types. To date, 
the vast majority of studies have focused on characterising the HD innate 
immune system, with work presented in Chapter 4 of this thesis 
demonstrating that HD myeloid cells have an abnormal proinflammatory 
transcriptional profile even in the absence of stimulation. However, while the 
phenotypic abnormalities associated with HD innate immune cells are now 
relatively well understood (Träger et al., 2014; Kwan et al., 2012b), very little 
is known about the adaptive immune system in HD.  
In contrast to the innate immune system, which provides an immediate 
generic response to a wide range of pathogens, the adaptive immune system 
generates a highly specific secondary response that is also known as 
immunological memory. The adaptive immune response is largely mediated 
by T lymphocytes, that produce cytokines to enhance or suppress the activity 
of other immune cells, and B lymphocytes, that generate antibodies following 
exposure to specific pathogens. T lymphocytes may be further categorised 
into a wide range of subtypes, including CD4+ helper T lymphocytes and 
CD8+ cytotoxic T lymphocytes. There is much interplay between the innate 
and adaptive immune systems, for example through the formation of cytokine 
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feedback loops; such interactions are required for both to function effectively 
(Iwasaki and Medzhitov, 2015; Shanker, 2010).  
Despite the advances made in the study of HD immunity, it is not currently 
clear whether such interplay is affected in HD, or if the cells of the adaptive 
immune system even experience comparable dysfunction to their innate 
immune counterparts. Answering this question is vital to fully understanding 
the mechanisms behind HD immune dysfunction, as the key role of T 
lymphocytes in common processes such as cytokine production means it is 
certainly possible that they contribute to the elevated peripheral levels seen 
in HD patients. Indeed, there is considerable overlap in the cytokines 
produced by the innate and adaptive immune systems; this is the case for IL-
6, increased levels of which are detectable in HD plasma up to 16 years 
before the predicted onset of motor symptoms (Björkqvist et al., 2008). It is a 
further possibility that dysfunction in each arm of the immune system 
contributes to that of the other; for example, elevated cytokine production by 
helper T lymphocytes would lead to an enhanced macrophage response that 
would exacerbate the ex vivo dysfunction that has previously been 
demonstrated in HD myeloid cells. This means it is not possible to conclude 
that the innate immune system is solely responsible for HD immune 
dysfunction until adaptive immunity has been comprehensively investigated. 
Previous work has shown that HD T lymphocytes express mHTT, the levels 
of which correlate with disease burden scores in a similar manner to that of 
HD monocytes (Weiss et al., 2012). Levels of the signature Th2 cytokine IL-4 
are also elevated in the peripheral blood of HD patients with advanced 
disease, suggesting that mHTT may have an adverse effect on T lymphocyte 
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function (Björkqvist et al., 2008). However, the same study found that 
circulating Ig levels are not altered in the plasma of HD patients, perhaps 
pointing away from widespread changes in HD adaptive immune function. 
Furthermore, a recent study found that T lymphocytes are not significantly 
enriched in post-mortem brain tissue from HD patients (Silvestroni et al., 
2009). However, this evidence remains largely circumstantial, and the 
functional properties of HD adaptive immune cells are yet to be directly 
studied in isolation. In order to answer the question of whether the peripheral 
adaptive immune system is contributing to HD pathogenesis, a 
comprehensive, multi-faceted approach to investigating the intrinsic biology 
of T lymphocytes is required. 
5.2 Aims 
1. To determine whether the frequencies of circulating immune cells are 
altered between human HD and control peripheral blood. 
2. To characterise the phenotype of human HD T lymphocytes by 
investigating proliferation and cytokine production. 
3. To examine the expression of key T lymphocyte related genes in 
human HD and control helper T lymphocytes. 
4. To determine whether HD peripheral immune dysfunction is universal 
or restricted to specific immune cell subsets. 
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5.3 Methods 
PBMCs were isolated using density centrifugation (Section 2.4.1), before 
CD4+ helper T lymphocytes were isolated using magnetic cell sorting 
(Section 2.4.2). T lymphocytes were stimulated using either anti-human CD3 
and anti-human CD28 functional grade antibodies or PHA-P (Section 2.4.4). 
Flow cytometric analysis of cell surface and intracellular markers was used to 
quantify peripheral immune subsets (Section 2.13). T lymphocyte 
proliferation was analysed using CFSE (Section 2.6.4), while T lymphocyte 
cytokine production was quantified using MSD cytokine assays (Section 
2.12.2). Cytokine values were normalised to total protein levels as measured 
by BCA assays (Section 2.11.2). Transcriptional profiling of CD4+ T 
lymphocytes was carried out using multiplex PCR arrays (Section 2.9). 
Statistical analysis was carried out according to Section 2.14.3. 
5.4 Contributions 
Flow cytometric analysis of immune cell subsets was carried out in 
collaboration with Dr Ulrike Träger. The remainder of the experiments were 
performed and analysed in their entirety by James Miller. Findings presented 
in this chapter were published in PLOS ONE (full manuscript included in the 
appendices of this thesis): 
Miller, J.R., Träger, U., Andre, R., Tabrizi, S.J. 2015. Mutant Huntingtin Does 
Not Affect the Intrinsic Phenotype of Human Huntington’s Disease T 
Lymphocytes. PLOS ONE [online], 10(11), e0141793. Available from:  doi: 
10.1371/journal.pone.0141793. 
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5.5 Results 
5.5.1 The circulating monocyte balance is altered between 
HD and control peripheral blood 
HD patients of all disease stages have been shown to have elevated levels 
of circulating proinflammatory cytokines and chemokines compared to 
controls (Björkqvist et al., 2008; Wild et al., 2011). While this is likely to be 
primarily due to transcriptional and functional alterations in HD myeloid cells 
(Träger et al., 2014), a potential contributing factor is a shift in the relative 
frequencies of immune cell subtypes in HD peripheral blood, leading to a 
change in the cytokine environment being produced. In order to address this, 
PBMCs were isolated from peripheral blood samples donated by HD and 
control subjects. The PBMCs were then then stained with antibodies to a 
wide range of cellular markers, before being analysed by flow cytometry. 
While the focus of this chapter is primarily on the cells of the adaptive 
immune system, innate immune cell subsets were also included in the 
antibody panels as their relative prevalence in HD peripheral blood has not 
been previously studied. This is especially important as primed circulating 
monocytes are likely to be a key source of the elevated peripheral cytokine 
levels seen in HD (see Chapter 4). Flow cytometric analysis revealed a 
significant (p < 0.01) increase in the frequency of classical (CD14++ CD16-) 
monocytes in HD compared to control PBMCs (Fig. 5.1; gating in Fig. 5.2). 
This raises the possibility that alterations in the circulating monocyte balance 
contribute to peripheral cytokine upregulation in HD. However, the frequency 
of alternative (CD14+ CD16++) monocytes was not found to be affected.  
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Figure 5.1.  The circulating monocyte balance is altered between HD and control 
peripheral blood. PBMCs were isolated from HD and control peripheral blood, before the 
frequencies of classical (CD14++ CD16-) and alternative (CD14+ CD16++) monocytes were 
measured by flow cytometry. The frequency of classical monocytes was found to be 
significantly increased in HD peripheral blood compared to control, while the frequency of 
alternative monocytes was unaffected. Statistical analysis was carried out using two-tailed 
unpaired Student’s t-tests. **P < 0.01. 
5.5.2 The frequencies of additional immune cell subsets are 
not altered between HD and control peripheral blood 
Concurrently, the same PBMC samples were used to analyse the 
frequencies of additional key cell types in the peripheral immune system 
(Table 5.1). In contrast to the changes seen in classical monocytes, no 
significant differences were seen in the frequencies of any of the major T 
lymphocyte subsets that were investigated (Fig. 5.3; gating in Fig. 5.4). This 
is consistent with a recent study showing that the frequency of CD3+ T 
lymphocytes is not altered between the spleen and bone marrow of R6/2 and 
wild-type mice (Träger et al., 2015). The activation levels of these T 
lymphocyte subsets were further assessed by CD62Llow expression; again, 
no differences were seen between the HD and control PBMCs (Fig. 5.5). 
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Figure 5.2.  Gating strategy for analysis of monocyte subsets. After gating on live 
cells using a FSC/SSC gate, a CD14 vs. CD16 plot was used to determine the percentages 
of classical (CD14++ CD16-) and alternative (CD14+ CD16++) monocytes. These populations 
were then confirmed using histograms for CCR2 (classical monocytes) and CCR5 
(alternative monocytes). 
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Figure 5.3.  The frequencies of CD3+ T lymphocyte subsets do not differ between 
HD and control peripheral blood. PBMCs were isolated from HD and control peripheral 
blood samples and the frequencies of a range of T lymphocyte populations were measured 
by flow cytometry using antibodies to T lymphocytes (CD3+), helper T lymphocytes (CD3+ 
CD4+) and cytotoxic T lymphocytes (CD3+ CD8+). Within the helper T lymphocyte population, 
the Th1 and Th2 subtypes were analysed using antibodies to CXCR3 and CCR4 
respectively. No significant differences were seen between HD and control for any of the cell 
subsets. Statistical analysis was carried out using two-tailed unpaired Student’s t-tests. 
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Figure 5.4.  Gating strategy for CD3+ T lymphocyte subset analysis. After gating on 
live cells using a FSC/SSC gate, a FSC vs. CD3 plot was used to determine the frequency 
of CD3+ T lymphocytes. Within the CD3+ population, the frequencies of CD4+ helper T 
lymphocytes and CD8+ cytotoxic T lymphocytes were determined, before the frequencies of 
CXCR3+ Th1 and CCR4+ Th2 lymphocytes within the CD4+ helper T lymphocyte population 
were determined. Activation levels of T lymphocytes were also determined based on 
CD62Llow expression. 
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Figure 5.5.  Activation levels of CD3+ T lymphocyte subsets are not altered 
between HD and control peripheral blood. Within the previously analysed T lymphocyte 
populations (Fig. 5.3.), the activation levels of each were measured using CD62L low 
expression. No significant differences were seen in the activation of any of the HD cell 
subsets compared to control. Statistical analysis was carried out using two-tailed unpaired 
Student’s t-tests. 
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An additional antibody panel was used to analyse the frequencies of Th17 
lymphocytes, Treg lymphocytes, NK cells and NKT cells. As with the above 
CD3+ T lymphocyte subsets, no significant differences were seen between 
HD and control for any of the cell subsets that were investigated (Fig. 5.6; 
gating in Fig. 5.7).  
 
Figure 5.6.  The frequencies of additional immune cell subsets are not altered 
between HD and control peripheral blood. The frequencies of additional immune cell 
subsets in HD and control peripheral blood were measured using antibodies to Th17 
lymphocytes (IL-17+), Treg lymphocytes (CD25+ FOXP3+), NK cells (CD3- CD56+) and NKT 
cells (CD3+ CD56+). No significant differences were seen between HD and control for any of 
the cell types that were analysed. Statistical analysis was carried out using two-tailed 
unpaired Student’s t-tests. 
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Figure 5.7.  Gating schematic for Th17 lymphocyte, Treg lymphocyte, NK cell and 
NKT cell analysis. After gating on live cells using a FSC/SSC gate, a CD3 vs. CD56 plot 
was used to determine the frequencies of NK cells (CD3- CD56+) and NKT cells (CD3+ 
CD56+). Within the CD3+ CD4+ T lymphocyte population, the frequencies of the Treg (CD25+ 
FOXP3+) and Th17 (IL-17+) lymphocyte subsets were also determined. 
Chapter 5 Adaptive immune biology in HD 
216 
 
Finally, the frequencies of the main cell types involved in humoral immunity 
were measured using antibodies to B lymphocytes and plasma cells. Once 
more, no significant differences in their frequencies were detected between 
the HD and control PBMC populations (Fig. 5.8; gating in Fig. 5.9). This is 
consistent with a previous study showing that B lymphocyte frequencies are 
not altered in the spleens of R6/2 and wild-type mice (Träger et al., 2015). 
These data suggest that, with the exception of classical monocytes, there are 
no substantial alterations in the relative frequencies of the major immune cell 
subsets in HD and control peripheral blood. 
Table 5.1.  Summary of immune cell subset analysis. 
Immune cell subset Cellular markers Altered in HD? 
Classical monocytes CD14++ CD16- Yes (increased) 
Alternative monocytes CD14+ CD16++ No 
T lymphocytes CD3+ No 
Helper T lymphocytes CD3+ CD4+ No 
Th1 lymphocytes CD3+ CD4+ CXCR3+ No 
Th2 lymphocytes CD3+ CD4+ CCR4+ No 
Cytotoxic T lymphocytes CD3+ CD8+ No 
Th17 lymphocytes CD3+ CD4+ IL-17+ No 
Treg lymphocytes CD3+ CD4+ CD25+ FOXP3+ No 
NK cells CD3- CD56+ No 
NKT cells CD3+ CD56+ No 
B lymphocytes CD19++ No 
Plasma cells CD19+ CD138+ No 
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Figure 5.8.  The frequencies of humoral immune cell subsets are not altered 
between HD and control peripheral blood. PBMCs were isolated from HD and control 
peripheral blood samples and the frequencies of B lymphocytes (CD19++) and plasma cells 
(CD19+ CD138+) were measured by flow cytometry. No significant differences were seen 
between HD and control for either cell subset. Statistical analysis was carried out using two-
tailed unpaired Student’s t-tests. 
 
Figure 5.9.  Gating schematic for humoral cell analysis. After gating on live cells 
using a FSC/SSC gate, a CD19 vs. CD138 plot was used to determine the frequencies of B 
lymphocytes (CD19++) and plasma cells (CD19+ CD138+). 
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5.5.3 T lymphocyte proliferation is not impaired in HD  
While the above data demonstrate that there are no changes in the 
frequencies of key adaptive immune cell subsets in HD peripheral blood, 
investigating the phenotype of these cells remains vital for determining 
whether the adaptive immune system is functionally affected by the 
expression of mHTT. Myeloid cells from HD patients display functional 
deficits when migrating to chemotactic stimuli and phagocytosing fluorescent 
beads (Kwan et al., 2012b; Träger et al., 2015). Here, HD T lymphocytes 
were investigated to identify comparable functional abnormalities. 
The ability of lymphocytes to rapidly proliferate in response to a stimulus is a 
key feature of adaptive immunity. PBMCs were isolated from peripheral 
blood samples donated by manifest HD and control subjects, before being 
stained with the intracellular dye CFSE. CFSE is a highly stable fluorescent 
dye that is evenly distributed between the two daughter cells produced when 
a cell divides. This allows the tracking of multiple cell divisions in vitro as a 
sequential halving of fluorescence intensity on flow cytometry (Quah et al., 
2007; Hawkins et al., 2007). After staining, the PBMCs were either left 
unstimulated, stimulated with anti-CD3 and anti-CD28 antibodies, or 
stimulated with PHA-P. This enabled testing of the cells’ responses to 
antigenic and mitogenic stimuli, respectively. Cultures were harvested after 
72, 96 and 120 h to build up a broad profile of the proliferative response. 
Additional flow cytometry antibodies were used to independently investigate 
proliferation in the T lymphocyte, helper T lymphocyte and cytotoxic T 
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lymphocyte populations (gating schematic in Fig. 5.10); these data were then 
analysed using a range of statistics outlined by Roederer (Roederer, 2011). 
The most common statistic used to analyse lymphocyte proliferation data is 
‘fraction diluted’, which uses a univariate CFSE gate to determine the 
percentage of cells in the final culture that have divided at least once. 
However, this is a somewhat simplistic assessment of the data, as it provides 
no information on the proportion of cells from the initial population that 
entered division, or indeed the number of divisions those cells have 
undergone. This information is provided by the ‘percentage divided’, 
‘proliferation index’ and ‘division index’ statistics (Table 5.2). The proliferative 
response of HD and control CD3+ lymphocytes was analysed using all four of 
the above statistics. However, no significant differences were seen for any of 
the experimental conditions at any of the time points that were studied (Figs. 
5.11-5.14). Similar results were obtained for the helper T lymphocyte and 
cytotoxic T lymphocyte subsets, with no significant differences observed for 
any of the experimental conditions or time points investigated (complete data 
in Appendices). These results demonstrate that proliferation in response to 
stimuli is not impaired in the major T lymphocyte populations in HD. 
Table 5.2.  Statistical parameters used for T lymphocyte proliferation assays. 
Statistic Description 
Fraction diluted The percentage of cells in the final culture that divided at least once. 
Percentage divided The percentage of cells from the initial culture that divided at least once. 
Proliferation index The average number of divisions undergone by the dividing cells only. 
Division index The average number of divisions undergone by all cells in culture. 
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Figure 5.10.  Gating strategy for T lymphocyte proliferation analysis. After gating on 
live cells using a FSC/SSC gate, non-viable cells were excluded using Fixable Viability Dye 
660. A FSC vs. CD3 plot was then used to identify the CD3+ T lymphocyte population, within 
which a CD4 vs. CD8 plot was used to identify the helper (CD3+ CD4+) and cytotoxic (CD3+ 
CD8+) T lymphocyte populations. A histogram was then used to analyse the CFSE 
fluorescence profile of each cell subset. The fraction diluted statistic was calculated by 
creating a univariate gate below the undivided peak, while all other proliferation statistics 
were calculated using the proliferation analysis tool included in the FlowJo software. 
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Figure 5.11.  Fraction diluted analysis of T lymphocytes. PBMCs were isolated from 
HD and control peripheral blood samples and stained with CFSE. The percentage of CD3+ T 
lymphocytes in the final culture that divided at least once (A) in the absence of stimulation, 
(B) with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 antibody stimulation, and (C) with 10 µg/ml 
PHA-P stimulation was then measured after 72, 96 and 120 h by flow cytometry. No 
significant differences were seen between HD and control for any of the experimental time 
points or conditions. Statistical analysis was carried out using two-tailed unpaired Student’s 
t-tests with a Holm-Šidak correction (alpha = 0.05) for multiple comparisons. 
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Figure 5.12.  Percentage divided analysis of T lymphocytes. PBMCs were isolated 
from HD and control peripheral blood samples and stained with CFSE. The percentage of 
CD3+ T lymphocytes from the initial culture that divided (A) in the absence of stimulation, (B) 
with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 antibody stimulation, and (C) with 10 µg/ml 
PHA-P stimulation was then measured after 72, 96 and 120 h by flow cytometry. No 
significant differences were seen between HD and control for any of the experimental time 
points or conditions. Statistical analysis was carried out using two-tailed unpaired Student’s 
t-tests with a Holm-Šidak correction (alpha = 0.05) for multiple comparisons. 
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Figure 5.13.  Proliferation index analysis of T lymphocytes. PBMCs were isolated 
from HD and control peripheral blood samples and stained with CFSE. The number of 
divisions that proliferating CD3+ T lymphocytes underwent (A) in the absence of stimulation, 
(B) with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 antibody stimulation, and (C) with 10 µg/ml 
PHA-P stimulation was then measured after 72, 96 and 120 h by flow cytometry. No 
significant differences were seen between HD and control for any of the experimental time 
points or conditions. Statistical analysis was carried out using two-tailed unpaired Student’s 
t-tests with a Holm-Šidak correction (alpha = 0.05) for multiple comparisons. 
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Figure 5.14.  Division index analysis of T lymphocytes. PBMCs were isolated from HD 
and control peripheral blood samples and stained with CFSE. The number of divisions that 
all CD3+ T lymphocytes underwent (A) in the absence of stimulation, (B) with 5 µg/ml anti-
CD3 and 2 µg/ml anti-CD28 antibody stimulation, and (C) with 10 µg/ml PHA-P stimulation 
was then measured after 72, 96 and 120 h by flow cytometry. No significant differences were 
seen between HD and control for any of the experimental time points or conditions. 
Statistical analysis was carried out using two-tailed unpaired Student’s t-tests with a Holm-
Šidak correction (alpha = 0.05) for multiple comparisons. 
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5.5.4 Cytokine production by ex vivo helper T lymphocytes is 
not altered in HD compared to control 
While these data demonstrate that T lymphocyte proliferation in response to 
a stimulus is not impaired in HD, perhaps the most important function of 
these cells is to produce a wide range of effector cytokines that are involved 
in directing the immune response. While HD patients have significantly 
elevated plasma levels of proinflammatory cytokines (Björkqvist et al., 2008), 
it is not currently clear what proportion of these excess cytokines are 
produced by the cells of either the innate or adaptive immune systems. While 
evidence to date strongly suggests that myeloid cells are the primary source, 
it is highly possible that T lymphocytes also contribute; indeed, there is 
overlap in the HD upregulated cytokines produced by these cell types, for 
example IL-6 and IL-8. Investigation of potential hyper-reactivity in HD T 
lymphocytes must therefore be carried out to form a more complete picture 
of the cell subsets responsible. 
To address this, helper T lymphocytes were isolated from peripheral blood 
samples donated by manifest HD and control subjects. Helper T lymphocytes 
were selected for investigation as they are one of the most important effector 
cell types in the adaptive immune system, and are involved in directing the 
vast majority of adaptive immune responses via the production of a wide 
range of cytokines. Following isolation, the helper T lymphocytes were 
stimulated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 antibodies, or left 
unstimulated. The cell culture supernatants were harvested after 48 h and 
analysed using a multiplex MSD assay for IFNγ, IL-1β, IL-2, IL-4, IL-6, IL-8, 
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IL-10, IL-12p70, IL-13 and TNFα. An additional singleplex assay was used to 
measure levels of IL-5. In contrast to the hyper-reactivity displayed by HD 
myeloid cells to LPS, no significant differences were seen in the levels of any 
of the eleven cytokines that were measured in the stimulated HD and control 
samples following normalisation to total protein levels (Fig. 5.15). 
Furthermore, while several of the cytokines were below the detection limits of 
the assay in the unstimulated samples, those that were measurable also 
showed no significant differences between HD and control (Fig. 5.16). These 
results demonstrate that cytokine production by helper T lymphocytes is not 
significantly affected by mHTT expression, and that these cells do not display 
a similar hyper-reactive response to immune stimuli as that seen in HD 
myeloid cells (Träger et al., 2014). 
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Figure 5.15.  Cytokine production by stimulated helper T lymphocytes is not altered 
in HD compared to control. CD4+ helper T lymphocytes were isolated from HD and control 
peripheral blood samples and stimulated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 
antibodies. Supernatants were collected after 48 h and cytokine profiling was carried out 
using MSD assays. No significant differences were seen in the levels of any of the cytokines 
produced by HD and control CD4+ helper T lymphocytes after normalisation to total protein 
levels. Statistical analysis was carried out using two-tailed unpaired Student’s t-tests. Data 
show mean concentrations ± SEM.  
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Figure 5.16.  Cytokine production by unstimulated helper T lymphocytes is not 
altered in HD compared to control. CD4+ helper T lymphocytes were isolated from HD and 
control peripheral blood samples and seeded without stimulation. Supernatants were 
collected after 48 h and cytokine profiling was carried out using MSD assays. No significant 
differences were seen in the levels of any of the detectable cytokines produced by HD and 
control CD4+ helper T lymphocytes after normalisation to total protein levels. Statistical 
analysis was carried out using two-tailed unpaired Student’s t-tests. Data show mean 
concentrations ± SEM.  
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5.5.5 The transcriptional profile of helper T lymphocytes is 
not dysregulated in HD compared to control 
While these experiments have suggested that the intrinsic phenotype of T 
lymphocytes is not affected by mHTT expression, it is still possible that there 
are transcriptional changes that do not have a detectable functional effect in 
an ex vivo setting. Data presented in Chapter 4 of this thesis demonstrates 
that mHTT has a substantial ‘priming’ effect on the transcriptome of HD 
monocytes; this is likely to be responsible for their hyper-reactive response to 
immune stimuli. While comparable phenotypic dysfunction has not been 
identified in HD T lymphocytes, assessment of their transcriptional profile is 
necessary for a more complete understanding of adaptive immunity in HD. 
Helper T lymphocytes were isolated from peripheral blood samples donated 
by manifest HD and control subjects and either left unstimulated or 
stimulated with 5 µg/ml anti-CD3 and 2 µg/ml antibodies for 8 h. The mRNA 
expression of eighty-four key T lymphocyte genes was then analysed using 
Human Th1 and Th2 Responses RT2 Profiler PCR Arrays.  
Analysis of the PCR array data revealed two genes that were significantly 
upregulated (p < 0.05) in the unstimulated HD samples compared to control 
(TNFSF4, PTGDR2; Table 5.3), and three genes that were significantly 
upregulated in the stimulated HD samples compared to control (TYK2, 
TNFRSF8, STAT6; Table 5.4). No genes were found to be significantly 
downregulated in either the unstimulated or stimulated HD samples 
compared to control. However, none of the upregulated genes had a fold 
change of > 1.8 between HD and control, and only two (PTGDR2 and 
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TNFRSF8) had a fold change of > 1.5. Furthermore, the expression of key 
signalling molecules such as MAPK8 (JNK1) and JAK1/2 was not altered in 
either the unstimulated or stimulated HD samples compared to control 
(complete list in Appendices).  
Consistent with the cytokine profiling data, the mRNA levels of IFNG, IL2, 
IL5, IL6, IL10, IL13 and TNF were not altered between HD and control in 
either the unstimulated or stimulated samples. Transcript levels of IL4 and 
IL12B were not detectable in the unstimulated samples, but were similarly 
unaffected in the stimulated samples. Unfortunately, IL1B and IL8 were not 
included in the genes covered by the PCR arrays. The lack of any change in 
IL6, IL10 and IL12B is a further contrast with HD myeloid cells, as previous 
studies and the work presented in Chapter 4 have shown that HD monocytes 
express significantly more mRNA for each of these cytokines than control 
cells (Träger et al., 2014). Taken together, these results demonstrate that 
sub-phenotypic transcriptional dysregulation is not a significant phenomenon 
in HD helper T lymphocytes. 
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Table 5.3.  The top twenty gene expression changes in unstimulated HD helper T 
lymphocytes. Data presented as fold change in the HD samples calculated from ΔΔ-CT 
values. Statistical analysis was carried out using two-tailed unpaired Student’s t-tests 
(control n = 12, HD n = 11); expression changes are ranked by p-value. 
Gene name Fold change p-value 
TNFSF4 1.471 0.008 
PTGDR2 1.788 0.014 
GATA3 1.177 0.056 
IL18R1 1.336 0.058 
IL5 2.245 0.063 
LAT 0.893 0.101 
IL2RA 1.154 0.102 
CSF2 0.490 0.124 
JAK1 1.108 0.137 
CCR4 1.258 0.183 
TLR6 1.497 0.198 
TNFRSF9 0.564 0.227 
IL13 0.689 0.227 
IL12RB2 0.789 0.255 
CD86 0.681 0.270 
IL10 1.580 0.271 
BCL6 0.737 0.276 
IL2 1.297 0.281 
IL15 0.858 0.296 
LTA 0.905 0.299 
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Table 5.4.  The top twenty gene expression changes in stimulated HD helper T 
lymphocytes. Data presented as fold change in the HD samples calculated from ΔΔ-CT 
values. Statistical analysis was carried out using two-tailed unpaired Student’s t-tests 
(control n = 12, HD n = 11); expression changes are ranked by p-value. 
Gene name Fold change p-value 
TYK2 1.176 0.002 
TNFRSF8 1.702 0.013 
STAT6 1.231 0.035 
TNFSF4 1.756 0.066 
JAK1 1.169 0.072 
CCR4 1.191 0.118 
IL18R1 1.129 0.149 
CD27 1.261 0.152 
STAT1 0.844 0.162 
IL15 0.800 0.184 
IL5 0.724 0.197 
TGFB3 1.536 0.211 
MAPK8 1.082 0.215 
CD28 1.104 0.237 
YY1 1.052 0.272 
GATA3 1.817 0.300 
IL9 0.704 0.308 
IL6R 1.174 0.319 
FASLG 1.320 0.319 
CCR5 1.194 0.327 
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5.6 Discussion 
Altered peripheral immunity is an established feature of HD pathogenesis, 
with increases in proinflammatory cytokine levels being detectable in 
circulating plasma up to sixteen years before the predicted onset of motor 
symptoms (Björkqvist et al., 2008). The majority of previous studies have 
focused on the intrinsic functional differences between HD and control 
immune cells, with HD myeloid cells being found to display a hyper-reactive 
cytokine response to LPS stimulation (Träger et al., 2014). While the 
functional changes in these cell types likely play a central role in mediating 
HD peripheral immune dysfunction, it is important to consider that changes in 
the circulating immune cell population may have a knock-on effect on the 
peripheral cytokine and chemokine environment. For example, an increase in 
the frequency of Th2 lymphocytes in HD blood would likely contribute to the 
upregulation of the signature Th2 cytokine IL-4 seen in advanced HD plasma 
(Björkqvist et al., 2008).  
This thesis demonstrates that HD patients have a significantly increased 
frequency of classical monocytes in their PBMC populations compared to 
controls. While there is considerable debate regarding the exact function of 
individual monocyte populations, classical monocytes are thought to form the 
majority of the total monocyte population and primarily circulate in the blood 
responding to inflammatory stimuli (Ziegler-Heitbrock, 2007). In contrast, 
alternative monocytes are believed to primarily localise to specific tissues in 
order to produce high levels of proinflammatory mediators. This suggests 
that the altered monocyte balance is unlikely to play a significant role in 
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mediating the cytokine increases seen in HD peripheral blood, as classical 
monocytes are thought to be primarily phagocytic in function with few 
inflammatory attributes (Mukherjee et al., 2015). In contrast, the frequency of 
the proinflammatory alternative monocyte population was not found to be 
significantly affected. While it is possible that the increase in classical 
monocyte frequency makes a minor contribution to peripheral cytokine 
levels, the wealth of functional data on HD monocytes provides a much more 
convincing explanation. 
Furthermore, data presented in this chapter show that the frequencies of a 
wide range of additional immune cells are not altered between HD and 
peripheral blood. This is consistent with a previous study which found that 
the frequencies of T and B lymphocytes are not altered in the spleen and 
bone marrow of R6/2 mice (Träger et al., 2015). Taken together, these 
results disprove the hypothesis that widespread changes in HD immune cell 
frequencies could be contributing to the altered cytokine environment seen in 
HD peripheral blood. These immune alterations are therefore likely to be 
almost exclusively the result of functional differences arising from the 
expression of mHTT, and not a shift in the relative prevalence of cell types 
producing specific cytokines.  
Data presented in Chapter 4 of this thesis suggest that basal 
proinflammatory priming in HD myeloid cells is likely to be a key mechanism 
in mediating peripheral immune dysfunction. However, this does not preclude 
other cell subsets from playing a contributory role. T lymphocytes are vital to 
adaptive immune function, and a comprehensive investigation of their 
function is needed to determine whether HD immune dysfunction is universal 
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or restricted to specific cell types. Indeed, the close interplay between T 
lymphocytes and myeloid cells, in the form of cell-cell interactions and 
cytokine feedback loops, means that T lymphocytes could even contribute to 
HD myeloid cell dysfunction via excessive stimulatory input (Shanker, 2010). 
Mutant HTT protein levels in human HD T lymphocytes have been found to 
correlate with disease burden scores in HD patients in a similar manner to 
mHTT levels in HD monocytes (Weiss et al., 2012). While mHTT expression 
should not be taken as a guarantee of phenotypic dysfunction, profiling of HD 
plasma found that levels of the signature Th2 cytokine IL-4 are increased in 
patients with advanced disease (Björkqvist et al., 2008). While largely 
circumstantial in isolation, the potential significance of these results 
necessitates a comprehensive investigation of the intrinsic biology of T 
lymphocytes in HD. 
HD myeloid cells have been shown to exhibit numerous functional deficits, 
including in migration and phagocytosis (Kwan et al., 2012b; Träger et al., 
2015). The results presented in this chapter demonstrate that HD T 
lymphocytes do not exhibit comparable abnormalities when proliferating in 
response to a stimulus. This was the case at all of the time points that were 
studied, and applied to both the percentage of cells that entered division and 
the number of divisions those cells underwent. More specific analysis of 
helper and cytotoxic T lymphocyte subsets similarly failed to yield any 
significant differences between HD and control.  
In addition to the resting proinflammatory transcriptional profile described in 
Chapter 4, HD myeloid cells display a hyper-reactive cytokine response to 
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LPS stimulation (Träger et al., 2014). However, no such increase in cytokine 
release was seen in HD helper T lymphocytes, both basally and in response 
to antigenic stimulation. This lack of functional distinction is supported by the 
flow cytometry data, as activation levels of T lymphocytes as measured by 
CD62Llow expression were not found to be altered between HD and control. 
These data suggest that, in contrast to myeloid cells, HD T lymphocytes do 
not suffer from any intrinsic functional impairment in response to mHTT 
expression. One explanation for this may be in the relative contributions of 
different intracellular signalling pathways to the function of each cell type. 
Previous work using cell lines and HD mouse models has shown that mHTT 
has a direct interaction with IKK, a key kinase in the NFκB pathway 
(Khoshnan et al., 2004). This leads to increased nuclear translocation of 
NFκB and an increase in the transcription of NFκB-regulated genes. In 
myeloid cells the NFκB pathway is vital for the production of proinflammatory 
cytokines such as IL-6 and TNFα (Hayden and Ghosh, 2011), and work 
presented in Chapter 4 of this thesis has shown that increased basal NFκB 
activity is likely to play a key role in mediating resting transcriptional 
dysregulation in HD monocytes. While the NFκB pathway is also involved in 
T lymphocyte signalling, additional transcription factors such as the NFAT 
and MAPK families are heavily involved in key processes such as cytokine 
production (Macian, 2005; Dodeller and Schulze-Koops, 2006). It is therefore 
possible that while similar NFκB dysfunction may exist in HD T lymphocytes, 
the reduced relative importance of the pathway means that compensatory 
mechanisms are in place to prevent phenotypic dysfunction. Furthermore, 
NFκB is known to be activated by different mechanisms in each cell type. 
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Myeloid cell NFκB signalling is typically activated via stimulation of the LPS 
receptor TLR4 (Okun et al., 2009), whereas T lymphocytes are classically 
stimulated through the TCR (Brownlie and Zamoyska, 2013). While TLR4 is 
expressed by helper T lymphocytes, its exact function remains unclear, and it 
has even been suggested to have a repressive effect on T lymphocyte 
activation (González-Navajas et al., 2010). There is also evidence that NFκB 
has anti-inflammatory functions in naïve CD4+ T lymphocytes, with 
overexpression of the NFκB family member NFκB1 (p50) leading to reduced 
transcription of IL-2 (Kang et al., 1992). Taken together, these data suggest 
that the lack of phenotypic abnormalities in HD T lymphocytes may be due to 
the altered and reduced role of NFκB signalling in T lymphocytes compared 
to myeloid cells. 
Mutant HTT has diverse effects on transcription, including the sequestration 
of transcription factors in aggregates and the direct binding of mHTT 
fragments to DNA (Chen-Plotkin et al., 2006; Benn et al., 2008), and 
transcriptional dysregulation has been consistently demonstrated in a wide 
range of HD tissues (Seredenina and Luthi-Carter, 2012). However, the 
degree to which individual signalling pathways are affected by mHTT 
expression is likely to vary considerably. PCR array analysis of helper T 
lymphocytes was used to show that widespread changes in key T 
lymphocyte related genes are lacking in HD compared to control in both the 
unstimulated and stimulated states. This is in marked contrast to the 
widespread resting enrichment of proinflammatory functional gene sets in HD 
myeloid cells described in Chapter 4. The expression of key signalling 
molecules such as MAPK8 (JNK1) and JAK1/2 was unaffected in HD T 
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lymphocytes, supporting the hypothesis that the normal function of 
alternative signalling pathways is able to compensate for potential NFκB 
pathway dysregulation. While the key Th2 transcription factor STAT6 was 
found to have increased expression in stimulated HD cells, no additional 
changes were seen in any related transcripts. Furthermore, it has been 
shown that JAK/STAT signalling is not significantly affected in HD myeloid 
cells (Träger et al., 2013), making it likely that the small increase in 
expression (fold change 1.23) observed in our dataset does not have a great 
deal of functional significance. Increased resting expression of 
proinflammatory cytokines such as IL6, IL10 and IL12B was also lacking in 
HD helper T lymphocytes, drawing a further contrast with the basal changes 
described in the transcriptome of HD myeloid cells. When combined with the 
functional data described above, these results lead to the conclusion that the 
intrinsic function of HD T lymphocytes is not significantly affected by the 
expression of mHTT. 
However, it is important to note that these results do not exclude the 
possibility of in vivo differences in T lymphocyte function, as excessive 
stimulation from hyper-reactive myeloid cells could provoke an increased T 
lymphocyte response independent of any intrinsic cellular dysfunction. This is 
one potential explanation for the increased IL-4 levels seen in the plasma of 
HD patients (Björkqvist et al., 2008), although it has also been suggested 
that increased secretion of this anti-inflammatory cytokine may be a 
compensatory response to the chronic increase in inflammatory mediators 
seen in HD plasma (Ellrichmann et al., 2013). This conclusion is supported 
by the increased IL-4 levels only being seen in the later stages of the 
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disease. Regardless, determining whether the in vivo activity of T 
lymphocytes is altered in response to excessive innate immune activation 
would require a series of complicated functional experiments, the scope of 
which is beyond the remit of this thesis. 
The results presented in this chapter have shown that the intrinsic phenotype 
of T lymphocytes is not significantly affected by the expression of mHTT. 
These findings advance our understanding of HD as a disease of the whole 
body, and support the work presented in Chapter 4 suggesting that abnormal 
myeloid cells are the most likely source of peripheral immune dysfunction in 
HD. This has important implications for potential novel therapies that aim to 
treat HD by modulating the peripheral immune system, as it shows that 
benefits are only likely to be achieved when targeting specific cell types. 
Furthermore, this chapter demonstrates the value of taking a systematic 
approach to investigating the function of individual cell types in HD, as the 
phenotypic effects of mHTT expression are clearly dependent on the cellular 
environment and the relative contributions of the signalling pathways the 
mutant protein interacts with. 
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5.7 Summary 
Work presented in this chapter investigated the frequencies of a wide range 
of immune cell subsets in HD and control peripheral blood, in order to 
determine whether a shift in the relative proportions of specific cell subsets 
could be a contributing factor in the elevated levels of proinflammatory 
cytokines seen in HD plasma. However, while HD PBMCs were found to 
contain a significantly higher proportion of classical monocytes than control 
PBMCs, the frequencies of all of the other major immune cell subsets that 
were investigated were found to be unchanged. Furthermore, this chapter 
investigated whether HD T lymphocytes exhibit similar phenotypic 
abnormalities to those displayed by HD myeloid cells. However, no 
significant differences were found between HD and control in tests of both 
proliferation and cytokine production, while PCR arrays were used to 
determine that the expression of key T lymphocyte related genes is not 
substantially affected in either unstimulated or stimulated HD helper T 
lymphocytes. These findings demonstrate that HD peripheral immune 
dysfunction is not universal, but is instead restricted to specific cell types that 
are primarily part of the innate immune system. 
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6 Conclusions and future work 
6.1 Allele-selective silencing as a therapeutic for HD 
Work presented in this thesis demonstrates for the first time the allele-
selective suppression of mHTT in primary human ex vivo patient cells. This 
was achieved using siRNA targeted to each allele of rs362331 in exon 50 of 
the HTT transcript. While previous studies have successfully shown 
selectivity using HD cell lines or animal models (Østergaard et al., 2013; 
Drouet et al., 2014), this study is the first to establish the feasibility of 
carrying out an experimental workflow comprising SNP genotyping, SNP 
linkage and targeted knockdown of the mutant allele in human HD patients. 
This is an important advance as it provides insight into the likely clinical 
application of this technology, with the added technical considerations 
associated with personalised genomic medicine.  
From a purely technical standpoint, this study shows that the potency and 
selectivity achieved using allele-specific siRNAs varies depending on the 
SNP in question, even when considering heterozygous SNPs with an 
equivalent base mismatch. This is consistent with previous studies using 
ASOs (Carroll et al., 2011), and can be seen in the greatly increased allele-
selectivity achieved when targeting rs362331 compared to rs362273 and 
rs362307. Extensive preclinical validation of potential SNP targets will 
therefore be crucial for the development of any allele-selective therapeutic, 
with a failure to achieve selectivity at the most prevalent SNP sites (e.g. 
rs362307) limiting the HD patients who would benefit from such an approach. 
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While this study has established the feasibility of individually treating patients 
based on their SNP genotype, it remains to be seen whether such an 
approach will ever be suitable for widespread clinical use. With even the 
most prevalent SNPs being heterozygous in less than 50 % of patients, a 
combined approach comprising individual clinical trials of multiple SNP-
targeted therapeutics would be required to cover even a majority of HD 
patients. The cost implications of such a strategy, not to mention the 
logistical difficulties associated with recruiting large cohorts of genotyped 
patients for clinical trials, are likely to prove prohibitive. This is compounded 
by the high level of technical difficulty associated with the SLiC technique 
required to link SNP alleles to mHTT (Liu et al., 2008), with widespread 
introduction into clinical laboratories seeming an unlikely proposition. Indeed, 
barring the development of straightforward genotyping techniques such 
personalised medical jiggery-pokery is likely to become the future preserve 
of the limited few wealthy enough to afford it. 
Furthermore, there are significant ethical issues associated with developing 
therapeutics to treat a minority of Caucasian patients when the majority of 
HD occurs in the developing world (Warby et al., 2011). The prevalence of 
SNP heterozygosities has been shown to vary widely between populations of 
different ethnic groups (Lombardi et al., 2009; Warby et al., 2009; Pfister et 
al., 2009), so it is likely that any drugs developed for Caucasian populations 
would not be widely usable elsewhere. Indeed, it is almost inconceivable that 
the sophisticated genotyping techniques required to use allele-selective 
therapeutics will be widely available in developing nations in the near future; 
even if a heterozygous SNP was applicable worldwide, the technology to 
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make use of it is not. There is therefore a convincing argument to be made 
that the resources required to develop these treatments would be better 
spent on therapeutics with universal applicability to HD patients. These are 
likely to focus on total HTT-lowering, with numerous animal studies offering 
encouraging data to suggest that partial suppression of wild-type HTT is 
tolerated in the mammalian brain (McBride et al., 2008; Grondin et al., 2012). 
If initial human trials provide similar results, it may be that allele-selective 
suppression is not required for the safe and effective treatment of HD. 
However, the leviathan practical considerations associated with taking allele-
selective silencing to clinical trials by no means diminish its vast potential as 
a research tool for dissecting the specific cellular roles of wild-type and 
mHTT. For example, work presented in this thesis has demonstrated that 
selectively lowering both wild-type and mHTT has equivalent effects on HD 
myeloid cell cytokine production. It is likely that the coming years will yield 
numerous studies in this vein, providing sophisticated data beyond what was 
previously available with total HTT-lowering or conditional HTT knockout. 
6.2 Myeloid cell function in HD 
Work presented in Chapter 4 of this thesis used modern RNA-Seq 
technology to characterise the entire HD myeloid cell transcriptome. This 
showed that mHTT-related dysfunction is not limited to the stimulated state, 
with HD monocytes demonstrating significant basal transcriptional changes. 
Pathway analysis of the dataset revealed that these transcriptional changes 
were largely proinflammatory in nature, including the first ever demonstration 
of increased resting cytokine expression in HD myeloid cells at either the 
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mRNA or protein level. Functional follow up revealed that increased basal 
NFκB activity is involved in mediating these changes, suggesting that mHTT 
has a priming effect on HD myeloid cells similar to that described in a murine 
HD microglial line (Crotti et al., 2014). This resting proinflammatory profile is 
likely to play a role in the hyper-reactive LPS response seen in HD myeloid 
cells (Träger et al., 2014). The discovery of resting dysfunction in HD myeloid 
cells provides valuable new insight into the peripheral pathogenesis of HD, 
as primed myeloid cells are likely to make a significant contribution to the 
elevated cytokine levels seen in HD plasma (Björkqvist et al., 2008).  
Interestingly, the selective lowering of wild-type and mHTT was not found to 
produce differential effects on cytokine production by HD myeloid cells in 
response to LPS. This suggests that wild-type HTT may have a novel role in 
immune cell function, and is consistent with previous data showing that total 
HTT-lowering in control cells also inhibits cytokine production (Träger et al., 
2014). As a greater reduction in IL-6 and TNFα levels was seen using anti-
total HTT siRNA compared to either allele-selective siRNA, it may well be 
that the total cellular HTT load is the key factor in determining cytokine 
production. However, this observation must be reconciled with the hyper-
reactive cytokine profile of HD myeloid cells, as this is presumably due to a 
mHTT-specific effect. Future work should therefore focus on dissecting the 
specific roles of wild-type and mHTT in myeloid cells, in addition to their 
relative contributions to cytokine production. 
Further investigation is also required to determine why HTT-lowering was 
unable to reverse the transcriptional changes seen in resting HD monocytes, 
as measured by both RNA-Seq and PCR. The most likely hypothesis is that 
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transcriptional changes take time to normalise following a reduction in 
cellular HTT levels, however the short-lived nature of monocytes ex vivo 
means this is challenging to investigate. It may be possible to overcome this 
using a monocyte cell line, although it remains to be seen whether such 
models recapitulate the transcriptional changes seen in primary human cells. 
It may also be valuable to investigate whether individual monocyte 
populations are differentially affected by mHTT expression, as this could lend 
additional relevance to the shift in monocyte frequencies seen in HD 
peripheral blood. However, the lack of inflammatory functions of the affected 
classical monocyte population still suggests that a major role for altered cell 
frequencies in HD immune dysfunction is unlikely (Mukherjee et al., 2015). 
6.3 Adaptive immune function in HD 
It was previously unknown whether HD peripheral immune dysfunction was 
universal or limited to specific cell types. Work presented in Chapter 5 of this 
thesis demonstrates that the intrinsic phenotype of T lymphocytes is not 
affected by mHTT expression, suggesting that the pathogenic effects of 
mHTT vary considerably from cell to cell. This is likely to be due to variations 
in the relative contributions of affected intracellular signalling pathways. 
However, the ex vivo data presented in this thesis does not rule out the 
possibility that the function of HD T lymphocytes is altered in vivo, as the 
formation of feedback loops with the innate immune system could result in an 
exaggeration of T lymphocyte function in response to excessive stimulation 
from myeloid cells. This is one potential explanation for the increase in IL-4 
levels seen in HD plasma (Björkqvist et al., 2008), and future work could 
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utilise co-culture experiments to determine whether interactions between 
innate and adaptive immune cells are affected in HD. 
These results demonstrate the need for the detailed investigation of 
individual cell types in order to determine their relative contributions to HD 
peripheral immune dysfunction. However, it will be important to direct the 
limited time and resources available for such studies to cell types for which 
there are convincing rationales. For example, while the effects of mHTT 
expression on B lymphocytes are yet to be analysed in depth, the lack of any 
change in circulating Ig levels in HD plasma casts serious doubt on the 
existence of any potential abnormalities (Björkqvist et al., 2008). Indeed, it 
could be argued that the lack of any in vivo change renders such 
investigation irrelevant in disease terms. As with so many things, it will be 
important to strike a balance between being comprehensive and practical 
when studying the function of further immune cell subsets in HD.  
6.4 The peripheral immune system as a therapeutic 
target in HD 
These results further raise the possibility that the peripheral immune system 
could be utilised as a novel therapeutic target for HD. It has already been 
shown that dampening the peripheral immune system has beneficial effects 
on disease progression in HD mouse models (Bouchard et al., 2012; Zwilling 
et al., 2011), and the basal myeloid cell dysfunction outlined in Chapter 4 
suggests the existence of a chronic problem that may be amenable to long-
term treatment with immunomodulatory drugs. This discovery also makes the 
dosing schedule of any potential intervention significantly easier, as it will not 
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need to be timed to coincide with specific infective events and is likely to be 
beneficial even in the absence of any inflammatory stimuli. 
Promisingly, the drugs to do this already exist to treat conditions such as 
rheumatoid arthritis, for which TNFα inhibition has been a therapeutic staple 
for many years. TNF inhibition has already been shown to provide 
therapeutic benefit in preclinical studies (Hsiao et al., 2014), and it should be 
relatively straightforward to extend this approach to patients. However, the 
degree to which this may provide long-term benefits remains to be seen, and 
must be weighed against the side effects associated with any drug which is 
taken to clinical trial. Alternative approaches may include targeting specific 
mechanisms associated with HD immune dysfunction, for example the NFκB 
pathway. However, the selectivity of drugs designed to do this remains 
questionable, and the multitude of cellular functions associated with NFκB 
raises serious questions about the potential for off-target toxic effects. 
One outstanding question relates to the ceiling of therapeutic benefit 
available from targeting the peripheral immune system. While mouse studies 
have suggested that neurological phenotypes may be improved by peripheral 
immune suppression, a similar effect is yet to be shown in humans or even 
primates. An ideal strategy would make use of an immunomodulatory drug 
that is able to cross the blood-brain barrier, as neuroinflammation has also 
been shown to be a key component of HD pathogenesis (Björkqvist et al., 
2009); this would allow two potential mechanisms to be treated with a single 
drug. Furthermore, agonising over the potential limitations of 
immunomodulation in HD is to a large extent disputing semantics. While 
even the most optimistic investigator would struggle to argue that this 
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approach will provide a complete cure for HD, the current lack of any 
medications that are able to slow HD progression makes this an avenue 
worth investigating, as even a modest symptomatic improvement would be 
invaluable in the wider patient context.  
This thesis therefore demonstrates the feasibility of tailoring therapeutic 
interventions to an individual’s genotype, and introduces this approach as a 
highly promising method for investigating the specific cellular functions of 
wild-type and mHTT. It further establishes that HD myeloid cells are basally 
abnormal as the result of a mHTT/NFκB-mediated priming effect, and shows 
that phenotypic dysfunction previously described in HD innate immune cells 
does not extend to the cells of the adaptive immune system. These findings 
advance our understanding of HD as a disease of the whole body, support 
the targeting of peripheral immunity as a therapeutic for HD, and reinforce 
the importance of peripheral immunity in the study of neurodegeneration. 
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Appendices 
A.1 RPMI 1640 media formulation 
Table A.1.  RPMI 1640 media formulation. Ingredients of RPMI 1640 media used for 
all cell culture experiments (Thermo Fisher Scientific catalogue number 31870-074). 
Components 
Molecular 
weight 
Concentration 
(mg/L) 
mM 
Amino acids 
Glycine 75.0 10.0 0.133 
L-Arginine 174.0 200.0 1.149 
L-Asparagine 132.0 50.0 0.379 
L-Aspartic acid 133.0 20.0 0.150 
L-Cystine 240.0 50.0 0.208 
L-Glutamic acid 147.0 20.0 0.136 
L-Histidine 155.0 15.0 0.097 
L-Hydroxyproline 131.0 20.0 0.153 
L-Isoleucine 131.0 50.0 0.382 
L-Leucine 131.0 50.0 0.382 
L-Lysine hydrochloride 146.0 40.0 0.274 
L-Methionine 149.0 15.0 0.101 
L-Phenylalanine 165.0 15.0 0.091 
L-Proline 115.0 20.0 0.174 
L-Serine 105.0 30.0 0.286 
L-Threonine 119.0 20.0 0.168 
L-Tryptophan 204.0 5.0 0.025 
L-Tyrosine 181.0 20.0 0.110 
L-Valine 117.0 20.0 0.171 
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Vitamins 
Biotin 244.0 0.2 8.197E-04 
Choline chloride 140.0 3.0 0.021 
D-Calcium pantothenate 477.0 0.25 5.241E-04 
Folic acid 441.0 1.0 0.002 
Niacinamide 122.0 1.0 0.008 
Para-aminobenzoic acid 137.0 1.0 0.007 
Pyridoxine hydrochloride 206.0 1.0 0.005 
Riboflavin 376.0 0.2 5.319E-04 
Thiamine hydrochloride 337.0 1.0 0.003 
Vitamin B12 1355.0 0.005 3.690E-06 
i-Inositol 180.0 35.0 0.194 
Inorganic salts 
Calcium nitrate (Ca(NO3)2-4H2O) 236.0 100.0 0.424 
Magnesium sulphate (MgSO4-7H2O) 246.0 100.0 0.407 
Potassium chloride (KCl) 75.0 400.0 5.333 
Sodium bicarbonate (NaHCO3) 84.0 2000.0 23.810 
Sodium chloride (NaCl) 58.0 6000.0 103.448 
Sodium phosphate dibasic (Na2HPO4) 142.0 800.0 5.634 
Other components 
D-Glucose (dextrose) 180.0 2000.0 11.111 
Glutathione (reduced) 307.0 1.0 0.003 
Phenol red 376.4 5.0 0.013 
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A.2 Patient details 
Table A.2.  Age and HTT CAG repeat length for all subjects who donated samples 
for the study presented in Chapter 3. Cohorts listed separately for each experiment. 
Experiment Subject group n 
Age 
(mean ± SD) 
CAG 
(mean ± SD) 
ATP assay analysis of lower EP 
GeRPs 
Control 2 52.3 ± 19.5 - 
HD 5 52.2 ± 10.9 43.2 ± 0.7 
qPCR analysis of lower EP 
GeRPS 
HD 5 60.1 ± 5.6 43.0 ± 0.6 
TR-FRET analysis of lower EP 
GeRPs 
HD 3 38.2 ± 11.8 51.3 ± 6.1 
Allele-selective suppression 
targeting rs362331 
HD 3 50.1 ± 10.3 44.0 ± 2.2 
Allele-selective suppression 
targeting rs362273 
HD 4 51.2 ± 13.3 42.8 ± 0.8 
Allele-selective suppression 
targeting rs362307 
HD 4 55.9 ± 10.2 43.3 ± 1.5 
siRNA dose-ranging targeting 
rs362331 
HD 5 57.2 ± 6.9 41.8 ± 0.7 
siRNA dose-ranging targeting 
rs362273 
HD 3 60.0 ± 4.8 42.3 ± 0.5 
siRNA dose-ranging targeting 
rs362307 
HD 3 61.3 ± 12.1 41.0 ± 0.8 
Protein analysis of anti-rs362331 
siRNA (C linked to mHTT) 
HD 3 43.4 ± 5.1 45.3 ± 2.6 
Protein analysis of anti-rs362331 
siRNA (T linked to mHTT) 
HD 5 51.1 ± 16.3 44.6 ± 2.7 
Cytokine analysis of anti-
rs362331 siRNA (IL-6 and TNFα) 
HD 5 49.9 ± 11.1 45.2 ± 2.6 
Cytokine analysis of anti-
rs362331 siRNA (IL-8) 
HD 4 46.2 ± 9.3 46.0 ± 2.2 
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Table A.3.   Age and HTT CAG repeat length for all subjects who donated samples 
for the study presented in Chapter 4. Cohorts listed separately for each experiment. 
Experiment Subject group n 
Age 
(mean ± SD) 
CAG 
(mean ± SD) 
RNA-Seq analysis of the monocyte 
transcriptome 
Control 33 48.9 ± 13.2 - 
HD 30 51.3 ± 11.0 44.4 ± 2.8 
IĸBα Western blotting 
Control 7 52.9 ± 16.2 - 
HD 9 62.1 ± 6.0 42.4 ± 2.6 
ERK and p38 Western blotting 
Control 10 55.3 ± 10.9 - 
HD 10 61.8 ± 5.8 42.4 ± 2.4 
RNA-Seq analysis of gene 
expression following HTT-lowering 
HD 6 50.8 ± 8.2 45.0 ± 1.8 
qPCR analysis of gene expression 
following HTT-lowering 
HD 9 52.3 ± 10.2 45.3 ± 1.7 
 
Table A.4.  Age and HTT CAG repeat length for all subjects who donated samples 
for the study presented in Chapter 5. Cohorts listed separately for each experiment. 
Experiment Subject group n 
Age 
(mean ± SD) 
CAG 
(mean ± SD) 
Monocyte and NK cell subset 
analysis 
Control 10 46.8 ± 10.9 - 
HD 11 57.0 ± 9.9 41.9 ± 1.5 
CD3+ T lymphocyte subset analysis 
– Th1 cells  
Control 5 44.9 ± 9.4 - 
HD 7 52.2 ± 10.0 42.3 ± 1.0 
CD3+ T lymphocyte subset analysis 
– all other cell types  
Control 9 46.2 ± 12.1 - 
HD 10 55.6 ± 9.9 42.0 ± 1.6 
NKT cell subset analysis 
Control 10 46.8 ± 10.9 - 
HD 10 56.2 ± 10.1 41.8 ± 1.5 
Th17 lymphocyte subset analysis 
Control 10 46.8 ± 10.9 - 
HD 10 55.6 ± 9.9 42.0 ± 1.6 
Treg lymphocyte, B lymphocyte and 
plasma cell subset analysis 
Control 6 46.1 ± 8.2 - 
HD 7 52.2 ± 9.2 42.3 ± 0.9 
Appendices 
253 
 
T lymphocyte proliferation assays 
Control 9 54.8 ± 7.4 - 
HD 8 56.2 ± 8.6 43.0 ± 2.4 
Stimulated T lymphocyte cytokine 
profiling – IL-1β 
Control 9 55.4 ± 12.6 - 
HD 9 57.4 ± 11.4 43.2 ± 1.9 
Stimulated T lymphocyte cytokine 
profiling – IL-12p70 
Control 8 56.1 ± 13.3 - 
HD 9 57.4 ± 11.4 43.2 ± 1.9 
Stimulated T lymphocyte cytokine 
profiling –  all other cytokines  
Control 10 56.4 ± 12.3 - 
HD 9 57.4 ± 11.4 43.2 ± 1.9 
Unstimulated T lymphocyte 
cytokine profiling – IL-2 
Control 6 53.9 ± 15.3 - 
HD 6 52.4 ± 10.2 44.0 ± 1.8 
Unstimulated T lymphocyte 
cytokine profiling – IL-6 
Control 8 57.1 ± 12.4 - 
HD 8 57.8 ± 12.1 43.0 ± 1.93 
Unstimulated T lymphocyte 
cytokine profiling – IL-8  
Control 9 55.1 ± 12.3 - 
HD 9 57.4 ± 11.4 43.2 ± 1.9 
Unstimulated T lymphocyte 
cytokine profiling – IL-10  
Control 5 57.7 ± 15.4 - 
HD 6 54.7 ± 11.9 43.5 ± 2.0 
Unstimulated T lymphocyte 
cytokine profiling – IL-13  
Control 5 57.1 ± 15.5 - 
HD 6 56.9 ± 14.2 43.5 ± 2.0 
Unstimulated T lymphocyte 
cytokine profiling – TNFα 
Control 9 55.4 ± 12.6 - 
HD 9 57.4 ± 11.4 43.2 ± 1.9 
PCR arrays  
Control 12 49.3 ± 15.3 - 
HD 11 58.7 ± 5.7 42.6 ± 1.4 
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A.3 Monocyte RNA-Seq results 
Table A.5.  Complete list of differentially expressed genes in unstimulated HD 
monocytes (FDR < 0.05). 
Gene ID Ensembl ID 
RPKM 
(Control) 
RPKM (HD) 
log2 fold 
change 
p-value FDR 
FAM124A ENSG00000150510 0.242 0.812 2.684 4.61E-08 6.05E-04 
IL19 ENSG00000142224 0.586 1.473 2.358 1.15E-07 7.57E-04 
IL23A ENSG00000110944 1.914 3.597 1.576 7.84E-07 2.55E-03 
FAM213B ENSG00000157870 7.837 5.201 -0.604 8.99E-07 2.55E-03 
TGFA ENSG00000163235 0.665 1.392 1.550 9.69E-07 2.55E-03 
FZD7 ENSG00000155760 0.397 0.246 -0.721 1.39E-06 3.04E-03 
C6orf223 ENSG00000181577 0.063 0.297 2.127 1.92E-06 3.60E-03 
PROCR ENSG00000101000 3.695 10.872 1.552 3.61E-06 5.69E-03 
NT5E ENSG00000135318 0.210 0.725 2.082 4.24E-06 5.69E-03 
SMO ENSG00000128602 0.259 0.124 -1.161 4.33E-06 5.69E-03 
CISH ENSG00000114737 2.723 5.161 1.439 5.90E-06 7.04E-03 
C6orf165 ENSG00000213204 0.038 0.086 1.205 6.57E-06 7.20E-03 
CCL19 ENSG00000172724 0.518 1.767 1.763 8.79E-06 8.89E-03 
PTGS2 ENSG00000073756 2.319 18.604 1.813 9.52E-06 8.93E-03 
HPSE ENSG00000173083 11.322 24.941 1.142 1.10E-05 9.68E-03 
VEGFA ENSG00000112715 5.475 14.251 0.898 1.35E-05 1.11E-02 
ANXA11 ENSG00000122359 136.875 105.621 -0.374 1.72E-05 1.33E-02 
CDK2 ENSG00000123374 5.534 7.186 0.390 1.88E-05 1.37E-02 
R3HCC1 ENSG00000104679 15.225 11.394 -0.421 2.18E-05 1.45E-02 
PGAP3 ENSG00000161395 2.943 2.310 -0.364 2.28E-05 1.45E-02 
TTLL7 ENSG00000137941 0.135 0.219 0.712 2.31E-05 1.45E-02 
NKX3-1 ENSG00000167034 0.025 0.195 2.157 2.44E-05 1.46E-02 
PLEKHN1 ENSG00000187583 0.858 1.466 0.793 2.57E-05 1.47E-02 
CSF2 ENSG00000164400 0.680 1.369 2.888 3.00E-05 1.55E-02 
SLC25A37 ENSG00000147454 8.575 22.865 1.291 3.03E-05 1.55E-02 
RASEF ENSG00000165105 0.003 0.041 3.580 3.16E-05 1.55E-02 
DNAJB13 ENSG00000187726 0.095 0.168 0.818 3.19E-05 1.55E-02 
FAM126A ENSG00000122591 2.424 3.294 0.457 3.51E-05 1.65E-02 
SERPINA9 ENSG00000170054 0.159 0.503 2.196 4.00E-05 1.81E-02 
CHORDC1 ENSG00000110172 16.382 20.651 0.346 4.38E-05 1.89E-02 
IL2RA ENSG00000134460 0.945 4.621 2.047 4.45E-05 1.89E-02 
CD300E ENSG00000186407 92.872 161.854 0.801 4.67E-05 1.92E-02 
IL12B ENSG00000113302 1.772 6.429 2.531 5.69E-05 2.27E-02 
BBS12 ENSG00000181004 0.641 0.810 0.345 6.02E-05 2.28E-02 
LEPREL1 ENSG00000090530 0.140 0.366 1.400 6.08E-05 2.28E-02 
PLXNB1 ENSG00000164050 0.649 0.917 0.507 6.41E-05 2.29E-02 
KANSL1L ENSG00000144445 2.326 2.828 0.293 6.64E-05 2.29E-02 
STAC ENSG00000144681 0.947 2.009 2.399 6.66E-05 2.29E-02 
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BBS7 ENSG00000138686 2.337 2.817 0.289 6.79E-05 2.29E-02 
MPND ENSG00000008382 7.750 5.647 -0.480 8.65E-05 2.69E-02 
STX1A ENSG00000106089 2.160 5.172 1.319 8.70E-05 2.69E-02 
IL6 ENSG00000136244 12.656 97.048 2.678 8.73E-05 2.69E-02 
SPARC ENSG00000113140 8.356 3.885 -1.161 9.11E-05 2.69E-02 
PTGES ENSG00000148344 0.767 3.161 1.797 9.18E-05 2.69E-02 
WASF1 ENSG00000112290 0.345 0.532 0.666 9.22E-05 2.69E-02 
NAGLU ENSG00000108784 8.155 6.428 -0.349 9.67E-05 2.76E-02 
GK5 ENSG00000175066 0.881 1.880 1.014 9.89E-05 2.77E-02 
ZNF414 ENSG00000133250 4.682 3.857 -0.284 1.10E-04 3.00E-02 
SERPINB7 ENSG00000166396 0.360 1.802 2.677 1.13E-04 3.03E-02 
NAT8L ENSG00000185818 0.052 0.032 -0.760 1.19E-04 3.12E-02 
ZDHHC13 ENSG00000177054 5.097 6.295 0.317 1.24E-04 3.18E-02 
FGF2 ENSG00000138685 0.013 0.081 2.371 1.26E-04 3.18E-02 
DLL4 ENSG00000128917 0.022 0.119 2.135 1.33E-04 3.29E-02 
HECW2 ENSG00000138411 0.142 0.278 0.955 1.38E-04 3.35E-02 
PVALB ENSG00000100362 0.457 0.122 -1.862 1.44E-04 3.43E-02 
TEFM ENSG00000172171 4.705 5.690 0.285 1.49E-04 3.43E-02 
MIR1249 ENSG00000221598 5.001 3.261 -0.636 1.49E-04 3.43E-02 
RETN ENSG00000104918 3.527 8.346 1.382 1.54E-04 3.46E-02 
INHBA ENSG00000122641 4.711 7.527 1.781 1.56E-04 3.46E-02 
PF4 ENSG00000163737 0.627 1.888 1.606 1.60E-04 3.50E-02 
EVC2 ENSG00000173040 0.096 0.194 0.999 1.67E-04 3.50E-02 
KCNJ15 ENSG00000157551 2.191 4.176 0.996 1.68E-04 3.50E-02 
TMEM54 ENSG00000121900 0.272 0.560 1.041 1.68E-04 3.50E-02 
CCL8 ENSG00000108700 41.093 103.771 2.142 1.74E-04 3.54E-02 
HHLA2 ENSG00000114455 0.092 0.194 1.492 1.75E-04 3.54E-02 
TYRO3 ENSG00000092445 0.160 0.233 0.566 1.81E-04 3.61E-02 
VCAN ENSG00000038427 9.829 19.306 0.975 1.85E-04 3.62E-02 
SOX5 ENSG00000134532 0.324 0.957 1.609 1.96E-04 3.70E-02 
SMPDL3A ENSG00000172594 12.351 25.672 1.036 1.99E-04 3.70E-02 
TIA1 ENSG00000116001 10.715 12.290 0.207 2.02E-04 3.70E-02 
ACOT2 ENSG00000119673 2.488 1.809 -0.475 2.04E-04 3.70E-02 
TSPAN33 ENSG00000158457 30.848 20.432 -0.630 2.05E-04 3.70E-02 
JRKL ENSG00000183340 1.980 2.281 0.225 2.06E-04 3.70E-02 
SCARF2 ENSG00000244486 0.183 0.126 -0.597 2.11E-04 3.75E-02 
CECR5 ENSG00000069998 16.022 12.869 -0.336 2.15E-04 3.77E-02 
PRDM8 ENSG00000152784 0.443 1.038 1.070 2.21E-04 3.81E-02 
CEP152 ENSG00000103995 1.331 1.645 0.3194 2.41E-04 4.08E-02 
CCL20 ENSG00000115009 9.411 46.334 2.219 2.42E-04 4.08E-02 
CHIT1 ENSG00000133063 0.406 0.327 -0.642 2.47E-04 4.10E-02 
DDX52 ENSG00000141141 8.645 9.481 0.143 2.50E-04 4.10E-02 
CASP5 ENSG00000137757 4.235 8.799 1.030 2.55E-04 4.13E-02 
MCTP2 ENSG00000140563 0.434 0.840 1.023 2.64E-04 4.20E-02 
SLC45A1 ENSG00000162426 0.093 0.062 -0.576 2.69E-04 4.20E-02 
RYR1 ENSG00000196218 0.463 0.296 -0.635 2.70E-04 4.20E-02 
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PPBP ENSG00000163736 104.558 372.454 1.865 2.76E-04 4.20E-02 
NOD2 ENSG00000167207 7.769 10.937 0.501 2.77E-04 4.20E-02 
LOXL2 ENSG00000134013 1.409 0.785 -0.811 2.80E-04 4.20E-02 
IFT81 ENSG00000122970 1.069 1.477 0.489 2.82E-04 4.20E-02 
PHTF1 ENSG00000116793 5.744 6.854 0.263 2.88E-04 4.20E-02 
KIAA0226L ENSG00000102445 6.743 11.080 0.743 2.88E-04 4.20E-02 
SDCCAG8 ENSG00000054282 12.135 15.482 0.366 3.11E-04 4.44E-02 
VWCE ENSG00000167992 0.390 0.229 -0.777 3.13E-04 4.44E-02 
CLDN1 ENSG00000163347 0.021 0.088 2.154 3.16E-04 4.44E-02 
PID1 ENSG00000153823 66.894 99.415 0.600 3.18E-04 4.44E-02 
SNX25 ENSG00000109762 1.150 1.816 0.700 3.33E-04 4.61E-02 
ATXN7L3 ENSG00000087152 24.959 27.604 0.153 3.40E-04 4.63E-02 
EDN1 ENSG00000078401 1.426 3.003 1.09 3.42E-04 4.63E-02 
KTN1 ENSG00000126777 47.133 53.741 0.201 3.54E-04 4.70E-02 
NEK11 ENSG00000114670 0.434 0.558 0.365 3.59E-04 4.70E-02 
KLC2 ENSG00000174996 1.256 1.676 0.431 3.60E-04 4.70E-02 
MCFD2 ENSG00000180398 8.660 9.670 0.175 3.64E-04 4.70E-02 
S100A12 ENSG00000163221 181.237 250.205 0.457 3.65E-04 4.70E-02 
ACSF3 ENSG00000176715 5.405 4.522 -0.260 3.69E-04 4.70E-02 
PPM1H ENSG00000111110 1.782 1.281 -0.472 3.72E-04 4.70E-02 
ZDHHC2 ENSG00000104219 6.655 8.800 0.414 3.82E-04 4.78E-02 
NAMPT ENSG00000105835 216.560 399.133 0.860 3.86E-04 4.78E-02 
OSM ENSG00000099985 4.084 12.513 1.443 4.02E-04 4.93E-02 
MAPRE3 ENSG00000084764 7.512 9.857 0.397 4.15E-04 4.96E-02 
TMPRSS9 ENSG00000178297 0.126 0.085 -0.605 4.19E-04 4.96E-02 
CXCL6 ENSG00000124875 12.417 43.757 1.805 4.23E-04 4.96E-02 
MMP8 ENSG00000118113 0.138 0.366 1.406 4.27E-04 4.96E-02 
GM2A ENSG00000196743 50.440 33.690 -0.585 4.36E-04 4.96E-02 
C3orf80 ENSG00000180044 0.026 0.083 1.643 4.38E-04 4.96E-02 
FAM177A1 ENSG00000151327 4.933 6.168 0.334 4.46E-04 4.96E-02 
C1orf233 ENSG00000228594 1.109 0.704 -0.703 4.59E-04 4.96E-02 
FGFR1OP2 ENSG00000111790 14.595 16.204 0.160 4.60E-04 4.96E-02 
SOX13 ENSG00000143842 0.258 0.158 -0.687 4.63E-04 4.96E-02 
CA13 ENSG00000185015 0.265 0.356 0.435 4.74E-04 4.96E-02 
SGK1 ENSG00000118515 80.937 59.608 -0.410 4.75E-04 4.96E-02 
PLCB4 ENSG00000101333 0.015 0.032 1.682 4.76E-04 4.96E-02 
MYEOV ENSG00000172927 0.122 0.282 1.281 4.76E-04 4.96E-02 
SERPINB9 ENSG00000170542 18.758 39.539 1.017 4.77E-04 4.96E-02 
ZNF654 ENSG00000175105 1.979 2.362 0.267 4.80E-04 4.96E-02 
C1orf115 ENSG00000162817 0.072 0.147 0.985 4.82E-04 4.96E-02 
NME7 ENSG00000143156 3.380 4.323 0.375 4.84E-04 4.96E-02 
FAM111A ENSG00000166801 7.942 9.530 0.273 4.84E-04 4.96E-02 
KRCC1 ENSG00000172086 17.549 19.998 0.196 4.84E-04 4.96E-02 
OTOF ENSG00000115155 0.165 0.598 1.814 4.86E-04 4.96E-02 
IGFN1 ENSG00000163395 0.090 0.509 1.710 4.88E-04 4.96E-02 
GTF2E2 ENSG00000197265 17.947 20.273 0.181 4.91E-04 4.96E-02 
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Table A.6.  Complete list of differentially expressed genes in HD monocytes 
following HTT-lowering (FDR < 0.05). 
Gene ID Ensembl ID 
RPKM 
(SCR 
siRNA) 
RPKM 
(Anti-HTT 
siRNA) 
log2 fold 
change 
p-value FDR 
COX5A ENSG00000178741 120.152 41.172 -1.562 4.76E-137 3.98E-133 
ECI2 ENSG00000198721 6.403 3.912 -0.737 6.82E-39 2.85E-35 
HTT ENSG00000197386 10.218 4.300 -1.280 1.00E-27 2.79E-24 
SRPR ENSG00000182934 62.426 43.624 -0.488 1.05E-20 2.19E-17 
PPARA ENSG00000186951 2.051 1.514 -0.471 1.16E-17 1.93E-14 
VAMP3 ENSG00000049245 52.249 37.049 -0.483 3.43E-17 4.78E-14 
SPG20 ENSG00000133104 26.372 17.912 -0.512 2.22E-13 2.57E-10 
ACP5 ENSG00000102575 563.842 319.723 -1.050 2.46E-13 2.57E-10 
CAPZA1 ENSG00000116489 107.840 84.262 -0.319 6.40E-13 5.94E-10 
NDUFA8 ENSG00000119421 22.077 17.142 -0.385 2.92E-12 2.44E-09 
C8orf33 ENSG00000182307 6.731 4.975 -0.445 3.81E-11 2.80E-08 
ARHGEF7 ENSG00000102606 6.301 5.296 -0.233 4.02E-11 2.80E-08 
HDGF ENSG00000143321 47.811 35.132 -0.459 1.03E-10 6.64E-08 
BAG5 ENSG00000166170 4.191 3.719 -0.185 1.37E-10 8.19E-08 
TOMM70A ENSG00000154174 14.166 12.552 -0.152 2.22E-10 1.24E-07 
CSE1L ENSG00000124207 18.510 16.133 -0.215 1.86E-09 9.69E-07 
CNOT11 ENSG00000158435 14.431 11.196 -0.355 2.56E-09 1.26E-06 
ACTG1 ENSG00000184009 705.135 1031.133 0.582 2.92E-09 1.35E-06 
UBE2D4 ENSG00000078967 3.913 3.028 -0.399 1.25E-08 5.49E-06 
HIF1AN ENSG00000166135 8.113 6.787 -0.241 1.99E-08 8.32E-06 
PAFAH1B1 ENSG00000007168 22.116 19.385 -0.178 2.42E-08 9.61E-06 
NLK ENSG00000087095 3.617 2.945 -0.280 4.29E-08 1.63E-05 
UBE3C ENSG00000009335 24.640 21.733 -0.151 5.04E-08 1.83E-05 
VTI1B ENSG00000100568 26.175 32.030 0.277 6.15E-08 2.14E-05 
MCFD2 ENSG00000180398 8.048 6.365 -0.358 6.78E-08 2.26E-05 
SUMO3 ENSG00000184900 45.921 36.797 -0.374 1.02E-07 3.27E-05 
CTNND1 ENSG00000198561 31.248 24.832 -0.313 1.93E-07 5.98E-05 
TMEM192 ENSG00000170088 7.396 6.356 -0.258 2.18E-07 6.51E-05 
HAT1 ENSG00000128708 38.753 29.463 -0.324 3.19E-07 9.19E-05 
NSUN2 ENSG00000037474 30.837 23.487 -0.357 3.61E-07 1.01E-04 
GTF3C4 ENSG00000125484 3.678 3.153 -0.218 4.15E-07 1.12E-04 
ACADS ENSG00000122971 8.727 6.559 -0.414 6.35E-07 1.66E-04 
ITGB1 ENSG00000150093 111.194 95.289 -0.205 9.19E-07 2.32E-04 
TALDO1 ENSG00000177156 417.422 334.931 -0.351 1.09E-06 2.61E-04 
GNS ENSG00000135677 166.870 120.949 -0.444 1.10E-06 2.61E-04 
ZNF720 ENSG00000197302 2.215 2.869 0.450 3.11E-06 7.20E-04 
SOAT1 ENSG00000057252 63.227 82.848 0.351 5.72E-06 1.29E-03 
GSS ENSG00000100983 25.511 29.332 0.212 7.56E-06 1.66E-03 
RNF214 ENSG00000167257 5.657 4.963 -0.224 8.68E-06 1.86E-03 
MRPL45 ENSG00000174100 9.426 8.063 -0.223 9.36E-06 1.95E-03 
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UQCR10 ENSG00000184076 23.029 28.690 0.310 2.02E-05 4.11E-03 
STX6 ENSG00000135823 12.326 8.202 -0.578 2.07E-05 4.11E-03 
SLC25A44 ENSG00000160785 7.604 6.485 -0.193 2.13E-05 4.14E-03 
PPT1 ENSG00000131238 331.211 231.084 -0.550 3.35E-05 6.36E-03 
SF3B2 ENSG00000087365 77.738 68.950 -0.144 3.52E-05 6.52E-03 
FURIN ENSG00000140564 34.831 25.430 -0.441 3.64E-05 6.61E-03 
CHSY1 ENSG00000131873 6.061 4.914 -0.243 5.35E-05 9.49E-03 
ZNF622 ENSG00000173545 18.959 16.352 -0.199 5.51E-05 9.58E-03 
SET ENSG00000119335 47.605 41.599 -0.210 6.62E-05 1.13E-02 
ABCC3 ENSG00000108846 17.374 12.400 -0.636 7.87E-05 1.31E-02 
ANKRD13C ENSG00000118454 3.369 2.863 -0.236 8.18E-05 1.34E-02 
PRR13 ENSG00000205352 82.505 73.800 -0.156 8.97E-05 1.44E-02 
RAB12 ENSG00000206418 29.276 21.229 -0.410 9.53E-05 1.50E-02 
GALNT2 ENSG00000143641 15.788 18.803 0.277 9.75E-05 1.51E-02 
TMEM184C ENSG00000164168 11.178 9.845 -0.182 1.04E-04 1.57E-02 
PANX1 ENSG00000110218 13.388 10.930 -0.257 1.24E-04 1.85E-02 
LEO1 ENSG00000166477 11.405 9.251 -0.267 1.47E-04 2.14E-02 
RECQL ENSG00000004700 24.388 20.266 -0.22568 1.51E-04 2.14E-02 
ZNF776 ENSG00000152443 1.778 1.451 -0.277 1.53E-04 2.14E-02 
SLC25A32 ENSG00000164933 6.041 6.816 0.247 1.56E-04 2.14E-02 
MPI ENSG00000178802 5.981 5.281 -0.263 1.56E-04 2.14E-02 
NBR1 ENSG00000188554 22.278 18.719 -0.251 1.70E-04 2.29E-02 
STRN ENSG00000115808 3.473 3.041 -0.214 1.77E-04 2.34E-02 
MIPEP ENSG00000027001 3.888 5.631 0.509 1.92E-04 2.47E-02 
TGOLN2 ENSG00000152291 37.632 33.288 -0.200 1.93E-04 2.47E-02 
SARS ENSG00000031698 56.071 47.449 -0.237 1.99E-04 2.52E-02 
FUBP1 ENSG00000162613 40.255 34.989 -0.140 2.20E-04 2.71E-02 
PSMA1 ENSG00000129084 110.274 94.206 -0.160 2.21E-04 2.71E-02 
DHRS7B ENSG00000109016 7.729 9.004 0.214 2.96E-04 3.57E-02 
MFSD10 ENSG00000109736 25.456 20.818 -0.290 2.99E-04 3.57E-02 
ANKRD40 ENSG00000154945 7.278 6.578 -0.158 4.11E-04 4.84E-02 
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A.4 Monocyte GSEA results 
Table A.7.  Complete list of enriched gene sets among the upregulated genes in 
unstimulated HD monocytes (FDR < 0.05). 
Pathway NES p-value FDR Description 
GO: 31347 5.631 8.96E-09 1.28E-04 Regulation of defence response 
MGI: 2419 5.378 3.77E-08 2.68E-04 Abnormal innate immunity 
MGI: 8835 5.077 1.92E-07 6.46E-04 
Abnormal intercellular signalling peptide or 
protein level 
GO: 6954 5.036 2.38E-07 6.46E-04 Inflammatory response 
GO: 31349 5.016 2.64E-07 6.46E-04 Positive regulation of defence response 
MGI: 8713 5.010 2.72E-07 6.46E-04 Abnormal cytokine level 
MGI: 3009 4.923 4.26E-07 8.67E-04 Abnormal cytokine secretion 
GO: 9615 4.760 9.68E-07 1.63E-03 Response to virus 
GO: 43900 4.727 1.14E-06 1.63E-03 Regulation of multi-organism process 
GO: 45088 4.710 1.24E-06 1.63E-03 Regulation of innate immune response 
MGI: 8469 4.677 1.46E-06 1.63E-03 Abnormal protein level 
KEGG: 5323 4.649 1.67E-06 1.63E-03 Rheumatoid arthritis 
GO: 1817 4.647 1.68E-06 1.63E-03 Regulation of cytokine production 
GO: 5125 4.643 1.72E-06 1.63E-03 Cytokine activity 
MGI: 2451 4.630 1.83E-06 1.63E-03 Abnormal macrophage physiology 
KEGG: 4060 4.624 1.88E-06 1.63E-03 Cytokine-cytokine receptor interaction 
GO: 2252 4.617 1.95E-06 1.63E-03 Immune effector process 
GO: 9617 4.590 2.22E-06 1.73E-03 Response to bacterium 
MGI: 1793 4.582 2.30E-06 1.73E-03 Altered susceptibility to infection 
MGI: 8568 4.509 3.26E-06 2.32E-03 Abnormal interleukin secretion 
GO: 5126 4.488 3.59E-06 2.44E-03 Cytokine receptor binding 
MGI: 5025 4.444 4.42E-06 2.82E-03 Abnormal response to infection 
GO: 46888 4.437 4.56E-06 2.82E-03 Negative regulation of hormone secretion 
GO: 45089 4.427 4.78E-06 2.84E-03 Positive regulation of innate immune response 
MGI: 2444 4.410 5.17E-06 2.94E-03 Abnormal T cell physiology 
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REACTOME: 287 4.358 6.56E-06 3.60E-03 Cytokine signalling in immune system 
KEGG: 4668 4.277 9.47E-06 5.00E-03 TNF signalling pathway 
GO: 70201 4.255 1.05E-05 5.32E-03 
Regulation of establishment of protein 
localization 
MGI: 2406 4.208 1.29E-05 6.16E-03 Increased susceptibility to infection 
REACTOME: 218 4.205 1.31E-05 6.16E-03 Chemokine receptors bind chemokines 
GO: 51607 4.199 1.34E-05 6.16E-03 Defence response to virus 
GO: 1819 4.188 1.41E-05 6.26E-03 Positive regulation of cytokine production 
GO: 71345 4.151 1.66E-05 7.14E-03 Cellular response to cytokine stimulus 
MGI: 10210 4.144 1.71E-05 7.15E-03 Abnormal circulating cytokine level 
GO: 35821 4.113 1.95E-05 7.83E-03 
Modification of morphology or physiology of 
other organism 
GO: 2218 4.110 1.98E-05 7.83E-03 Activation of innate immune response 
MGI: 8751 4.090 2.16E-05 8.30E-03 Abnormal interleukin level 
GO: 43122 4.073 2.32E-05 8.70E-03 
Regulation of I-kappaB kinase/NF-kappaB 
cascade 
GO: 30595 4.024 2.86E-05 1.02E-02 Leukocyte chemotaxis 
GO: 72527 4.022 2.89E-05 1.02E-02 
Pyrimidine-containing compound metabolic 
process 
GO: 50727 4.018 2.93E-05 1.02E-02 Regulation of inflammatory response 
GO: 5929 3.996 3.22E-05 1.09E-02 Cilium 
GO: 2696 3.972 3.56E-05 1.18E-02 Positive regulation of leukocyte activation 
GO: 7243 3.960 3.75E-05 1.21E-02 Intracellular protein kinase cascade 
GO: 30334 3.940 4.07E-05 1.29E-02 Regulation of cell migration 
GO: 50900 3.928 4.28E-05 1.33E-02 Leukocyte migration 
GO: 51251 3.916 4.50E-05 1.36E-02 Positive regulation of lymphocyte activation 
GO: 51817 3.912 4.58E-05 1.36E-02 
Modification of morphology or physiology of 
other organism involved in symbiotic interaction 
GO: 2758 3.900 4.81E-05 1.40E-02 
Innate immune response-activating signal 
transduction 
GO: 2694 3.891 4.99E-05 1.42E-02 Regulation of leukocyte activation 
GO: 51223 3.870 5.44E-05 1.52E-02 Regulation of protein transport 
MGI: 5416 3.854 5.81E-05 1.59E-02 Abnormal circulating protein level 
GO: 1816 3.849 5.93E-05 1.59E-02 Cytokine production 
GO: 70851 3.832 6.36E-05 1.68E-02 Growth factor receptor binding 
GO: 2237 3.819 6.70E-05 1.73E-02 Response to molecule of bacterial origin 
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GO: 45580 3.799 7.26E-05 1.80E-02 Regulation of T cell differentiation 
GO: 2000145 3.799 7.26E-05 1.80E-02 Regulation of cell motility 
GO: 60326 3.796 7.35E-05 1.80E-02 Cell chemotaxis 
GO: 32880 3.793 7.44E-05 1.80E-02 Regulation of protein localization 
MGI: 8556 3.769 8.20E-05 1.95E-02 Abnormal tumour necrosis factor secretion 
GO: 2221 3.762 8.43E-05 1.97E-02 Pattern recognition receptor signalling pathway 
GO: 32101 3.758 8.56E-05 1.97E-02 Regulation of response to external stimulus 
GO: 19221 3.727 9.69E-05 2.14E-02 Cytokine-mediated signalling pathway 
GO: 43903 3.726 9.73E-05 2.14E-02 
Regulation of symbiosis, encompassing 
mutualism through parasitism 
GO: 50778 3.725 9.77E-05 2.14E-02 Positive regulation of immune response 
GO: 5813 3.702 1.07E-04 2.31E-02 Centrosome 
GO: 51249 3.691 1.12E-04 2.37E-02 Regulation of lymphocyte activation 
GO: 45321 3.683 1.15E-04 2.41E-02 Leukocyte activation 
GO: 72528 3.679 1.17E-04 2.42E-02 
Pyrimidine-containing compound biosynthetic 
process 
GO: 45619 3.673 1.20E-04 2.44E-02 Regulation of lymphocyte differentiation 
GO: 2000116 3.646 1.33E-04 2.65E-02 
Regulation of cysteine-type endopeptidase 
activity 
KEGG: 4630 3.643 1.35E-04 2.65E-02 JAK-STAT signalling pathway 
GO: 32496 3.640 1.36E-04 2.65E-02 Response to lipopolysaccharide 
GO: 50867 3.637 1.38E-04 2.65E-02 Positive regulation of cell activation 
GO: 43901 3.633 1.40E-04 2.66E-02 Negative regulation of multi-organism process 
GO: 10942 3.617 1.49E-04 2.79E-02 Positive regulation of cell death 
MGI: 8555 3.602 1.58E-04 2.92E-02 Abnormal interferon secretion 
MGI: 8588 3.599 1.60E-04 2.92E-02 Abnormal circulating interleukin level 
GO: 45621 3.583 1.70E-04 3.06E-02 Positive regulation of lymphocyte differentiation 
GO: 44003 3.569 1.79E-04 3.19E-02 
Modification by symbiont of host morphology or 
physiology 
GO: 45582 3.502 2.31E-04 4.06E-02 Positive regulation of T cell differentiation 
GO: 2697 3.496 2.36E-04 4.10E-02 Regulation of immune effector process 
GO: 50870 3.458 2.72E-04 4.67E-02 Positive regulation of T cell activation 
GO: 43068 3.439 2.92E-04 4.95E-02 Positive regulation of programmed cell death 
GO: 2757 3.434 2.97E-04 4.98E-02 Immune response-activating signal transduction 
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Table A.8.  Complete list of enriched gene sets among the downregulated genes 
in stimulated HD monocytes (FDR < 0.05). 
Pathway NES p-value FDR Description 
GO: 72594 5.819 2.96E-09 1.88E-05 
Establishment of protein localization to 
organelle 
GO: 6412 5.803 3.26E-09 1.88E-05 Translation 
GO: 6605 5.443 2.62E-08 1.01E-04 Protein targeting 
REACTOME: 1287 5.222 8.85E-08 2.55E-04 Translation 
GO: 22411 5.120 1.53E-07 3.04E-04 Cellular component disassembly 
GO:  33365 5.113 1.59E-07 3.04E-04 Protein localization to organelle 
GO: 6612 5.044 2.28E-07 3.75E-04 Protein targeting to membrane 
GO: 5773 4.947 3.77E-07 5.43E-04 Vacuole 
GO: 70972 4.876 5.41E-07 6.93E-04 Protein localization to endoplasmic reticulum 
MGI: 3947 4.799 7.97E-07 9.19E-04 Abnormal cholesterol level 
GO: 6413 4.693 1.35E-06 1.37E-03 Translational initiation 
GO: 72599 4.677 1.46E-06 1.37E-03 
Establishment of protein localization to 
endoplasmic reticulum 
GO: 45047 4.665 1.54E-06 1.37E-03 Protein targeting to ER 
REACTOME: 1165 4.646 1.69E-06 1.39E-03 
SRP-dependent co-translational protein 
targeting to membrane 
GO: 6613 4.623 1.89E-06 1.45E-03 
Co-translational protein targeting to 
membrane 
MGI: 5278 4.604 2.07E-06 1.49E-03 Abnormal cholesterol homeostasis 
GO: 6614 4.562 2.53E-06 1.65E-03 
SRP-dependent co-translational protein 
targeting to membrane 
GO: 44391 4.547 2.72E-06 1.65E-03 Ribosomal subunit 
GO: 32984 4.547 2.72E-06 1.65E-03 Macromolecular complex disassembly 
GO: 44445 4.522 3.06E-06 1.76E-03 Cytosolic part 
KEGG: 3010 4.509 3.26E-06 1.79E-03 Ribosome 
REACTOME: 190 4.473 3.86E-06 1.93E-03 CAP-dependent translation initiation 
REACTOME: 383 4.473 3.86E-06 1.93E-03 Eukaryotic translation initiation 
MGI: 3949 4.459 4.12E-06 1.98E-03 Abnormal circulating lipid level 
GO: 6414 4.415 5.05E-06 2.33E-03 Translational elongation 
GO: 43241 4.373 6.13E-06 2.69E-03 Protein complex disassembly 
GO: 3735 4.367 6.30E-06 2.69E-03 Structural constituent of ribosome 
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GO: 43624 4.348 6.87E-06 2.83E-03 Cellular protein complex disassembly 
GO: 5764 4.330 7.46E-06 2.83E-03 Lysosome 
GO: 323 4.330 7.46E-06 2.83E-03 Lytic vacuole 
MGI: 180 4.325 7.63E-06 2.83E-03 Abnormal circulating cholesterol level 
MGI: 3982 4.308 8.24E-06 2.97E-03 Increased cholesterol level 
GO: 5840 4.299 8.58E-06 3.00E-03 Ribosome 
GO: 19058 4.278 9.43E-06 3.20E-03 Viral infectious cycle 
REACTOME: 2 4.240 1.12E-05 3.53E-03 3’-UTR-mediated translational regulation 
REACTOME: 621 4.240 1.12E-05 3.53E-03 
L13A-mediated translational silencing of 
caeruloplasmin expression 
REACTOME: 512 4.237 1.13E-05 3.53E-03 
GTP hydrolysis and joining of the 60S 
ribosomal subunit 
REACTOME: 415 4.229 1.17E-05 3.56E-03 Formation of a pool of free 40S subunits 
GO: 22626 4.220 1.22E-05 3.61E-03 Cytosolic ribosome 
MGI: 5178 4.201 1.33E-05 3.83E-03 Increased circulating cholesterol level 
GO: 7005 4.185 1.43E-05 4.01E-03 Mitochondrion organization 
REACTOME: 782 4.173 1.50E-05 4.03E-03 Nonsense-mediated decay 
REACTOME: 780 4.173 1.50E-05 4.03E-03 
Nonsense-mediated decay enhanced by the 
exon junction complex 
REACTOME: 556 4.164 1.56E-05 4.06E-03 
Influenza viral RNA transcription and 
replication 
GO: 6401 4.161 1.58E-05 4.06E-03 RNA catabolic process 
GO: 184 4.152 1.65E-05 4.13E-03 
Nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 
KEGG: 4142 4.130 1.81E-05 4.45E-03 Lysosome 
REACTOME: 382 4.116 1.93E-05 4.63E-03 Eukaryotic translation elongation 
GO: 19080 4.102 2.05E-05 4.80E-03 Viral genome expression 
GO: 5775 4.098 2.08E-05 4.80E-03 Vacuolar lumen 
GO: 6415 4.091 2.15E-05 4.85E-03 Translational termination 
GO: 956 4.075 2.30E-05 5.10E-03 
Nuclear-transcribed mRNA catabolic 
process 
REACTOME: 1349 4.032 2.77E-05 6.01E-03 Viral mRNA translation 
GO: 6402 4.025 2.85E-05 6.05E-03 mRNA catabolic process 
MGI: 745 4.022 2.89E-05 6.05E-03 Tremors 
REACTOME: 839 3.992 3.28E-05 6.74E-03 Peptide chain elongation 
GO: 19083 3.978 3.47E-05 7.02E-03 Viral transcription 
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REACTOME: 384 3.967 3.64E-05 7.23E-03 Eukaryotic translation termination 
REACTOME: 554 3.963 3.70E-05 7.23E-03 Influenza infection 
REACTOME: 555 3.936 4.14E-05 7.96E-03 Influenza life cycle 
GO: 43202 3.926 4.32E-05 8.00E-03 Lysosomal lumen 
REACTOME: 1041 3.925 4.34E-05 8.00E-03 RNA polymerase I transcription 
REACTOME: 781 3.923 4.37E-05 8.00E-03 
Nonsense-mediated decay independent of 
the exon junction complex 
GO: 6839 3.916 4.50E-05 8.10E-03 Mitochondrial transport 
GO: 44437 3.906 4.69E-05 8.32E-03 Vacuolar part 
GO: 5793 3.854 5.81E-05 1.01E-02 
Endoplasmic reticulum-Golgi intermediate 
compartment 
REACTOME: 1038 3.848 5.95E-05 1.02E-02 RNA polymerase I promoter clearance 
GO: 8202 3.777 7.94E-05 1.34E-02 Steroid metabolic process 
GO: 10035 3.773 8.06E-05 1.35E-02 Response to inorganic substance 
GO: 44433 3.725 9.77E-05 1.61E-02 Cytoplasmic vesicle part 
GO: 34976 3.710 1.04E-04 1.68E-02 Response to endoplasmic reticulum stress 
MGI: 8469 3.689 1.13E-04 1.80E-02 Abnormal protein level 
MGI: 3983 3.660 1.26E-04 1.99E-02 Decreased cholesterol level 
GO: 61024 3.656 1.28E-04 1.99E-02 Membrane organization 
GO: 6066 3.640 1.36E-04 2.09E-02 Alcohol metabolic process 
GO: 16044 3.593 1.63E-04 2.48E-02 Cellular membrane organization 
REACTOME: 1037 3.588 1.67E-04 2.49E-02 RNA polymerase I chain elongation 
GO: 6984 3.554 1.90E-04 2.80E-02 ER-nucleus signalling pathway 
KEGG: 5322 3.460 2.70E-04 3.94E-02 Systemic lupus erythematosus 
GO: 32940 3.455 2.75E-04 3.96E-02 Secretion by cell 
GO: 22613 3.442 2.89E-04 4.11E-02 Ribonucleoprotein complex biogenesis 
GO: 42254 3.404 3.32E-04 4.67E-02 Ribosome biogenesis 
REACTOME: 647 3.389 3.51E-04 4.87E-02 Meiotic recombination 
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A.5 Monocyte IPA® results 
Table A.9.  Complete list of upstream regulators inferred to be significantly 
activated in unstimulated HD monocytes. Significance defined as activation z-score ≥ 2, 
p-value of overlap < 0.01.  
Upstream regulator Molecule type Activation z-score p-value of overlap 
TNF Cytokine 5.764 2.18E-13 
IL1B Cytokine 5.754 8.08E-14 
MYD88 Other 4.761 2.92E-12 
IFNG Cytokine 4.635 3.09E-07 
IL1A Cytokine 4.536 1.69E-11 
TLR3 Transmembrane receptor 4.323 1.99E-09 
RELA Transcription regulator 4.122 5.86E-08 
NFκB (complex) Complex 4.077 2.63E-08 
TLR9 Transmembrane receptor 3.773 4.33E-07 
TLR2 Transmembrane receptor 3.77 3.94E-09 
STAT3 Transcription regulator 3.701 2.34E-07 
IL6 Cytokine 3.654 7.39E-06 
TICAM1 Other 3.651 2.59E-08 
ERK1/2 Group 3.636 5.33E-06 
TLR4 Transmembrane receptor 3.61 7.68E-12 
SMARCA4 Transcription regulator 3.584 1.83E-04 
MYC Transcription regulator 3.528 1.54E-03 
CSF2 Cytokine 3.435 4.46E-03 
ERK Group 3.381 2.58E-07 
TLR7 Transmembrane receptor 3.368 2.61E-04 
PDGF BB Complex 3.35 1.83E-07 
SAMSN1 Other 3.317 1.51E-04 
TNFSF12 Cytokine 3.265 1.52E-05 
Jnk Group 3.255 3.83E-06 
LCN2 Transporter 3.221 3.54E-07 
IL17A Cytokine 3.213 7.05E-05 
IL2 Cytokine 3.12 1.39E-04 
CD14 Transmembrane receptor 3.091 6.84E-09 
IL18 Cytokine 3.081 6.29E-05 
EZH2 Transcription regulator 3.074 3.96E-03 
TBK1 Kinase 3.053 5.03E-07 
EGFR Kinase 2.991 1.83E-07 
HIF1A Transcription regulator 2.979 8.80E-06 
NOD2 Other 2.952 3.94E-05 
Akt Group 2.949 3.15E-03 
IRF1 Transcription regulator 2.925 2.48E-04 
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TLR Group 2.904 7.53E-06 
NFKB1 Transcription regulator 2.897 6.74E-10 
PPIF Enzyme 2.887 6.92E-05 
PTGS2 Enzyme 2.849 3.03E-04 
DOCK8 Other 2.828 1.94E-03 
SASH1 Other 2.828 2.33E-03 
ERBB2 Kinase 2.814 1.63E-03 
RNASE1 Enzyme 2.8 1.91E-07 
RNASE2 Enzyme 2.76 2.37E-06 
MET Kinase 2.759 7.28E-04 
MAPK8 Kinase 2.72 2.25E-05 
P38 MAPK Group 2.707 1.40E-07 
ETS1 Transcription regulator 2.693 4.97E-03 
PTPRJ Phosphatase 2.646 1.08E-03 
IL15 Cytokine 2.611 1.39E-03 
PRKCE Kinase 2.6 6.37E-04 
TLR5 Transmembrane receptor 2.595 1.20E-05 
F7 Peptidase 2.592 1.59E-05 
PARP1 Enzyme 2.589 1.94E-03 
NAMPT Cytokine 2.58 1.49E-06 
TRAF3IP2 Other 2.575 1.52E-04 
AHR Nuclear receptor 2.566 6.70E-04 
TGFA Growth factor 2.564 1.26E-04 
TP63 Transcription regulator 2.505 5.46E-03 
OSM Cytokine 2.503 6.63E-05 
KRT17 Other 2.449 3.85E-04 
KLK5 Peptidase 2.449 1.69E-05 
TMEM173 Other 2.433 1.07E-03 
F2 Peptidase 2.425 1.32E-04 
TRPV4 Ion channel 2.425 1.03E-04 
PRKCA Kinase 2.423 7.67E-03 
LDL Complex 2.421 6.87E-04 
TIRAP Other 2.418 9.71E-07 
IL17C Cytokine 2.412 4.96E-06 
AGER Transmembrane receptor 2.41 5.41E-05 
SRC Kinase 2.407 4.33E-03 
PPRC1 Transcription regulator 2.401 3.47E-03 
IL33 Cytokine 2.397 1.88E-03 
FCGR2A Transmembrane receptor 2.395 1.69E-05 
CLEC7A Transmembrane receptor 2.395 1.69E-05 
CEBPB Transcription regulator 2.391 3.32E-04 
MAP2K1/2 Group 2.386 4.81E-03 
GM-CSF Group 2.385 3.02E-04 
IRF5 Transcription regulator 2.354 1.88E-03 
XBP1 Transcription regulator 2.351 3.48E-03 
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NFATC2 Transcription regulator 2.325 7.12E-03 
Cg Complex 2.294 2.70E-04 
MAPK9 Kinase 2.274 4.97E-03 
Mek Group 2.271 1.73E-03 
Lymphotoxin-α1-β2 Complex 2.236 4.02E-05 
JAK2 Kinase 2.236 9.62E-03 
C5 Other 2.224 1.26E-04 
CD40LG Cytokine 2.223 9.37E-06 
PADI2 Enzyme 2.219 8.87E-05 
IL6R Transmembrane receptor 2.219 1.72E-03 
BCL2 Transporter 2.219 1.24E-03 
IL23A Cytokine 2.213 3.99E-04 
TLR1 Transmembrane receptor 2.213 1.26E-04 
RET Kinase 2.213 2.56E-04 
NFKBIA Transcription regulator 2.213 2.60E-08 
PF4 Cytokine 2.213 6.08E-05 
RETN Other 2.204 8.87E-05 
IRAK4 Kinase 2.193 5.74E-08 
ICAM1 Transmembrane receptor 2.19 9.81E-04 
P2RX7 Ion channel 2.19 1.73E-04 
CCL5 Cytokine 2.188 1.61E-04 
FN1 Enzyme 2.183 2.79E-03 
TXNIP Other 2.183 7.07E-03 
MAVS Other 2.17 1.38E-04 
Ap1 Complex 2.166 5.42E-04 
HSPD1 Enzyme 2.158 1.26E-04 
LEPR Transmembrane receptor 2.157 5.21E-03 
HSP90B1 Other 2.152 5.10E-04 
KITLG Growth factor 2.15 8.58E-03 
TRAF6 Enzyme 2.142 1.72E-03 
IL12B Cytokine 2.138 1.65E-05 
TNFRSF1A Transmembrane receptor 2.122 1.76E-07 
EGF Growth factor 2.121 2.00E-04 
IFNA2 Cytokine 2.046 5.39E-04 
Ige Complex 2.025 2.16E-04 
CAMP Other 2.024 1.88E-03 
TANK Other 2.018 4.39E-05 
BCR (complex) Complex 2.013 6.58E-03 
IL32 Cytokine 2.012 8.88E-06 
EGR1 Transcription regulator 2.011 6.55E-04 
MIF Cytokine 2.01 1.52E-04 
TGIF1 Transcription regulator 2 2.12E-04 
NLRC4 Other 2 7.46E-05 
NEK6 Kinase 2 1.31E-04 
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Table A.10.  Complete list of upstream regulators inferred to be significantly 
inhibited in unstimulated HD monocytes. Significance defined as activation z-score ≤ -2, 
p-value of overlap < 0.01.  
Upstream regulator Molecule type Activation z-score p-value of overlap 
miR-155-5p  Mature microRNA -3.39 1.92E-09 
HMOX1 Enzyme -3.088 1.14E-05 
COL18A1 Other -2.975 4.32E-04 
IL10RA Transmembrane receptor -2.879 1.92E-05 
THRA Nuclear receptor -2.828 5.36E-04 
FBXO32 Enzyme -2.646 1.18E-07 
DUSP1 Phosphatase -2.606 2.05E-08 
IL37 Cytokine -2.605 6.05E-08 
PROC Peptidase -2.6 9.71E-07 
IgG Complex -2.523 1.65E-06 
TAB1 Enzyme -2.433 7.97E-05 
NLRP12 Other -2.372 1.67-04 
INSIG1 Other -2.309 5.60E-05 
Alpha catenin Group -2.282 5.01E-04 
BPIFA1 Other -2.216 1.52E-05 
SOCS1 Other -2.213 2.50E-03 
ZFP36 Transcription regulator -2.207 9.43E-10 
CD3 Complex -2.198 6.91E-04 
TRAIP Enzyme -2.176 3.08E-04 
CD28 Transmembrane receptor -2.158 4.97E-03 
ITGB2 Transmembrane receptor -2.157 2.79E-05 
RPSA Translation regulator -2.156 3.18E-06 
ARRB2 Other -2.144 1.59E-05 
Nr1h Group -2.103 5.85E-04 
ABCA1 Transporter -2.08 1.52E-04 
PTGER4 G-protein coupled receptor -2.019 1.77E-03 
TRAF3 Other -2.019 8.60E-04 
SERPINE1 Other -2 1.44E-03 
USP18 Peptidase -2 2.50E-03 
Cdc42 Enzyme -2 1.21E-03 
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A.6 T lymphocyte proliferation assay results 
Table A.11.  Analysis of T lymphocyte proliferation data using the fraction diluted 
statistic. Fraction diluted is calculated as the percentage of cells in the final culture that 
have divided at least once. Control n = 9, HD n = 8. Data shown as mean ± SEM. 
Cell type Treatment Time point 
Fraction diluted 
Control HD 
T lymphocytes 
(CD3+) 
Unstimulated 72 h 1.00 ± 0.39 1.69 ± 0.71 
Unstimulated 96 h 4.13 ± 0.85 3.59 ± 1.30 
Unstimulated 120 h 6.95 ± 0.98 5.46 ± 1.87 
Anti-CD3 + CD28 72 h 62.17 ± 7.73      69.19 ± 5.96 
Anti-CD3 + CD28 96 h 85.56 ± 5.14 79.91 ± 7.81 
Anti-CD3 + CD28 120 h 93.92 ± 2.02 96.15 ± 1.33 
PHA-P 72 h 70.68 ± 4.89 58.05 ± 8.28 
PHA-P 96 h 83.71 ± 3.62 70.90 ± 9.25 
PHA-P 120 h 87.97 ± 2.70 76.05 ± 7.27 
Helper T 
lymphocytes 
(CD3+ CD4+) 
Unstimulated 72 h 0.82 ± 0.35 1.26 ± 0.44 
Unstimulated 96 h 3.18 ± 0.52 3.26 ± 1.35 
Unstimulated 120 h 6.29 ± 1.24 5.24 ± 1.98 
Anti-CD3 + CD28 72 h 66.54 ± 6.57 75.51 ± 4.64 
Anti-CD3 + CD28 96 h 88.42 ± 3.99 83.13 ± 6.83 
Anti-CD3 + CD28 120 h 95.83 ± 1.03 97.69 ± 1.00 
PHA-P 72 h 68.29 ± 6.20 65.89 ± 4.57 
PHA-P 96 h 84.99 ± 2.04 79.98 ± 3.65 
PHA-P 120 h 87.89 ± 1.86 84.41 ± 1.94 
Cytotoxic T 
lymphocytes 
(CD3+ CD8+) 
Unstimulated 72 h 1.09 ± 0.43 4.36 ± 2.83 
Unstimulated 96 h 7.06 ± 2.17 4.82 ± 1.88 
Unstimulated 120 h 11.15 ± 2.44 8.29 ± 3.61 
Anti-CD3 + CD28 72 h 73.59 ± 7.51 73.20 ± 6.03 
Anti-CD3 + CD28 96 h 87.48 ± 5.56 85.24 ± 6.62 
Anti-CD3 + CD28 120 h 93.57 ± 3.21 96.54 ± 1.52 
PHA-P 72 h 72.32 ± 7.99 63.76 ± 10.91 
PHA-P 96 h 85.54 ± 5.14 71.91 ± 12.91 
PHA-P 120 h 90.14 ± 3.69 75.46 ± 12.02 
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Table A.12.  Analysis of T lymphocyte proliferation data using the percentage 
divided statistic. Percentage divided is calculated as the percentage of cells from the initial 
culture that divided at least once. Control n = 9, HD n = 8. Data shown as mean ± SEM. 
Cell type Treatment Time point 
Percentage divided 
Control HD 
T lymphocytes 
(CD3+) 
Unstimulated 72 h 0.32 ± 0.08 0.31 ± 0.07 
Unstimulated 96 h 1.12 ± 0.22 1.36 ± 0.42 
Unstimulated 120 h 1.05 ± 0.22 1.06 ± 0.26 
Anti-CD3 + CD28 72 h 42.68 ± 6.91 48.01 ± 6.84 
Anti-CD3 + CD28 96 h 59.73 ± 6.37 51.78 ± 9.02 
Anti-CD3 + CD28 120 h 60.80 ± 6.70 65.09 ± 6.39 
PHA-P 72 h 53.01 ± 4.95 40.02 ± 7.24 
PHA-P 96 h 54.17 ± 4.63 43.98 ± 7.26 
PHA-P 120 h 52.58 ± 3.27 39.11 ± 6.51 
Helper T 
lymphocytes 
(CD3+ CD4+) 
Unstimulated 72 h 0.20 ± 0.08 0.28 ± 0.08 
Unstimulated 96 h 0.96 ± 0.18 1.11 ± 0.49 
Unstimulated 120 h 1.11 ± 0.31 1.18 ± 0.49 
Anti-CD3 + CD28 72 h 46.24 ± 5.56 54.71 ± 5.85 
Anti-CD3 + CD28 96 h 64.98 ± 5.03 58.96 ± 9.53 
Anti-CD3 + CD28 120 h 67.44 ± 4.04 79.15 ± 5.27 
PHA-P 72 h 52.19 ± 5.59 47.95 ± 4.21 
PHA-P 96 h 58.91 ± 2.91 53.95 ± 3.72 
PHA-P 120 h 58.90 ± 2.21 50.10 ± 2.84 
Cytotoxic T 
lymphocytes 
(CD3+ CD8+) 
Unstimulated 72 h 0.78 ± 0.32 0.61 ± 0.17 
Unstimulated 96 h 1.51 ± 0.40 1.55 ± 0.51 
Unstimulated 120 h 1.29 ± 0.19 1.58 ± 0.47 
Anti-CD3 + CD28 72 h 52.86 ± 7.61 49.65 ± 7.10 
Anti-CD3 + CD28 96 h 63.10 ± 8.72 57.48 ± 9.04 
Anti-CD3 + CD28 120 h 63.90 ± 9.16 67.33 ± 8.27 
PHA-P 72 h 53.14 ± 9.93 44.92 ± 9.07 
PHA-P 96 h 56.00 ± 8.66 47.10 ± 10.22 
PHA-P 120 h 52.66 ± 7.94 44.17 ± 9.67 
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Table A.13.  Analysis of T lymphocyte proliferation data using the proliferation 
index statistic. Proliferation index is calculated as the average number of divisions 
undergone by the dividing cells only. Control n = 9, HD n = 8. Data shown as mean ± SEM. 
Cell type Treatment Time point 
Proliferation index 
Control HD 
T lymphocytes 
(CD3+) 
Unstimulated 72 h 1.25 ± 0.04 1.39 ± 0.14 
Unstimulated 96 h 1.60 ± 0.06 1.47 ± 0.08 
Unstimulated 120 h 2.13 ± 0.05 1.75 ± 0.17 
Anti-CD3 + CD28 72 h 1.59 ± 0.09 1.62 ± 0.08 
Anti-CD3 + CD28 96 h 2.33 ± 0.13 2.49 ± 0.15 
Anti-CD3 + CD28 120 h 3.27 ± 0.16 3.51 ± 0.20 
PHA-P 72 h 1.58 ± 0.06 1.58 ± 0.05 
PHA-P 96 h 2.19 ± 0.08 2.07 ± 0.12 
PHA-P 120 h 2.61 ± 0.16 2.30 ± 0.14 
Helper T 
lymphocytes 
(CD3+ CD4+) 
Unstimulated 72 h 1.22 ± 0.04 1.42 ± 0.15 
Unstimulated 96 h 1.49 ± 0.05 1.48 ± 0.07 
Unstimulated 120 h 2.04 ± 0.06 1.76 ± 0.13 
Anti-CD3 + CD28 72 h 1.49 ± 0.07 1.61 ± 0.07 
Anti-CD3 + CD28 96 h 2.09 ± 0.12 2.43 ± 0.16 
Anti-CD3 + CD28 120 h 3.05 ± 0.15 3.33 ± 0.23 
PHA-P 72 h 1.42 ± 0.04 1.45 ± 0.05 
PHA-P 96 h 1.94 ± 0.05 1.88 ± 0.11 
PHA-P 120 h 2.22 ± 0.15 2.06 ± 0.11 
Cytotoxic T 
lymphocytes 
(CD3+ CD8+) 
Unstimulated 72 h 1.49 ± 0.24 1.99 ± 0.55 
Unstimulated 96 h 1.94 ± 0.11 1.69 ± 0.13 
Unstimulated 120 h 2.31 ± 0.24 1.86 ± 0.23 
Anti-CD3 + CD28 72 h 1.88 ± 0.13 1.81 ± 0.18 
Anti-CD3 + CD28 96 h 2.80 ± 0.17 3.00 ± 0.27 
Anti-CD3 + CD28 120 h 3.88 ± 0.19 3.65 ± 0.27 
PHA-P 72 h 2.04 ± 0.11 1.79 ± 0.13 
PHA-P 96 h 2.84 ± 0.15 2.44 ± 0.22 
PHA-P 120 h 3.32 ± 0.22 2.76 ± 0.30 
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Table A.14.  Analysis of T lymphocyte proliferation data using the division index 
statistic. Division index is calculated as the average number of divisions undergone by all 
cells in culture. Control n = 9, HD n = 8. Data shown as mean ± SEM. 
Cell type Treatment Time point 
Division index 
Control HD 
T lymphocytes 
(CD3+) 
Unstimulated 72 h 0.004 ± 0.001 0.005 ± 0.001 
Unstimulated 96 h 0.018 ± 0.004 0.020 ± 0.006 
Unstimulated 120 h 0.022 ± 0.004 0.020 ± 0.006 
Anti-CD3 + CD28 72 h 0.72 ± 0.15 0.81 ± 0.16 
Anti-CD3 + CD28 96 h 1.44 ± 0.20 1.35 ± 0.28 
Anti-CD3 + CD28 120 h 2.13 ± 0.31 2.31 ± 0.27 
PHA-P 72 h 0.86 ± 0.10 0.63 ± 0.12 
PHA-P 96 h 1.21 ± 0.14 0.95 ± 0.18 
PHA-P 120 h 1.38 ± 0.13 0.94 ± 0.19 
Helper T 
lymphocytes 
(CD3+ CD4+) 
Unstimulated 72 h 0.003 ± 0.001 0.004 ± 0.001 
Unstimulated 96 h 0.014 ± 0.003 0.016 ± 0.006 
Unstimulated 120 h 0.022 ± 0.006 0.021 ± 0.010 
Anti-CD3 + CD28 72 h 0.71 ± 0.11 0.90 ± 0.13 
Anti-CD3 + CD28 96 h 1.46 ± 0.16 1.49 ± 0.29 
Anti-CD3 + CD28 120 h 2.06 ± 0.17 2.66 ± 0.26 
PHA-P 72 h 0.75 ± 0.09 0.69 ± 0.06 
PHA-P 96 h 1.15 ± 0.07 1.03 ± 0.11 
PHA-P 120 h 1.32 ± 0.12 1.04 ± 0.09 
Cytotoxic T 
lymphocytes 
(CD3+ CD8+) 
Unstimulated 72 h 0.009 ± 0.003 0.011 ± 0.005 
Unstimulated 96 h 0.031 ± 0.010 0.025 ± 0.009 
Unstimulated 120 h 0.032 ± 0.007 0.032 ± 0.014 
Anti-CD3 + CD28 72 h 1.06 ± 0.21 0.98 ± 0.23 
Anti-CD3 + CD28 96 h 1.88 ± 0.33 1.78 ± 0.39 
Anti-CD3 + CD28 120 h 2.57 ± 0.42 2.49 ± 0.38 
PHA-P 72 h 1.15 ± 0.25 0.87 ± 0.19 
PHA-P 96 h 1.66 ± 0.30 1.29 ± 0.30 
PHA-P 120 h 1.79 ± 0.33 1.37 ± 0.33 
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A.7 T lymphocyte PCR array results 
Table A.15.  Complete list of expression changes observed in unstimulated HD 
helper T lymphocytes (ranked by p-value). Data presented as fold change calculated from 
ΔΔ-CT values, statistical analysis carried out using unpaired two-tailed Student’s t-tests. 
Gene name Fold change p-value 
TNFSF4 1.471 0.008 
PTGDR2 1.788 0.014 
GATA3 1.177 0.056 
IL18R1 1.336 0.058 
IL5 2.245 0.063 
LAT 0.893 0.101 
IL2RA 1.154 0.102 
CSF2 0.490 0.124 
JAK1 1.108 0.137 
CCR4 1.258 0.183 
TLR6 1.497 0.198 
TNFRSF9 0.564 0.227 
IL13 0.689 0.227 
IL12RB2 0.789 0.255 
CD86 0.681 0.270 
IL10 1.580 0.271 
BCL6 0.737 0.276 
IL2 1.297 0.281 
IL15 0.858 0.296 
LTA 0.905 0.299 
STAT6 2.548 0.307 
CREBBP 1.089 0.318 
IL6 0.309 0.319 
SPP1 0.317 0.322 
CTLA4 1.082 0.335 
EBI3 0.409 0.348 
IL4R 1.080 0.352 
CD40LG 1.090 0.354 
CD28 1.067 0.369 
GFI1 1.167 0.370 
MAPK8 1.055 0.372 
IL18 0.684 0.375 
IRF1 0.897 0.388 
CCL7 0.608 0.391 
TBX21 1.203 0.400 
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TNF 0.856 0.417 
IFNG 0.780 0.422 
CD4 1.051 0.452 
IL6R 1.054 0.459 
LAG3 1.043 0.459 
FASLG 1.106 0.464 
NFATC2 1.089 0.474 
NFATC1 0.955 0.512 
CD27 0.942 0.522 
IL1R1 1.114 0.527 
IRF4 0.977 0.537 
IL24 1.049 0.587 
SLC11A1 0.994 0.603 
PTPRC 0.964 0.616 
IL7 1.078 0.671 
HAVCR2 0.839 0.672 
CCR2 1.116 0.677 
YY1 1.029 0.682 
IL7R 0.956 0.710 
CXCR3 1.166 0.711 
IL27RA 0.969 0.741 
IL13RA1 0.675 0.743 
JAK2 1.083 0.749 
CD80 0.899 0.763 
CCR5 1.031 0.775 
ICOS 0.962 0.777 
STAT1 0.972 0.787 
STAT4 1.007 0.808 
TGFB3 1.137 0.811 
TYK2 1.013 0.825 
PCGF2 0.985 0.831 
VEGFA 0.661 0.898 
SOCS1 0.983 0.911 
MAF 1.052 0.919 
TLR4 0.855 0.937 
CCL5 1.146 0.956 
CCR3 0.961 0.956 
SOCS5 0.992 0.969 
CEBPB 0.947 0.971 
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Table A.16.  Complete list of expression changes observed in stimulated HD helper 
T lymphocytes (ranked by p-value). Data presented as fold change calculated from ΔΔ-CT 
values, statistical analysis carried out using unpaired two-tailed Student’s t-tests. 
Gene name Fold change p-value 
TYK2 1.176 0.002 
TNFRSF8 1.702 0.013 
STAT6 1.231 0.035 
TNFSF4 1.756 0.066 
JAK1 1.169 0.072 
CCR4 1.191 0.118 
IL18R1 1.129 0.149 
CD27 1.261 0.152 
STAT1 0.844 0.162 
IL15 0.800 0.184 
IL5 0.724 0.197 
TGFB3 1.536 0.211 
MAPK8 1.082 0.215 
CD28 1.104 0.237 
YY1 1.052 0.272 
GATA3 1.817 0.300 
IL9 0.704 0.308 
IL6R 1.174 0.319 
FASLG 1.320 0.319 
CCR5 1.194 0.327 
CD40LG 1.119 0.336 
VEGFA 1.126 0.348 
IL2RA 1.036 0.350 
IL12RB2 0.712 0.351 
NFATC2 1.088 0.360 
TLR6 0.848 0.361 
EBI3 0.848 0.366 
SPP1 0.949 0.367 
IL18 0.539 0.370 
IL27 0.747 0.376 
PTGDR2 1.122 0.381 
IL4 0.743 0.383 
BCL6 1.080 0.411 
IL10 0.932 0.446 
IL27RA 1.040 0.452 
CTLA4 1.082 0.452 
SLC11A1 0.820 0.458 
NFATC1 1.055 0.468 
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PCGF2 0.899 0.470 
GFI1 1.095 0.474 
LAT 0.838 0.500 
HAVCR2 1.040 0.503 
IL12B 1.018 0.504 
TNFRSF9 1.162 0.506 
IL4R 0.920 0.507 
CSF2 1.173 0.511 
IRF4 1.024 0.517 
CEBPB 1.117 0.532 
IL2 0.858 0.574 
SOCS5 1.036 0.585 
STAT4 1.046 0.590 
CCR3 0.773 0.593 
JAK2 1.025 0.595 
IL1R1 0.990 0.626 
TNF 0.987 0.626 
IL7 1.079 0.646 
CCR2 1.181 0.647 
CREBBP 1.027 0.648 
IL6 0.672 0.666 
CD4 1.115 0.697 
LTA 1.071 0.704 
CCL7 0.396 0.721 
IL1RL1 1.578 0.738 
CXCR3 0.965 0.738 
SOCS1 0.941 0.739 
LAG3 1.033 0.760 
TLR4 0.935 0.774 
TBX21 0.926 0.783 
IL3 0.777 0.783 
CD86 0.904 0.806 
IL24 0.959 0.825 
PTPRC 1.003 0.826 
CD80 0.982 0.884 
IL13 0.955 0.920 
IFNG 0.808 0.929 
IL13RA1 0.949 0.938 
CCL5 1.059 0.947 
ICOS 1.002 0.953 
IRF1 0.999 0.976 
IL7R 1.006 0.979 
MAF 0.924 0.987 
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